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Zusammenfassung 
Zusammenfassung 
 
Bakterielle Naturstoffe wie von den gut studierten Aktinomyceten weisen eine hohe 
strukturelle Diversität und interessante Bioaktivitäten auf und stellen daher attraktive 
Zielstrukturen für Forschung und klinische Anwendung dar. 
Die vorliegende Arbeit beschäftigt sich mit der Identifizierung, Aufklärung und Manipulation 
der Biosynthesewege zu Cinnabaramiden aus Streptomyces sp. JS360 und Bottromycinen aus 
Streptomyces sp. BC16019. Über Synthetische Biotechnologie wurde die Produktion 
verbessert und neue Derivate dieser Naturstoffe erzeugt.  
Mittels Vorläufer-dirigierter Biosynthese und Mutasynthese wurden neue Cinnabaramid-
Derivate mit interessanten Bioaktivitäten hergestellt. Für die Bottromycine wurde eine 
heterologe Produktionsplattform etabliert, die Produktionsausbeuten optimiert und nach 
rationaler Modifikation des Biosyntheseweges neue Bottromycin-Analoga identifiziert.  
Zudem wurde ein Enzym, welches entscheidend an der Bildung einer ungewöhnlichen 
Polyketid-Verlängerungseinheit für die Cinnabaramid-Biosynthese beteiligt ist, detailliert 
biochemisch und strukturell charakterisiert. Über Mutationen in der Bindetasche gelang es, 
die Substratspezifität des Enzyms zu verändern, welches ausgehend von Enolat-Derivaten 
über reduktive Carboxylierung Dicarbonsäuren generiert. Die erhaltenen Resultate lieferten 
tiefere Einblicke in die Biochemie dieser Enzymfamilie und stellen eine Grundlage zur  
Erzeugung veränderter Polyketide mit verbesserten pharmazeutischen Eigenschaften dar. 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Abstract 
 
Bacterial natural products like from the well-studied actinomycetes display diverse structural 
features and interesting bioactivities making these secondary metabolites attractive targets for 
scientific research and clinical application.  
The present thesis deals with the identification, elucidation and engineering of biosynthetic 
pathways of the natural products cinnabaramides from Streptomyces sp. JS360 and 
bottromycins from Streptomyces sp. BC16019. Synthetic biotechnology tools were employed 
to improve production yields and to produce novel derivatives via biosynthetic engineering.  
Precursor-directed biosynthesis and mutasynthesis approaches allowed the generation of 
novel cinnabaramide derivatives exhibiting intriguing bioactivities. For bottromycins, a 
heterologous production platform was established, optimized for higher production yields and 
novel analogues were identified after rational pathway modification.  
Moreover, detailed biochemical and structural characterization of a key enzyme involved in 
the formation of an unusual polyketide extender unit during cinnabaramide biosynthesis was 
performed. By active site mutations it was possible to change the substrate specificity of the 
enzyme, which generates dicarboxylic acids by reductive carboxylation of enolate derivatives. 
The obtained results provided deeper insights into the biochemistry of this enzyme family and 
set the stage for generation of deliberately altered polyketides with improved pharmaceutical 
properties. 
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A. Introduction 
1. Natural products in drug discovery 
Over a thousand years one fact has been recognized and utilized by humans, nature produces an 
enormous number of metabolites with an amazing variety of structural diversity and bioactivities. The 
first insight into this nature’s creativity occurred more than 200 years ago when Friedrich Sertürner 
isolated morphine from Papaver somniferum,
[1]
 which is regarded as the initiation of modern natural 
product research. Later on, inspired by the discovery of the β-lactam antibiotic penicillin from 
Penicillium notatum by A. Fleming, H. W. Florey and R. B. Chian,
[2]
 pharmaceutical research 
underwent a “golden era” including a massive screening of microorganisms resulting in discoveries of 
plenty of new antibiotics, many of which are still used in clinic today.
[3]
 To date, approximately 40% 
of drugs in clinical use are either natural products or derivatives thereof.
[4]
 They are broadly applied 
either in clinics, such as antibiotics, antitumor and immunosuppressive agents, or in agriculture and 
veterinary applications, such as growth promoters, insecticides, herbicides and antiparasitic agents 
(Figure A1).
[5-8]
  
Accompanying the diverse biological activities of natural products is tremendous structural diversity 
which cannot be obtained from alternative sources.
[9]
 In order to deal with the increasing development 
of the multi-drug resistant organisms, the lack of effective therapy for many severe diseases and the 
side effects caused by current medicines, searching for novel natural products is not only necessary but 
urgent.  
Compared to other origins of natural products, such as plants or insects, microorganisms are predicted 
to be the most promising source of novel natural products for two reasons: 1) many past evidences 
have proven that microorganisms, especially Actinomycetes, possess a great ability to produce 
pharmaceutically relevant metabolites; 2) in the prokaryotic world only a very small percentage of 
microorganisms have been explored for production of natural products and consequently the potential 
to discover novel natural compounds is very promising.
[10]
 Thus, further exploration of 
microorganisms in order to identify novel bioactive compounds has excellent prospects. 
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Figure A1. Selected examples of natural products derived from microbes used in the clinic/clinical trials, 
agriculture, and veterinary applications. The structure, name, original producer and type of application are 
given.  
 
2. Streptomycetes, proficient producers of natural products 
2.1 Ecology of Streptomycetes 
Streptomycetes, which belong to the bacterial order Actinomycetals, are ubiquitous in nature. They are 
soil-dwelling and able to colonize new areas through growth as a vegetative hyphal mass which can 
differentiate into spores that assist in spread and persistence.
[11]
 Most of the time the relatively high 
numbers of Streptomycetes exist in soil as inactive spores, which are a semi-dormant stage in the life 
cycle and can survive for long periods.
[12]
 Because the spores can impart resistance to low nutrient and 
poor water availability, Streptomyces cultures can even be recovered from 70 year old soil samples. As 
one of the common characteristics of Actinomycetes, Streptomycetes are able to produce many 
extracellular enzymes (cellulases, xylanases, amylases, maltases, etc.) in soil, which can decompose 
various complex mixtures of polymers from dead plants, animals and fungi.
[13;14]
 Through this they 
play a very important role in biodegradation by recycling of nutrients associated with recalcitrant 
polymers.
[15]
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2.2 Streptomycetes as key players in microbial natural products research  
For over 60 years Streptomycetes have been well known as one of the most important producers of 
pharmaceutically relevant bioactive metabolites including antibiotics, antitumor agents, 
immunosuppressants, antiparasitic agents, herbicides and enzyme-inhibiting agents.
[16]
 Since the 
groundbreaking discovery of streptomycin as the first Actinomycete antibiotic in 1944,
[17]
 more than 
two-thirds of naturally derived antibiotics are produced by Actinomycetes, most of which belong to 
Streptomyces species. By 1995, 55% of ca.12000 known antibiotics originated from Streptomycetes 
and another 11% from other Actinomycetes.
[18]
 Amongst them there are a number of commercially 
important drugs (Figure A2) including the antibiotics erythromycin A, produced by 
Saccharopolyspora erythraea, vancomycin, produced by Amycolatopsis orientalis, tetracycline, 
produced by Streptomyces aureofaciens and anticancer agent doxorubicin, produced by Streptomyces 
peucetius.
[19]
 Due to the very successful history of Streptomyces spp. as an exceptional resource of 
pharmaceutically relevant bioactive metabolites, continued investigation of novel bioactive 
compounds with new chemical structures and/or biological activities from Streptomycetes is definitely 
still highly interesting to both natural product researchers and the pharmaceutical industry.  
 
Figure A2. Drugs originating from Streptomycetes. The structure, name, original producer and type of 
application are given.  
 
2.3 Alternative natural product producers  
On the other hand, because of the relatively high probability of hitting a known compound originating 
from the resources having close phylogenetic relationships or living in similar environmental 
conditions, it is assumed that the novel producer classes, such as marine resources and other not 
intensively explored microbes, could correlate to the potentials to chemical novelty. Thus, intensive 
efforts have also been made on discovery of bioactive metabolites originating from other 
microorganisms in the last years. These studies mainly deal with marine bacteria (e.g. marine 
Actinomycetes), cyanobacteria, myxobacteria, and pathogenic bacteria (e.g. Pseudomonads). Among 
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them, myxobacteria showed especially promising potential as proficient producers of novel bioactive 
compounds.
[20]
 The most prominent myxobacterial secondary metabolites by far are the cytotoxic 
epothilones from Sorangium species.
[21]
 In 2007, a semisynthetic epothilone B analogue ixabepilone 
(Ixempra
®
) was approved by the American Food and Drug Administration (FDA) for the treatment of 
breast cancer.
[22]
 
 
3. Biosynthetic logic of microbial natural products 
Up to present, natural products can be mostly classified into five groups based on their structural and 
biosynthetic commonality: terpenoids, alkaloids, polyketides (PKs), nonribosomal peptides (NRPs) 
and ribosomally synthesized and post-translationally modified peptides (RiPPs). Because the latter 
three groups are involved in the present work, they will be introduced in detail below. 
A great majority of microbial natural products are biosynthesized from simple monomeric building 
blocks such as amino acids or short chain carboxylic acids on giant multifunctional enzymes named 
nonribosomal peptide synthetases (NRPSs) and polyketide syntheses (PKSs), respectively.
[23;24]
 
Although they have differences in utilization of building blocks, substrate activation and condensation 
mechanisms, both classes of enzymes share notable similarities in the modular architecture of various 
catalytic domains and assembly-line like mechanism. Based on the so-called “multiple carrier thio-
template mechanism”,[23] PKSs and NRPSs exhibit a multimodular organization consisting of 
repetitive catalytic units called modules, each of which is responsible for incorporation of one specific 
residue into the elongating "ketide" or "peptide" chain. Furthermore, each module can be subdivided 
into domains which represent the catalytic subunits in charge of individual biosynthetic steps of 
precursor loading, condensation, optional modifications and release of final products from the 
assembly line. The central tenet of this model is that chain elongation proceeds while the intermediates 
are tethered via covalent tethering of all the substrates, intermediates and products. For this, each 
carrier protein (CP) domain must be post-translationally modified by a dedicated 
phosphopantetheinyltransferase (PPTase) enzyme which catalyzes the in trans transfer of a 4’-
phosphopantetheine (Ppant) moiety from coenzyme A to a highly conserved serine residue in the CP 
resulting in the conversion of the catalytically inactive apo-CP to active holo-CP (Figure A3).
[25-27]
 
The choice of this thioester chemistry for activation of both acyl monomers and aminoacyl monomers 
provides the thermodynamic driving force and kinetically accessible nucleophiles for the Claisen (in 
case of polyketide) or amide bond (in case of nonribosomal peptide) condensations.
[25]
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Figure A3. The post-translational modification of apo-CP converted to holo-CP by PPTase. 
 
Apart from polyketides (PKs) and nonribosomal peptides (NRPs), ribosomally synthesized and post-
translationally modified peptides (RiPPs) are another major class of natural products that have become 
increasingly more accessible thanks to recent genome sequencing efforts.
[28;29]
 RiPPs are produced by 
all three domains of life, such as lanthipeptides, thiopeptides and microcins from bacteria, amatoxins 
and phallotoxins from fungi, cyclotides and orbitides from plants, conopeptides from cone snails.
[29]
 
Typically, RiPPs are extensively post-translationally modified and thus possess a restricted 
conformational flexibility which endows them with a better target recognition, metabolic stability and 
chemical functionality.
[29]
 Compared to the biosynthetic concept of PKSs and NRPSs, RiPPs 
biosynthesis is initiated by a ribosomally generated precursor peptide encoded by a structure gene. 
After the precursor peptide undergoes a variety of post-translational modifications (PTMs) upon 
binding to the corresponding post-translationally modifying enzymes, a final proteolytic cleavage of 
the leader peptide occurs, leading to the conversion of the precursor peptide into the final product 
which exhibits high chemical diversity and various biological activities. 
In most cases, the genes encoding the biosynthetic pathway of a particular natural product are 
clustered together within the microbial genome. The first proof of this viewpoint was provided by 
Malpartida and Hopwood in 1984.
[30]
 They isolated and cloned a continuous DNA fragment from 
Streptomyces coelicolor which contained complete genetic information required for biosynthesis of the 
antibiotic actinorhodin. It turned out that the cloned DNA fragment could not only complement the 
production of actinohodin in the non-producing mutants, but also be heterologously expressed in 
Streptomyces parvulus. Based on this rule, researchers could easily identify the biosynthetic gene 
cluster of natural products through single gene localization by straightforward chromosomal walking. 
Typically these gene clusters also harbour transcriptional regulators and genes responsible for self-
resistances in upstream or downstream areas.
[31]
 However, many examples of split gene clusters are 
firstly found in myxobacteria.
[32-35]
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3.1 Biochemistry of nonribosomal peptide synthetases  
A minimal functional NRPS module requires three essential domains: an adenylation (A) domain, a 
peptidyl carrier protein (PCP) domain, also referred to a thiolation (T) domain and a condensation (C) 
domain. Every cycle of chain elongation is initiated by the action of an A domain which specifically 
selects, activates and transfers an amino acid to the PCP domain in the same module.
[36]
 In addition to 
20 proteinogenic amino acids, various nonproteinogenic amino acids and aryl acids can also be 
recognized and processed as monomeric building blocks. This fact endows nonribosomal peptides 
(NRPs) with a large diversity of chemical structures and biological activities. The specificity of A 
domains towards corresponding amino acids play a crucial role in the peptide sequence of the final 
natural product and the biological activity as well. A successful crystallization and structural analysis 
of a prototype A domain with its amino acid substrate and ATP revealed the structural basis of 
substrate recognition and activation.
[37]
 Combined with primary sequence alignment analyses to other 
A domains, 8-10 amino acids within the substrate binding pocket could be identified. These residues 
could be defined as specificity-conferring code for substrate prediction of NRPSs.
[38]
 After the amino 
acid residue is transferred to the PCP domain, the C domain subsequently catalyzes the peptide bond 
formation between an amino acyl or peptidyl-S-PCP intermediate from the upstream module to the 
amino acyl moiety attached to the respective downstream module. As a result, the peptide chain is 
elongated via one amino acid residue and the product is tethered covalently to the downstream PCP 
domain. The peptide chain extension can be followed to the last module in the same fashion. In most 
cases, a fourth domain, the thioesterase (TE) domain, turns out to be essential for final product release 
from the biosynthetic template. A TE domain is usually located at the C-terminus of the last 
biosynthetic module and catalyzes the release of product from the assembly line in linear, cyclic or 
branched cyclic forms.
[39;40]
 All reactions catalyzed by essential NRPS domains are schematically 
summarized in Figure A4. 
In addition to the domains described above, a number of optional domains have also been found in 
NRPSs which can contribute to structural diversity of NRPs. For example, the methylation (MT) 
domain can catalyze the transfer of a methyl group from S-adenosyl-L-Methionine (SAM) to the 
nitrogen or carbon atom of a PCP-bound amino acid.
[41]
 The epimerization (E) domain can convert the 
thioester-bound amino acid of an amino acyl-S-PCP or a peptidyl-S-PCP from L- into D- 
configuration.
[42;43]
 Heterocyclization (HC) domain is a substitution of the usual C domain in modules 
incorporating threonine, serine and cysteine residues. HC domains catalyze not only the peptide bond 
formation but also mediate the formation of the five-membered thiazoline or oxazoline 
heterocycles.
[44;45]
 Thiazoline or oxazoline heterocycles are often further oxidized to thiazoles or 
oxazoles by oxidation (Ox) domains using flavin mononucleotide (FMN) as a cofactor.
[46]
 It is 
noteworthy that Ox domains are strictly associated with the presence of HC-domains.
[23]
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Figure A4. Schematic display of NRPS biochemistry.  
 
3.2 Biochemistry of polyketide synthases 
Analogous to NRPSs, a minimal functional PKS module also requires three essential domains: an 
acyl-transferase (AT) domain, an acyl carrier protein (ACP) domain and a,β-ketoacyl synthase (KS) 
domain. Typically, a PKS module contains all the three domains except the loading module, which is 
responsible for initiating the selection of starter units of modular PKS (referred to as type I PKS, other 
types of PKSs are introduced below). Two architectures have been found to date: one type of loading 
module contains all the three domains, of which the KS domain is catalytically inactive because the 
active site cysteine residue is replaced by a glutamine residue, commonly referred to as a KS
Q
 
domain.
[47]
 In this case, the AT-KS-ACP architecture selects malonyl-CoA or methylmalonyl-CoA 
followed by decarboxylation catalyzed by a KS
Q
 domain yielding acetate or propionate as a starter unit. 
Another type of loading module consists of an AT and an ACP domain. In this case, the AT domain 
directly selects a coenzyme A activated short chain (e.g. acetyl-CoA, propionyl-CoA), a branched-
chain or an aromatic monocarboxylic acid.
[48-50]
 After the processing of loading modules, the starter 
unit is delivered onto the KS domain of the next extension module. In extension modules, different 
from the A domain of NRPS, by which the selected building block is activated via consumption of 
ATP, the AT domain prefers to select the pre-activated CoA thioesters of short dicarboxylic acids (e.g. 
malonyl-CoA and methylmalonyl-CoA) as extender units which then get transferred to the 
corresponding ACP domain of the same module. However, there is growing evidence for the 
biosynthesis and incorporation of unusual extender units such as hydroxylmalonyl-CoA, 
methoxylmalonyl-CoA, aminomalonyl-CoA, ethylmalonyl-CoA and chloroethylmalonyl-CoA.
[51-55]
 
Similar to the PCP domain of NRPSs, the ACP domain is responsible for the transport of building 
blocks and is involved in the elongation of intermediates while the KS domain catalyzes the elongation 
reaction via the condensation between extender unit and the growing chain. The reaction is initiated 
with the transfer of the acyl-S-ACP intermediate of an upstream module to the conserved cysteine 
residue of the KS domain. Meanwhile, the KS domain catalyzes the decarboxylation of the extender 
unit tethered to the ACP of the corresponding module, resulting in a nucleophilic attack on the 
thioester of the ketide chain tethered to the cysteine residue of the KS domain. Via this condensation 
step a C2-unit extended β-keto-acyl-S-ACP intermediate is formed.
[23;56]
 Following the same path, this 
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prolonged intermediate is further transferred to the KS domain of next module and undergoes a chain 
elongation reaction again. All reactions catalyzed by essential PKS domains are schematically 
summarized in Figure A5. 
Similar to NRPs, to enhance the structural diversity PKSs also contain a variety of optional domains 
acting on β-keto groups in certain modules after the chain elongation step.[57] The auxiliary domains of 
the PKS mainly refer to the ketoreductase (KR) domain, the dehydratase (DH) domain and the 
enoylreductase (ER) domain. All three domains can stepwise reduce the β-keto moiety before transfer 
onto the KS domain of next module. The KR domain catalyzes the reduction of a β-keto group to a β-
hydroxyl group by using the cofactor nicotinamide adenine dinucleotide phosphate (NADPH). 
Subsequently, this β-hydroxyl intermediate can be further dehydrated resulting in an α,β-enoyl 
intermediate which can be fully reduced into a saturated acyl chain by the ER domain which also uses 
NADPH as cofactor. 
In addition to type I modular PKS, type II and type III PKS systems are also found in nature. Type II 
PKS contains a series of discrete monofunctional enzymes forming a multienzyme complex, which is 
employed iteratively to produce polycyclic, aromatic natural products.
[57]
 Type III PKS use a single 
catalytic activity including decarboxylation, condensation, cyclization and aromatization to 
accomplish the whole biosynthesis process.
[58;59]
 Another distinct difference between type III PKS and 
other two types lies in that they use CoA-esters as substrates instead of acyl-S-ACP intermediates. 
 
 
Figure A5. Schematic display of PKS biochemistry.  
 
3.3 PKS/NRPS or NRPS/PKS hybrids 
The similar structural organization and catalytic logic between PKS and NRPS make the cooperation 
of these multimodular enzymes possible. The combination of PKS and NRPS allows for immense 
variety of structures. The biosynthetic mechanisms of these PKS and NRPS hybrids could be 
classified into two types.
[60;61]
 The first type refers to no functional interactions between PKS and 
NRPS. In this case, the PKS and NRPS moieties are independently biosynthesized and finally coupled 
together by discrete enzymes. The phytotoxic coronatine biosynthetic pathway in Pseudomonas 
syringae is a representative for this type of hybrid system.
[62-64]
 A putative ligase is proposed to 
catalyzed the final combination of coronafacic acid (PK part) and the coronamic acid (NRP part) 
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which are separately synthesized. Another type of PKS/NRPS hybrid system refers to the functional 
interactions between PKS and NRPS modules, meaning that a NRPS-bound peptidyl intermediate is 
directly transferred and elongated further by a PKS module or a PKS-bound acyl intermediate is 
directly transferred and subsequently elongated by a NRPS module. To date, quite a number of natural 
products have been discovered to follow such a type of PKS and NRPS hybrid pathway.
[55;65-68]
 In this 
case, the intermodular communication is critical for the functionality of the hybrid systems. For a 
PKS/NRPS interface, the C domain of NRPS must recognize the upstream acyl intermediate and 
catalyze the condensation between the ketide chain bound to the upstream ACP domain and the amino 
acid bound to the downstream PCP domain. Analogous, for a NRPS/PKS interface, the KS domain 
must accept the peptidyl intermediate bound to upstream PCP and condense it with the downstream 
acyl-S-ACP. Besides, another crucial factors for a functional hybrid system lie in the availability of a 
PPTas with a broad substrate specificity which can activate both types of CPs (ACPs and PCPs). To 
date, several biochemically characterized PPTases (MtaA, Sfp, Svp) turned out to be able to activate 
both ACPs and PCPs.
[69-71]
   
 
3.4 Biochemistry of ribosomally synthesized and post-translationally modified peptides 
In most cases, biosynthesis of ribosomally synthesized and post-translationally modified peptides 
(RiPPs) starts with a linear precursor peptide 20 - 110 residues in length which is encoded by a so-
called structure gene.
[29]
 Precursor peptides can be further subdivided into different functional 
segments: core peptides, leader peptides, optional recognition sequences and signal sequences.
[29]
 Core 
peptides comprise all the amino acid residues that will be transformed into a mature natural product. 
Leader peptides, which are predominately appended to the N-terminus of core peptides, guide the 
biosynthetic process by recognition of post-translational modification (PTM) enzymes and export of 
final products.
[72]
 In eukaryotes, an additional signal sequence located at the C-terminus of the leader 
peptide is often responsible for directing intermediates to appropriate cellular compartments where the 
PTMs occur. Sometimes the precursor peptide also contains an optional recognition sequence at the C-
terminus for excision and cyclization to form the final product.
[73-75]
 A typical RiPPs biosynthetic 
pathway is displayed in Figure A6. 
The tremendous post-translational modifications are the outstanding feature of RiPPs. Along with the 
explosion of genome data, it has been revealed that many RiPP biosynthetic pathways employ the 
common enzymes to realize post-translational modifications. Just to name some of them, radical-SAM 
dependent methyltransferases encoding genes exist in thiopeptides
[76]
 and proteusins
[77]
 biosynthetic 
pathways, oxazoline/oxzaole and thiazoline/thiazole forming enzymes are found to participate in 
biosynthesis of thiopeptides
[76;78-81]
 and linear azole-containing peptides (LAPs),
[81-83]
 serine/threonine 
dedydratase that is commonly involved in lanthipeptides biosynthesis can also been used in 
proteusins,
[77]
 thiopeptides and LAPs biosynthesis,
[79;80;84;85]
 N- to C- (head to tail) heterocyclization 
occurs in biosynthesis of cyanobactins,
[86]
 amatoxins,
[87]
 bacteriocins,
[88]
 cyclotides
[89]
 and 
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lanthipeptides.
[90]
 Besides, various sulfur chemistry including the conversion of thiols of cycteine to 
disulfides, thioethers or sulfxides are involved in biosynthetic processes of lanthipeptides, cyclotides, 
thiopeptides, LAPs and cyanobactins, etc.
[29]
 The great variety of post-translational modifications 
endow the RiPPs with immense structural stability and diversity as well as high potential to valuable 
bioactivities.  
 
Figure A6. Schematic overview of a general RiPP biosynthetic pathway. 
 
4. Ways to produce and manipulate natural products  
Despite the simplicity of building blocks needed for assembly of PKs, NRPs or RiPPs, such as short 
chain carboxylic acids, amino acids and aryl acids, the structural complexity including numerous 
oxygen-containing substituents and an abundance of stereo centers extremely constrains their chemical 
syntheses route.
[91]
 Thus, microbial fermentation to generate these natural products is obviously much 
more economical and time-saving. However, this approach also faces various difficulties, e.g., low 
yield of target product in the native producer, tough cultivation conditions of the native producer or 
lack of genetic manipulation accessibility of the native producers.
[92;93]
 All of those leave the 
mobilization and expression of the corresponding biosynthetic gene cluster into an amenable 
heterologous host as a sufficient alternative to generate the desired natural product with improved 
yield and further allow the characterization and genetic engineering of the biosynthetic pathway for 
the generation of novel derivatives. In addition, establishment of a heterologous expression system can 
also elucidate the role of cryptic or silent gene clusters uncovered by genome sequencing projects in 
the post-genomics era.
[93]
  
 
4.1 Heterologous expression: General aspects 
With respect to heterologous expression of complex natural products, several general considerations 
should be taken into account: 1) identification of the corresponding biosynthetic pathway in the 
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original producer. In the past decade, plenty of natural product biosynthetic gene clusters have been 
revealed from the increasing amount of genome sequencing data.
[94]
 In silico identification and 
verification of the corresponding biosynthetic gene clusters from the genome sequences becomes a 
prerequisite for performance of heterologous expression; 2) a suitable vector containing the genetic 
elements of DNA transfer and integration into the host chromosome, functional promoter architecture, 
and the corresponding regulatory elements in the related host are also required. Traditionally, genomic 
libraries are constructed by using cosmids/fosmids that can bear an insert of size 30-35 kb or a 
bacterial artificial chromosome (BAC) that can accept an insert over 100 kb; 3) an amenable 
heterologous host is the most important aspect to be considered. First, the phylogenetic distance 
between the native producer and heterologous host should be considered. Generally, the more closely 
related the heterologous host is to the original producer, the more efficient is the transcriptional 
functionality of the biosynthetic pathway. Besides, closely related species may also share similar 
codon usage to the native producer, which may assure translational efficiency. With respect to 
heterologous expression of PKs and NRPs, the host must be able to post-translationally modify the 
giant multifunctional enzymes resulting in their active holo form, which is catalyzed by a suitable 
PPTase with broad specificity (Figure A3). Additionally, a pool of required precursors comprising 
CoA-activated short chain carboxylic acids, proteinogenic and nonproteinogenic acids must be 
supplied in adequate quantities to the host. Lastly, the aspect of self-resistance has to be considered, 
especially in cases where the target product exhibits antibacterial activity corresponding genes 
responsible for self-resistance are necessary to be transferred into host strain.
[93;95]
 All these aspects 
have been elaborated on in recent reviews.
[93]
 
It is noteworthy to state that even if all the elements described above have been taken into account, a 
successful and sufficient expression of a complex heterologous biosynthetic pathway still cannot be 
guaranteed in reality. This could be explained by several reasons, e.g., the expression levels of 
enzymes involved in the pathway in the heterologous host are different and they could require very 
diverse optimal expression conditions,
[93]
 or that the complex regulatory system does not work as well 
as in the native producer, etc. Thus, further genetic engineering is desired to optimize the heterologous 
expression levels and eventually generate novel derivatives.  
 
4.2 Genetic engineering of expression constructs 
First of all, the common problem for genetic manipulation of the large natural product pathways is that 
they cannot be modified by classical restriction enzymes. A very efficient and straightforward method 
Red/ET technology is quite beneficial to solve this problem. Red/ET recombineering is an in vivo 
technique that can be employed to specifically and precisely target the DNA molecules by 
homologous recombination using short homologous arm sequences in Escherichia coli mediated by 
phage-derived protein pairs, RecE/RecT from Rec phage or Redα/Redβ from lambda phage (Figure 
A7).
[96;97]
 Compared to conventional cloning technologies, Red/ET recombineering is completely 
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independent of DNA restriction enzymes. Furthermore, since the short homologous arm sequences can 
be synthesized chemically, in principle, any nucleotide of target DNA (cosmid, fosmid and BAC) can 
be altered by a variety of modifications, e.g., insertion, deletion, fusion, point mutation, sub-cloning or 
direct cloning.
[98-100]
  
A number of successful examples have been accomplished in our group using Red/ET technique for 
expression and engineering of large biosynthetic pathways. In 2005, a method was developed by 
Wenzel, et al. to reconstitute the hybrid NRPS and PKS myxochromide S pathway from 
myxobacterium Stigmatella aurantiaca on one expression construct and heterologously express 
myxochromide in Pseudomonas putida resulting a much higher yield of native producer.
[92]
 Perlova, et 
al. also used Red/ET to stitch together two cosmids containing the entire myxothiazole biosynthetic 
pathway and heterologously expressed myxothiazole in Myxococcus xanthus
[101]
 as well as 
Pseudomonas putida.
[102]
 In last ten years, further examples showed how efficient and promising this 
technique is for construction of large complex biosynthetic pathways and subsequent heterologous 
expression.
[103-106]
 
 
 
Figure A7. Mechanism of Red/ET recombination. 
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5. Generation of “unnatural” natural products via synthetic biotechnology 
Oftentimes natural products are a very promising starting points for drug discovery; however, due to 
their physicochemical properties they are usually far from being ideal for clinical application.
[107]
 Thus, 
analogue development of natural products is necessary to improve the bioavailability as well as the 
bioactivity. In addition, to fully understand the natural products’ mode of action based on the 
structure-activity relationship (SAR) studies a library of natural product analogues are often required 
to determine the essential functional groups for activity. Whilst the increasingly released genome data 
and fast development of genetic engineering and manipulation methods the combined use of biological 
and chemical tools to establish a natural products library are increasingly approached in comparison to 
the traditional total synthesis.
[108;109]
 There are several successful approaches that have been employed 
to generate a variety of natural product analogues. Among them, the precursor-directed biosynthesis 
and mutasynthesis that have been used in this thesis will be introduced in detail below (Figure A8).  
The application of precursor-directed biosynthesis to natural products analogues generation, although 
an old concept, has been increasingly utilized over the past decade.
[107]
 It makes use of the tolerant 
flexibility of natural product biosynthetic enzymes enabling the acceptance of unnatural building 
blocks resulting in altered various unnatural products. Once the biosynthetic logic and its substrate 
specificity are well understood, unnatural precursors can be rationally designed, chemically 
synthesized and subsequently fed into the growth media of corresponding microorganisms. They are 
subsequently incorporated in the biosynthetic pathways due to substrate flexibility of the biosynthetic 
enzymes. By this approach, natural product analogues can be obtained through feeding of designed 
unnatural building blocks into the culture of the wild type producer. Therefore, the most limiting factor 
of this approach lies in the flexibility of substrate specificity. Moreover, the production of those 
analogues is always competing with that of the natural products which often leads to an insufficient 
yield of the unnatural analogues. Furthermore, owing to the structural similarity between the natural 
and unnatural products, the alongside produced native natural products make the downstream 
chromatographic separation more challenging and time-consuming. A representative example is the 
generation of analogues of antibiotic diazepinomycin. Ratnayake, Carter and coworkers demonstrated 
that the diazepinomycins are biosynthesized from tryptophan and anthranilate, which inspired 
researchers to explore whether the biosynthetic enzymes could be flexible to incorporate non-native 
analogues of these two precursors.
[110]
 Thus, they conducted the precursor-directed biosynthesis 
approach by feeding 4-, 5-, and 6-F-tryptophans and various 5-halo-anthranilates individually to the 
cultures of Micromonospora sp. DPJ15. It turned out that the biosynthetic assembly line could 
sufficiently incorporate the 5-, 6-F-tryptophans and 5-F-anthranilate into the assembly line while the 
administrated 5-Cl-anthranilate, 5-Br-anthranilate and 5-I-anthranilate were not utilized as 
substrates.
[110]
 The selective incorporation of fed non-native precursors and relatively low 
incorporation rates corroborates that the precursor-directed biosynthesis approach is dependent on the 
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flexibility of the biosynthetic assembly line and the yield of generated novel derivatives is limited by 
the competition from the native compound. 
 
 
Figure A8. Schematic display of concepts of precursor-directed biosynthesis and mutasynthesis.  
 
Another often applied strategy for the generation of natural product analogues is mutasynthesis. This 
concept was first raised over 40 years ago using mutants of antibiotic neomycin producer 
Streptomyces fradiae to generate novel antibiotics.
[111]
 Since then, this strategy has been applied to 
many other classes of compounds including siderophores,
[112]
 nucleosides,
[113]
 nonribosomal 
peptides
[114;115]
 and polyketides.
[116]
 In this case, the target biosynthetic pathway is blocked at a crucial 
step in corresponding mutants, which are able to employ unnatural building blocks into the 
biosynthetic pathway to jump-start the assembly line yielding unnatural analogues of interest. The 
major approach to mutasynthesis is the disruption of the essential gene(s) responsible for biosynthesis 
combined with feeding of the corresponding intermediates (so-called mutasynthons) to complement 
the production of the novel unnatural compounds upon the fed substrates.
[117]
 Similar to precursor-
directed biosynthesis mutasynthesis is also dependent on the substrate flexibility of the natural 
biosynthetic enzymes. However, compared to precursor-directed biosynthesis the advantage of this 
approach lies in that there is no competition with the production of natural compounds at all, which 
allows a sufficient yield of the unnatural products and a simplified downstream compound separation 
process. This approach potentially allows the assessment to generation of a library of unnatural 
compounds. With respect to this, Moore and his colleagues employed this strategy to generate the 
fluorinated analogues to salinosporamides, a family of chlorinated compounds from Salinispora 
tropica CNB-440 exhibiting a highly potential proteasome inhibitory activity from.
[118-120]
 Moore and 
colleagues disrupted the salL gene encoding the chlorinase and subsequently complemented the salL-
deficient mutant with chemically synthesized 5’-fluoro-5’deoxyadenosine (5’-FDA). The resultant 
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fluorosalinosporamide was able to serve as a reversible inhibitor with a much greater activity than 
deschlorosalinosporamide.
[121;122]
 
In addition to precursor-directed biosynthesis and mutasynthesis, semi-synthetic approaches, 
combinatorial biosynthesis, post-biosynthetic modification and chemogenetics, etc. have also been 
increasingly applied for the generation of natural product analogues.
[107]
 A combinatorial application 
of these biological and chemical tools is becoming more popular and productive than using a single 
approach. 
 
6. Outline of the dissertation  
The overall goal of the work described in this thesis dealt with study and engineering of natural 
product biosynthetic pathways from Streptomycetes. Two novel bioactive compound families have 
been intensively studied: the cytotoxic and antifungal cinnabaramides from Streptomyces sp. JS360 
and the antibacterial bottromycins from Streptomyces sp. BC16019, both of which represent promising 
lead structures for potential drug development.
[123-126]
  
The cinnabaramides (Figure A9) are mixed PKS and NRPS natural products, which were recently 
isolated from a terrestrial Streptomycete Streptomyces sp. JS360.
[123]
 They interfere with the 
proteasome and thus potentially inhibit the growth of cancer cells. The compounds exhibit a γ-lactam-
β-lactone bicyclic ring structure attached to a cyclohexenyl unit and a hexyl side chain originating 
from an unusual PKS extender unit.
[123]
 Apart from the hexyl side chain, significant structural 
similarity was found between cinnabaramide and the salinosporamides containing a chlorinated ethyl 
side chain instead (Figure A9). Salinosporamides are a class of antitumor compounds produced by 
Salinispora tropica CNB-440.
[127-129]
 The salinosporamides exhibit potent cancer cell cytotoxicity and 
exert their effects via binding to the 20S proteasome core particle, thereby inducing cell-cycle arrest 
and programmed cell death (apoptosis).
[130]
 The mode of action studies of salinosporamides 
demonstrated that the key to the superior activity lies in the chlorine atom attached to the side chain 
which is required for the irreversible binding to the target.
[131]
  
 
Figure A9. Structures of cinnabaramides produced by Streptomyces sp. JS360 and salinosporamide A 
produced by Salinispora tropica. 
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Thus, we intended to generate chlorinated analogues of the cinnabaramides and screen their 
bioactivities after mining the cinnabaramide gene cluster with subsequent genetic and molecular 
engineering approaches. These results were described in publication I and publication III. 
Meanwhile, we intended to determine the formation of the unusual extender unit incorporated into the 
PKS pathway. One key enzyme encoded by cinF, a gene involved in the downstream processing of the 
cinnabaramide biosynthetic gene cluster, was supposed to be responsible for the formation of the 
unusual extender unit hexylmalonyl-CoA in the PKS assembly line. Therefore, biochemical and 
structural characterization of this enzyme was planned to figure the detailed reaction mechanism out. 
All the data and analyses were reported in publication II. 
The second part of this thesis refers to the in-depth studies on the biosynthetic pathway of the highly 
modified octapeptide bottromycins (Figure A10). Bottromycins were first discovered as antibacterial 
peptides with promising activity against Gram-positive bacterial and mycoplasma from the 
fermentation broth of Streptomyces bottropensis.
[126;132-135]
 Later on it was shown that their 
antibacterial ability extends to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant Enterococci (VRE).
[136]
 Mode of action studies revealed the aminoacyl-tRNA binding site (A 
site) on the 50S ribosome as the target of bottromycins ultimately leading to the inhibition of protein 
synthesis.
[137-139]
 Bottromycins represent octapeptides exhibiting an internal tetrapeptide cycle formed 
via a unique amidine linkage. Furthermore, the compound harbors an exo-thiazole and several 
unnatural amino acids which carry methyl-groups at non-activated carbons posing additional 
challenges for synthetic approaches aimed towards drug development. In this work, we intended to 
improve the structure and production yield using synthetic biotechnological approaches. To achieve 
this goal, the biosynthetic genes from Streptomyces sp. BC16019 were firstly identified by Dr. Shwan 
Rachid. This work uncovered a ribosomal locus required for bottromycin biosynthesis and identified 
bottromycins as a novel class of RiPPs exhibiting a variety of unprecedented features exemplified by 
the absence of a N-terminal leader sequence on the structure gene. After establishment of a 
heterologous expression platform, the yield was optimized and novel bottromycin analogues were 
identified using synthetic biotechnology approaches. In addition, some evidences for the formation of 
the exo-thiazole ring and a rare macrocyclodehydration mechanism leading to amidine ring formation 
was also provided. All the results were presented in publication IV. 
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Figure A10. Structures of bottromycin A2 and B2 produced by Streptomyces sp. BC16019. Intriguing 
structure features were highlighted in gray. 
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Introduction
Natural products continue to fulfill their enormous potential in
the development of future drugs and to serve as compounds
of interest both in their natural forms and as semisynthetic or
synthetic derivatives. Drugs derived from natural products are
used for therapy for more than 87% of human diseases, and
include anticancer, antifungal, antibacterial, anticoagulant, anti-
parasitic, and immunosuppressant agents, amongst others.[1,2]
An important role in drug discovery in the past century has
been played by microorganisms, in particular bacteria of the
genus Streptomyces, which produce secondary metabolites in
unprecedented chemical diversity, exhibiting a remarkable
array of biological activity. Many of them are clinically valuable
agents.[3, 4] The metabolites isolated from this genus are mostly
end products of the enzymes of two major types of biosyn-
thetic pathways: the non-ribosomal peptide synthetases
(NRPSs) and the polyketide synthases (PKSs).[4] NRPSs and PKSs
are made up of so-called modules, which are sets of distinct
active sites for catalyzing each condensation and chain-elonga-
tion step.[5,6] Each module in an NRPS or a PKS consists of cer-
tain obligatory or core domains for addition of each peptide or
ketide unit and a variable number of optional domains respon-
sible for modification of the peptide/ketide backbone.[7,8]
The terrestrial Streptomyces sp. JS360 is known to produce
cinnabaramides A–G, each exhibiting a g-lactam-b-lactone bi-
cyclic ring structure attached to a cyclohexenyl unit, together
with a hexyl side chain.[9] With the exception of the hexyl side
chain, significant structure similarity was found between these
compounds and the salinosporamides (Scheme 1), a class of
PKS/NRPS antitumor metabolites isolated from the marine acti-
nomycetes Salinispora tropica CNB-440[10–12] and Salinospora
The cinnabaramides and salinosporamides are mixed PKS/
NRPS natural products isolated from a terrestrial streptomycete
and a marine actinomycete, respectively. They interfere with
the proteasome and thus potentially inhibit the growth of
cancer cells. The compounds exhibit a g-lactam-b-lactone bi-
cyclic ring structure attached to a cyclohexenyl unit and a PKS
side chain. As a first step towards improving anticancer activity
and permitting genetic approaches to novel analogues, we
have cloned and characterized the cinnabaramide biosynthetic
genes from Streptomyces sp. JS360. In addition to the expected
PKS and NRPS genes, the cluster encodes functionalities for
the assembly of the hexyl side chain precursor. The corre-
sponding enzymes exhibit relaxed substrate specificities to-
wards a number of synthesized precursors, enabling produc-
tion of novel chlorinated cinnabaramides. These were isolated
and analyzed for activity, revealing that derivatives bearing a
chlorine atom in the PKS side chain show higher inhibitory po-
tentials towards the proteasome’s proteolytic subunits (espe-
cially the trypsin and chymotrypsin units) and higher cytotoxic-
ities towards human tumor cell lines than the parent cinnabar-
amide A. Although their activities towards the proteasome
were weaker than that of salinosporamide A, the cinnabara-
mides were found to inhibit the growth of various fungi with
greater potency.
Scheme 1. Structures of cinnabaramides and salinosporamides. A) Cinnabar-
amide A (R1=OH, R2=H), cinnabaramide B (R1=R2=OH), and cinnabara-
mide C (R1=R2=H). B) Cinnabaramide D (R1=R2=OH) and cinnabaramide E
(R1=OH, R2=H). C) Salinosporamide A (R=Cl) and salinosporamide B
(R=H).
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pacifica CNT-113.[13] Both cinnabaramides and salinosporamides
exhibit potent cancer cell cytotoxicities and exert their effects
through binding to the 20S proteasome core particle, thereby
inducing cell cycle arrest and programmed cell death (apopto-
sis).[9, 14–16] The key to the superior activity of salinosporamide A
versus the cinnabaramides is assumed to be the presence of
the chlorine atom attached to the side chain, which is required
for the drug’s irreversible binding to its biological target and is
thus a major reason for the compound’s effectiveness against
cancer.[17]
We anticipated that the factor behind the varying side
chains in the two compound classes should be a biosynthetic
enzyme responsible for forming a hypothetical and unusual
hexylmalonyl-CoA extender unit. By mining the substrate toler-
ance of this enzyme towards chlorinated and unsaturated fatty
acid-CoA esters and using feeding experiments we succeeded
in generating chlorinated analogues of the cinnabaramides
and in analyzing their bioactivities.
Results and Discussion
To achieve our goal, we first set out to identify the biosynthetic
machinery of cinnabaramides. Because the overall structure of
cinnabaramides is suggestive of a biosynthetic origin based
upon PKS and NRPS machinery and because the gene cluster
for salinosporamides (sal) is known,[18] a cosmid library was
constructed from the genome of strain JS360 and screened for
the corresponding gene cluster in an approach based on
hybridization with degenerated PKS and NRPS (as described in
the Experimental Section).
Within the identified cin gene cluster, at least six likely struc-
tural genes were designated cinA–F, encoding two PKS mod-
ules and a split NRPS module distributed over the first two
genes (cinA and cinB), followed by a standalone ketosynthase,
a P450 monooxygenase, a standalone thioesterase, and a
homologue of crotonyl-CoA carboxylase/reductase (Ccr; cinF)
(Table 1 and Scheme 2A), which can be assigned to roles in
cinnabaramide core biosynthesis. Further genes are encoded
upstream and downstream of the gene cluster and would be
expected to be involved in production of the biosynthesis pre-
cursors (cinQ and cinP), post-assembly-line modification of the
compound (cinL), bacterial resistance against the compound
(cinJ), and regulation of the gene cluster (cinRI and cinRII)
(Table 1). It is likely that the biosynthesis of cinnabaramides is
carried out in a thiotemplated fashion, in which intermediates
are covalently tethered to phosphopantetheinyl arms of carrier
proteins (Scheme 2B).[19] CinA consists of an atypically arranged
starter module and one extension module (ACP-KS-AT1-AT2-
ACP-C). We assume that the initiation step is selection and
loading to the ACP of the starter unit acetyl-CoA by the first
AT domain. According to the chemical structure of the com-
pound, the second PKS module catalyzes chain elongation of
acetyl-S-ACP with the unusual extender unit hexylmalonyl-S-
ACP and results in the incorporation of the hexyl side chain. A
bioinformatics-based approach to identify the substrate specif-
icity of CinA-ATs, in comparison with the ATs of other biosyn-
thetic pathways,[20] indeed showed conserved residues in the
ATs implicated in binding of dicarboxylated extender units
(Table 1). Interestingly, the substrate specificity of AT1 is pre-
dicted to be for acetyl-CoA and the conserved residues are
almost identical to the salinosporamide domain. AT2, however,
is different from AT2 in its salinosporamide counterpart. Unex-
pectedly, it also differs from the hexylmalonyl-CoA-specific
TugC-AT3 (Table S1B in the Supporting Information) involved in
the biosynthesis of thuggacins—macrolide antibiotics bearing
hexyl side chains—from the myxobacterium Sorangium cellulo-
sum So ce895, which are also produced through a NRPS/PKS
biosynthetic pathway.[21–23]
The C-terminal domains of CinA and CinB form the terminal
NRPS module of the assembly line, and the highly homologous
domain set in the salinosporamide gene cluster is known to
activate the nonproteinogenic amino acid b-hydroxy-2’-cyclo-
hexenylalanine.[12,24] Because of the structural similarity of the
two compounds, and because the deduced substrate specifici-
ty code of the CinB A domain (DLMNVGGV; determined as
described previously[25,26]) showed a significant degree of simi-
larity to that of the SalB A domain (DLLSNGGV), we propose
elongation of the cinnabaramide intermediate by extension
with b-hydroxy-2’-cyclohexenylalanine (Scheme 2B). The result-
ing PCP-tethered cinnabaramide intermediate is then thought
to undergo an intramolecular condensation promoted by the
ketosynthase (CinC) to generate the g-lactam ring, which pro-
vides the CinB-bound alcohol substrate that gives rise to the
offloaded b-lactone product. It is assumed that the standalone
CinE catalyzes release and cyclization of the intermediate to
generate the b-lactone ring of the compound. The gene clus-
ter harbors genes (cinQ and cinP) that encode putative l-
amino acid aminotransferases and a prephenate dehydratase,
respectively (Table 1). Similar enzymes have also been de-
scribed in the salinosporamide biosynthesis pathway—it was
suggested that these were involved in cyclohexenyl-alanine
building block formation—and inactivation of a prephenate
dehydratase homologue gene (salX) in the sal cluster led to
the elimination of all natural salinosporamides.[12,27]
It has been reported that the salinosporamide biosynthetic
enzymes responsible for the activation and incorporation of
the native sal-specific amino acid exhibit relaxed substrate spe-
cificities towards a number of aliphatic amino acids.[28] In that
work, Moore and co-workers used a comprehensive approach
that combined chemical synthesis with metabolic engineering
to generate a series of salinosporamide analogues with altered
bioactivities against human cancer cell lines. Two salinospora-
mide derivatives with saturated cyclohexane or cyclopentane
rings were prepared by mutasynthesis, through administration
of derivatives and branched-chain amino acids to a culture of
the S. tropica salX mutant strain.[29]
To establish the function of cinQ in the salinosporamide
gene cluster we inactivated the gene by insertion of an inacti-
vation plasmid (pCN2) into the Streptomyces JS360 genome,
leading to complete elimination of cinnabaramide biosynthesis
in the mutant. When we attempted to restore product forma-
tion by feeding cyclopentyl-dl-alanine to the culture, new
compounds exhibiting the expected masses were indeed de-
tected. NMR spectroscopic examination of the purified cinna-
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baramide A analogue (C18H29NO4: m/z : 324.2 [M+H]
+) revealed
that the derivatives made by mutasynthesis were novel cinna-
baramides each carrying a cyclopentyl instead of cyclohexenyl
ring (Table S1 and Figures S1 and S4).
Because the cinD gene encodes a putative cytochrome P450
enzyme we suggest that this enzyme is involved in post-
assembly-line hydroxylation of the compound to produce the
b-hydroxycyclohex-2-enylalanine residue in cinnabaramides A,
B, D, and E.
Administration of deuterated cyclohexenyl-serine to the cul-
ture of Streptomyces JS360 showed no incorporation of the
compound into the cinnabaramides, which indicates that the
cinnabaramide biosynthesis enzymes exhibit no tolerance
toward alteration in the b-position of the amino acid precursor.
Interestingly, the salinosporamide megasynthetase was shown
to tolerate both secondary and tertiary carbons in the g-posi-
tion of the amino acid precursor, but substitution in the b-
position was also not accepted.[12] The authors suggested that
the latter substitution might directly affect the function of the
cytochrome P450 enzyme (SalD) in the pathway.
A second copy of a cytochrome P450 is encoded by cinL in
the upstream region of the cin gene cluster (Table 1). Because
cinL shows no counterpart in the salinosporamide pathway we
suggest that the corresponding protein plays a role in hydrox-
ylation of cinnabaramides B and D at C12, whereas cinD is
responsible for production of the C5 hydroxy functionality in
A, B, and D (Scheme 2B).
After identifying the biosynthetic pathway of cinnabara-
mides, we predicted that the hexyl side chain of the com-
pound might originate from a hexylmalonyl-CoA extender unit
(Schemes 2B and 3A). This assumption was based on previous
observations in other biosynthetic pathways involving unusual
Table 1. Deduced functions of the ORFs identified within the cinnabaramide gene cluster based on percentage sequence similarity/identity to previously
known proteins as well as to the salinosporamide biosynthetic gene cluster determined by use of BLAST searching and clustalW alignment.
Gene Protein Residues
[aa]
Proposed function Sequence identity/similarity to [%][a] Accession
number
Sequence identity/similarity to
Salinispora tropica CNB-440[18] [%][b]
cinA CinA 2040 PKS/NRPS (ACP1-KS-AT1-
AT2-ACP2-C)
SalA, PKS/NRPS, Salinispora tropica CNB-440,
62/72
ABP73645 SalA, PKS/NRPS, 60/71
cinB CinB 585 NRPS (A-ACP) SalB, NRPS, Salinispora tropica CNB-440, 66/76 ABP73646 SalB, NRPS, 61/71
cinC CinC 596 ketosynthase SalC, erythronolide synthase, Salinispora tropica
CNB-440, 66/79
YP_
001157874
SalC, erythronolide synthase, 63/76
cinD CinD 414 cytochrome P450 SalD, cytochrome P450 hydroxylase, Salinispora
tropica CNB-440, 76/88
ABP73648 SalD, cytochrome P450 hydroxylase,
72/84
cinE CinE 277 thioesterase SalF, thioesterase, Salinispora tropica CNB-440,
70/80
ABP73650 SalF, thioesterase, 64/74
cinF CinF 448 octenoyl-CoA reductase/
carboxylase
crotonyl-CoA reductase, Streptomyces hygro-
scopicus, 93/96
AAR32675 SalG, 4-chlorocrotonyl-CoA reductase/
carboxylase, 67/81
cinRI CinRI 333 regulatory protein, LysR
family
LysR family transcriptional regulator, Strepto-
myces griseus subsp. griseus NBRC 13350, 48/60
YP_
001828298
–
cinH CinH 733 NRPS NRPS, Streptomyces avermitilis MA-46801, 50/60 NP_822023 –
cinI CinI 506 acyl-CoA dehydrogenase acyl-CoA dehydrogenase, Streptomyces bing-
chenggensis BCW-1, 40/55
ADI05331 –
cinJ CinJ 281 20S proteasome b-subu-
nit
20S proteasome b-subunit, Streptomyces aver-
mitilis MA-4680, 74/88
NP_823988 SalI, proteasome b-subunit, 40/60
cinK CinK 66 ferredoxin-2 ferredoxin-2, Streptomyces diastaticus, 55/73 P18325 –
cinL CinL 402 cytochrome P450 putative cytochrome P450, Streptosporangium
roseum DSM 43021, 49/63
YP_
003340485
–
cinM CinM 280 phenazine biosynthesis
(oxidizing protein)
PhzF family phenazine biosynthesis protein,
Salinispora tropica CNB-440, 69/80
YP_
001157895
PhzF family phenazine biosynthesis
protein, 69/80
cinN CinN 95 hypothetical protein hypothetical protein Strop_1042,
Salinispora tropica CNB-440, 71/78
YP_
001157894
hypothetical protein strop_1042,
71/78
cinO CinO 329 ornithine cyclodeaminase ornithine cyclodeaminase, Salinispora tropica
CNB-440, 71/83
YP_
001157893
ornithine cyclodeaminase, 71/83
cinP CinP 205 prephenate dehydratase BacA, prephenate dehydratase, Bacillus amylo-
liquefaciens, 36/58
Q8KWT1 –
cinQ CinQ 331 l-amino acid aminotrans-
ferase
SalW, l-amino acid transferase, Salinispora
tropica CNB-440, 70/80
YP_
001157891
SalW, l-amino acid transferase,
36/79
cinR CinR 447 phenyl-acetate-CoA ligase hypothetical protein Strop_1038, Salinispora
tropica CNB-440, 70/81
YP_
001157890
hypothetical protein Strop_1038,
70/81
cinS CinS 352 3-oxoacyl-(acyl-carrier
protein) synthase III
3-oxoacyl-(acyl-carrier protein), Streptomyces
hygroscopicus, 90/93
AAR32677 –
cinT CinT 591 acyl-CoA ligase acyl-CoA ligase, Streptomyces hygroscopicus,
87/92
AAR32676 –
cinRII CinRII 323 regulatory protein, LuxR
family
LuxR transcriptional regulator, Streptomyces
flavogriseus, 49/65
ZP_
05802671
–
[a] Protein Blast (Database: nonredundant protein sequences (nr)). [b] Geneious alignment (cost matrix: BLOSUM62, Gap open penalty: 11, Gap extension
penalty: 3)
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extender units of polyketides and predominantly the work re-
lating to the ethylmalonyl-CoA pathway in Rhodobacter sphaer-
oides. In this pathway, reductive carboxylation of (E)-crotonyl-
CoA by a crotonyl-CoA carboxylase/reductase (Ccr) enzyme[30]
with use of the purified enzyme in vitro has been described.
Similar biochemical steps have also been reported to be in-
volved in the production of the PKS extender units ethylma-
lonyl-CoA and chloroethylmalonyl-CoA in the salinosporamide
biosynthesis pathway.[31] Another example has been reported
in the biosynthesis of the NRPS/PKS macrolide thuggacin, iso-
lated from Sorangium cellulosum So ce895, in which it was pro-
posed that the hexyl side chain of the compound originates
from extension by the unusual PKS extender hexylmalonyl-
CoA, which is thought to be generated from octenyl-CoA by
the Ccr homologue TgaD.[21] In the cinnabaramide gene cluster
we found a gene (cinF) encoding for a protein showing 90%
sequence identity (at the protein level) to a putative Ccr from
Streptomyces hygroscopicus (Accession No. AAR32675). Howev-
er, sequence identity to TgaD is very low. We inactivated cinF
by insertion of the inactivation plasmid pCN1 into the genome
of Streptomyces sp. JS360 through homologous recombination,
resulting in a mutant incapable of producing cinnabaramides.
We thus hypothesize that CinF catalyzes the reductive carboxy-
lation of octenoyl-CoA or -ACP, leading to 2-carboxyoctanoyl-
CoA or 2-carboxyoctanoyl-ACP, respectively (Schemes 3B and
4). Notably, the octenoyl-CoA and octenoyl-ACP precursors to
the proposed building blocks are intermediates furnished
either from the fatty acid degradation or the fatty acid biosyn-
thesis pathways.
We speculated that the corresponding free acids obtained
from administration to the growth media might be activated
in the cell and thus enable mutasynthesis of analogues, and
consequently next turned our attention towards the produc-
tion of chlorinated cinnabaramides. A precursor-directed bio-
synthesis strategy was applied by feeding of the bacterial cul-
ture with chlorinated precursors. Accordingly, (E)-6-chlorooct-2-
enoic acid, (E)-8-chlorooct-2-enoic acid, and their correspond-
ing N-acetylcysteamine (NAC) thioesters were chemically syn-
thesized (Figure S1) and added to the culture of the bacteria
(Scheme 3C). Organic extracts of the culture supernatants
were analyzed by HPLC-MS, which unambiguously showed in-
corporation of these precursors into cinnabaramide A (and into
other cinnabaramide derivatives; data not shown) bearing a
chlorine atom (Figure 1). After scale-up of the precursor feed-
ing experiment, these compounds were also isolated to purity
by preparative HPLC (details provided in the Supporting Infor-
Scheme 2. A) Organization of the cin biosynthetic gene cluster from Streptomyces sp. JS360 and of the sal biosynthetic gene cluster from Salinospora tropica.
Genes of similar function in both salinosporamide and cinnabaramide biosynthesis : genes involved in construction of the core structure g-lactam-b-lactone bi-
cyclic ring ( ), genes involved in assembly of the nonproteinogenic amino acid b-hydroxycyclohex-2’-enylalanine ( ), genes involved in regulation and resist-
ance (&). Specific genes existing only in the cinnabaramide biosynthesis cluster : genes involved in the 2-carboxyl-CoA pathway ( ) and genes involved in
hydroxylation of C12 in cinnabaramides B and D ( ). Specific genes existing only in the salinosporamide biosynthesis cluster : partial transposases (&), genes
involved in the chloroethylmalonyl-CoA pathway ( ). Genes of unknown function in biosynthesis of cinnabaramides and salinosparamides (&). B) Proposed
PKS/NRPS biosynthesis pathway for production of cinnbaramides.
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mation) in order to allow their unambiguous structure elucida-
tion.
1D and 2D NMR spectroscopy for structure elucidation
(Table S4 and Figure S4), combined both with LC-MS data and
with high-resolution ESI-MS (for comparison with cinnabarami-
de A; Scheme 4 and Table S2), identified the structures as
novel chlorinated cinnabaramides with chlorine atoms at C15
or C17. From these results, we reason that the cinnabaramide
PKS extender module is able to accept chlorinated substrates
and to incorporate them into the assembly line. No production
of chlorinated cinnabaramides was found when the
bacterial culture was supplemented with (E)-4-chloro-
oct-2-enoic acid, so we postulate that the presence
of the chlorine atom at this position might influence
the substrate in such a way that it cannot be proper-
ly positioned in the CinA-AT2 active site. Alternatively,
CinF might not accept this substrate for reductive
carboxylation.
Novel cinnabaramide A derivatives were isolated
and screened against the human 20S proteasome
(more precisely, against the proteolytic subunits with
chymotrypsin-like (CT-L), trypsin-like (T-L), and cas-
pase-like (C-L) activities) in vitro. As shown in Table 2,
salinosporamide A has a higher inhibitory potential
towards all three proteolytic subunits than the tested
cinnabaramides. The IC50 values determined for the
CT-L activity were all in the low nanomolar range, as
reported previously,[9,32–34] although the chloro deriva-
tives are more potent than the parent compound.
With regard to inhibition at the T-L active site, 15-
chlorocinnabaramide A showed the highest activity
amongst the derivatives. The additional chlorine
might serve as a leaving group and in this way en-
hance cinnabaramide’s potency for inhibiting the b2
proteolytic subunit, as described earlier for inhibition
at the CT-L site by salinosporamide A.[17] In the case
of C-L activity, cinnabaramide A and its analogues ex-
hibited IC50 values in the high nanomolar range.
As shown in Table 3, the cytotoxic activities of the
novel 15-chloro derivative were superior to those of
cinnabaramide A, whereas the 17-chloro derivative
showed enhanced bioactivity only towards human
myeloma RPMI-8226 cells. These findings are consistent with
the results from the proteasome inhibition experiments. In
general, the cytotoxic effects are still significantly weaker than
those of salinosporamide A.
In addition to proteasome inhibition, the cinnabaramides
showed strong antifungal activity. Although Botrytis cinerea
was found to be insensitive towards the compounds, both
Mucor plumbeus and Pyricularia oryzae were affected by low
concentrations of the cinnabaramides, as well as by salinospor-
amide A (as shown in Table S3). Interestingly, the last com-
pound showed the weakest antifungal activity, despite being
much more potent than the cinnabaramides against the con-
currently tested cancer cell lines. The chlorinated cinnabara-
mides and the cyclopentyl analogue of cinnabaramide A, how-
ever, were slightly less active than their parent compound.
Experimental Section
General microbiological and molecular biology methods : The
cinnabaramide producer JS360 was grown in Q6 medium, which
led to maximal production rate as described previously.[9] Cells of
Escherichia coli were grown in Luria–Bertani (LB) medium at 37 8C.
dNTPs, restriction enzymes, T4 DNA ligase, isopropyl b-d-thiogalac-
topyranoside (IPTG), and X-gal were purchased from Fermentas.
Ammonium persulfate and gel electrophoresis materials were ob-
Scheme 3. A) Biosynthetic pathway producing the cinnabaramide hexyl side chain. B) Pu-
tative role of CinF (carboxylase/reductase) in the pathway. C) Culture feeding with 6- or
8-chlorooct-2-enoic acid as an analogue precursor for the biosynthesis of chlorinated cin-
nabaramides.
Scheme 4. The presumed mechanism for production of the PKS extender
unit hexylmalonyl-CoA, which is required for the formation of the hexyl side
chain in cinnabaramides.
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tained from Roth, Germany. Oligonucleotides were purchased from
Sigma. Standard methods for DNA isolation and manipulation
were used.[36,37] DNA fragments were isolated from agarose gels by
use of the NucleoSpin Extract gel-extraction kit (Macherey–Nagel).
Southern genomic library analysis was performed with the DIG
DNA labeling and detection kit (Roche). Hybridization was carried
out at 42 8C for homologous probes with stringent washing at
68 8C. For heterologous probes, hybridization was performed at
42 8C with stringent washing at 60 8C. PCR reactions were per-
formed with Taq DNA polymerase (Fermentas) or Pfu polymerase
(Stratagene). Conditions for amplification with an Eppendorf Mas-
tercycler were as follows: denaturation, 30 s at 95 8C; annealing,
30 s at 48–65 8C; extension, 45 s at 72 8C; 30 cycles and a final ex-
tension for 10 min at 72 8C. PCR products were purified by use of
the High Pure PCR Product Purification kit (Boehringer Mannheim).
Construction of Streptomyces JS360 genomic cosmid library :
Chromosomal DNA of the bacteria was prepared as described pre-
viously.[37] Partial digestion of the bacterial genome was performed
with Sau3AI enzyme to provide fragments of about 35–40 kbp.
The fragments were dephosphorylated and ligated into pOJ436
cosmid pretreated with PvuII, dephosphorylated, and restricted
with BamHI. The ligation mixture was packaged with Gigapack III
Gold (Stratagene) packaging extract and transduction of the result-
ing phages into E. coli HS966 created a genomic library of 2304
clones. For colony hybridization, the colonies were transferred
twice onto a 22.222.2 cm nylon membrane with a QPix (Hamp-
shire, UK) colony picker.[38]
Screening of the cosmid library for the cinnabaramide gene
cluster : From the chemical structures of the cinnabaramides we
expected involvement of a PKS/NRPS gene cluster in biosynthesis
of the compound. The bacterial cosmid library was therefore first
screened for PKS genes by hybridization with a homologous keto-
synthase (KS) probe generated from the bacterial genome under
low-stringency conditions, with use of the degenerate oligonucleo-
tides KS1UP and KSD1.[39] Furthermore, an adenylation probe
(NRPS) was generated from the bacterial genome with the aid of
the degenerate primers NRPS-A1-up: (5’-CGG CTC CAC CGG CAC
[ACGT]CC [ACGT]AA [AG]GG [ACGT]G-3’) and NRPS-H1-dn: (5’-CGG
CCG AGG TCG CC[ACGT] GT[ACGT] C[GT][AG] TA-3’), and used for
hybridization of the cosmid library. Seven of the KS-positive cos-
mids were positively cross-hybridized with the NRPS probe and
were subjected to PCR analysis for amplification of KS and NRPS-
adenylation fragments. The PCR fragments were cloned into
pCR2.1TOPO vector (Invitrogen) and sequenced. The PCR frag-
ments generated from cosmid C:A17 showed significant homology
to KS and adenylation-domain sequences from the salinospora-
mide gene cluster. After cosmid end-sequencing from the T3 and
the T7 termini of the pOJ436, the cosmid was thus sequenced on
both strands, by use of a shotgun library as described previously,[40]
and the sequence was introduced into the EMBL nucleotide data-
base (accession number: FR687018).
Bioinformatics analysis : All sequence similarity searches were car-
ried out at the amino acid level in the Gene Bank database with
use of the BLAST program (release 2.0). Amino acid and nucleotide
Figure 1. HPLC-MS analyses with extracted ion chromatograms (EICs) for m/z
values of cinnabaramide A (tR=16.9 min; dashed line) and new cinnabarami-
de A derivatives. A) Feeding of strain JS360 with cyclopentyl-alanine result-
ing in the production of cyclopentyl-alanine cinnabaramide A (tR=
16.49 min). B) Feeding of JS360 with 6- or 8-chlorooct-2-enoic acid or their
SNAC derivatives, resulting in the production of cinnabaramide A analogues
chlorinated at C15 or C17 (tR=16.30 min), respectively. The two chlorinated
compounds had identical retention times on the applied system and
showed similar levels of production.
Table 2. Inhibition of the b1, b2, and b5 proteolytic subunits of human
20S proteasome by salinosporamide A and by cinnabaramide A and its
analogues.
Compound C-L (b1) IC50 [nm]
[a] T-L (b2) CT-L (b5)
salinosporamide A 32.714.7 18.710.5 3.14.8
cinnabaramide A 248.68.4 216.012.3 11.97.4
17-chlorocinnabaramide A 265.810.7 442.56.8 8.85.5
15-chlorocinnabaramide A 402.910.5 88.98.3 9.35.9
cyclopentyl-cinnabaramide A 301.27.8 301.29.1 64.95.3
[a] IC50 values were obtained by linear regression of kinetics measure-
ments and secondary hyperbolic regression.
Table 3. Cytotoxicities of salinosporamide A and of cinnabaramide A and
its analogues towards human tumor cell lines[a] as evaluated by MTT
assay[b] or by PI staining[c] .
Compound HCT-116[b] RPMI-8226[c]
IC50 [mm]
[d]
SW480[b]
salinosporamide A 0.0470.003 0.0140.001 0.0132.3105
cinnabaramide A 5.9060.301 1.9400.490 0.9310.141
17-chlorocinnabaramide A 7.2860.050 0.8410.190 0.9770.011
15-chlorocinnabaramide A 2.3760.433 0.3410.001 0.4570.007
cyclopentylcinnabaramide A 16.8930.235 n.d. n.d.
[a] HCT-116: colon carcinoma. RPMI-8226: myeloma. SW480: colon adeno-
carcinoma. [d] Values represent the average of two independent measure-
ments. Incubation times: [c] 4 d, or [b] 5 d. The observed IC50 values were
of the same order of magnitude as those previously reported.[10,33,35] n.d. :
not determined.
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sequences were aligned with the aid of the Vector NTI advance 11
and Geneious 4.8.4 software packages (Invitrogen, USA, and Bio-
matters, New Zealand, respectively).
Inactivation in the cinnabaramide gene cluster : Inactivation of
cinF, encoding octenoyl-CoA reductase/carboxylase (Ocr), and of
cinQ, encoding a putative branched-chain amino acid aminotrans-
ferase, was performed by integration of the inactivation plasmids
pCN1 and pCN2, respectively, into the Streptomyces JS360 genome.
Internal fragments of the cinF (1044 bp) and cinQ (847 bp) with
frame shift mutation in the 5’-end sequence were generated by
PCR by use of the oligonucleotides CinF-up (5’-ATG TAG CAG CTT
GTC CCG AGC CGT A-3’) and CinF-dn (5’-TTG TCG AAG GTG TGC
AGG TAG-3’), and of CinQ-up (5’-CAG TGA CAG CGC GAC CCT CAT
C-3’) and CinQ-dn (5’-CAC GTC CCT GCC GGA GAG-3’; inserted nu-
cleotides highlighted in bold). Next, the PCR products were cloned
into the pCR2.1-TOPO vector (Invitrogen) for sequence analysis,
and excised by use of the restriction enzymes EcoRV and HindIII.
The resulting inserts were then subcloned into EcoRV and HindIII
cloning sites of the conjugative plasmid pKC1132,[41] creating the
inactivation plasmids pCN1 and pCN2. The plasmids were then in-
troduced into E. coli ET12567/pUZ8002. Appropriate transformants
were then used for conjugation with JS360 spores as described
previously.[42] Plates containing putative exconjugants were over-
laid with apramycin (60 mgmL1) and nalidixic acid (25 mgmL1).
Because pKC1132 cannot replicate in Streptomyces, apramycin-
resistance strains could be produced only by homologous recom-
bination between the conjugative plasmids and the genes in the
JS360 genome. To confirm integration of the plasmid into the
genome, and thus disruption of the genes, PCR analysis with the
aid of the primer pTOPO-Hind (5’-GAG CTC GGA TCC ACT AGT-3’)
in combination with each of CinF-out (5’-ATC ATT TCA AGG TAC
TTC-3’), CinQ-out (5’-CTC GGT GTA CAG CTC GCG-3’), and CinQ-out
(5’-TTC TCA CGG AAG TCG ATC T-3’) of the bacterial genome locat-
ed upstream or downstream regions of the cloned fragments was
performed. PCR fragments 1163 bp and 980 bp were only amplified
from genome of the mutants JS360-cinF and JS360-cinQ .
Feeding experiments : JS360 was grown in YMG medium at 30 8C
for 24 h and was then transferred to Q6 medium (25 mL) supple-
mented variously with dl-3-cyclopentyl-alanine, deuterated cyclo-
hexenyl-serine, 4-chlorooct-2-enoic acid, 4-chlorooct-2-enoyl-SNAC,
6-chlorooct-2-enoic acid, 6-chlorooct-2-enoyl-SNAC, 8-chlorooct-2-
enoic acid, 8-chlorooct-2-enoyl-SNAC, crotonic acid, pent-2-enoic
acid, hex-2-enoic acid, or hept-2-enoic acid (all 0.1 mm). These
compounds were each added in three portions to the bacterial cul-
ture after 0, 6, and 12 h, and further incubated for 24 h. To investi-
gate for production of cinnabaramides or their derivatives, culture
supernatant (20 mL) was extracted three times with ethyl acetate
(20 mL). After removal of the solvent in vacuo, the remainder was
dissolved in methanol (1 mL) and 5 mL of the solution was injected
for HPLC-MS analysis.
Synthesis of precursors for feeding experiments
A) Synthesis of (E)-4-chlorooct-2-enoic acid: (E)-Oct-3-enoic acid
(5 g, 35.2 mmol, Sigma—Aldrich) was added dropwise at RT under
nitrogen to a solution of phenylselenium chloride (3.4 g,
17.6 mmol) in dry acetonitrile (200 mL). Molecular sieves (4 ) were
added, followed over 20 h by a solution of N-chlorosuccinimide
(5.15 g, 38.5 mmol) in dry acetonitrile (100 mL). After addition, the
mixture was stirred at RT for 2 d. The solvent was removed under
reduced pressure and the residue was diluted with diethyl ether
(100 mL). The solid formed was removed by filtration and the
filtrate was washed with water (425 mL). The organic layer was
dried over MgSO4 and the solvent was removed in vacuo. After
purification by flash column chromatography over silica gel (with
cyclohexane/ethyl acetate as mobile phase), the target compound
(1.6 g) was obtained. Because NMR analysis indicated that the
sample still contained oct-2-enoic acid (about 10%) as a side prod-
uct, the compound was further purified by distillation at 0.1 mbar/
175 8C to yield 4-chlorooct-2-enoic acid (93% purity by 1H NMR,
1.3 g, 21%, Figures S2 and S3).
B) Synthesis of (E)-6-chlorooct-2-enoic acid and its correspond-
ing SNAC derivative
Methyl 4-chlorohexanoate : A solution of g-ethylbutyrolactone (25 g,
0.22 mol) in dry MeOH (250 mL) was saturated with HCl (g). The re-
action mixture was stirred at RT in a sealed tube for 4 d. Excess HCl
was removed and the reaction mixture was concentrated to dry-
ness. The crude product was diluted with water (100 mL) and ex-
tracted with CH2Cl2 (375 mL). The organic layer was washed with
a saturated solution of NaHCO3, dried over MgSO4, and concentrat-
ed to dryness. The product was purified by distillation (bp=72–
74 8C at 11 mbar) to yield 20.4 g (60%).
4-Chlorohexanal : A solution of DIBAL-H in CH2Cl2 (1m, 130 mL) was
added at 78 8C to a solution of methyl 4-chlorohexanoate (20.4 g,
0.12 mol) in dry CH2Cl2 (112 mL). The reaction mixture was stirred
at this temperature for 1 h, after which it was poured into ice/
conc. HCl (140 g/28 mL). The aqueous layer was extracted with
CH2Cl2 (250 mL). The combined organic layers were dried over
MgSO4 and the solvent was removed under reduced pressure. The
desired product (17.8 g) was obtained and used without further
purification.
(E)-6-Chlorooct-2-enoic acid : A mixture of 4-chlorohexanal (17.8 g,
0.12 mol) and malonic acid (16.5 g, 0.16 mol) in dry pyridine
(37 mL) was stirred at 30 8C for 4 d, at 60 8C for 1 h, and finally at
95 8C for 1 h. The reaction mixture was poured into ice/6m HCl
solution (200 mL) and extracted with Et2O (3100 mL). The organic
layer was extracted with NaOH solution (3m, 250 mL). The aque-
ous layer was acidified with HCl (10%) to pH 2 and then extracted
with Et2O (375 mL). The new organic layer was dried over MgSO4
and the solvent was removed under reduced pressure to yield the
desired compound (16.3 g, 77% over two steps), which was used
without further purification.
Corresponding NAC thioester : EDAC (3.33 g, 17.4 mmol) was added
to a solution of (E)-6-chlorooct-2-enoic acid (2 g, 11.3 mmol) and N-
acetylcysteamine (1.64 g, 13.7 mmol) in dry DMF (115 mL). The re-
action mixture was stirred at RT overnight. HCl solution (10%) was
added (50 mL), and the mixture was diluted with water (100 mL)
and extracted with CH2Cl2 (2150 mL). The organic layer was
washed with brine, dried over MgSO4, and concentrated to dry-
ness. The product was purified by flash column chromatography
(silica gel, cyclohexane/ethyl acetate) and preparative HPLC (H2O/
acetonitrile). The desired compound (295 mg, 93% yield) was ob-
tained (Figures S2 and S3).
C) Synthesis of (E)-8-chlorooct-2-enoic acid and its correspond-
ing SNAC derivative
6-Chlorohexanal : A solution of sodium bichromate dihydrate (25 g,
0.084 mol) in water (312 mL) was added dropwise at reflux to a
solution of 6-chlorohexanol (25 g, 0.18 mol) and H2SO4 (25 mL) in
water (156 mL), and at the same time the same amount of water
was distilled off. More water was added (30 mL) and simultaneous-
ly distilled off from the reaction mixture. The distillate was extract-
ed with Et2O (3100 mL). The organic layer was dried over MgSO4
and concentrated to dryness. The product obtained (17.8 g) was a
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mixture of the starting alcohol and the desired corresponding alde-
hyde (1:1), and it was used without further purification for the next
step.
(E)-8-Chlorooct-2-enoic acid : The mixture of 6-chlorohexanol and 6-
chlorohexanal (1:1, 17.8 g, about 7.9 g/66 mmol of the aldehyde),
together with malonic acid (8.25 g, 79.2 mmol) in dry pyridine
(18 mL), was stirred at 30 8C for 4 d, at 60 8C for 1 h, and finally at
95 8C for 1 h. The reaction mixture was poured into ice/6m HCl so-
lution (100 mL) and extracted with Et2O (350 mL). The organic
layer was extracted with NaOH solution (3m, 225 mL). The aque-
ous layer was acidified with HCl (10%) to pH 2 and extracted with
Et2O (350 mL). The new organic layer was dried over MgSO4 and
the solvent was removed under reduced pressure to yield the
desired compound (10.8 g), which was used without further purifi-
cation.
Corresponding NAC thioester : EDAC (3.12 g, 16.3 mmol) was added
to a solution of (E)-8-chlorooct-2-enoic acid (1.9 g, 10.8 mmol) and
N-acetylcysteamine (1.64 g, 12.9 mmol) in dry DMF (108 mL). The
reaction mixture was stirred at RT overnight. HCl solution (10%,
50 mL) was added, and the mixture was diluted with water
(100 mL) and extracted with CH2Cl2 (2150 mL). The organic layer
was washed with brine, dried over MgSO4, and concentrated to
dryness. The product was purified by flash column chromatogra-
phy (silica gel, cyclohexane/ethyl acetate) and afterward by prepa-
rative HPLC (H2O/acetonitrile). The desired compound (460 mg,
about 15%) was obtained (Figures S2 and S3).
D) Investigation of the synthesis of (E)-5-chlorooct-2-enoic acid :
Unfortunately, attempts to synthesize (E)-5-chlorooct-2-enoic acid
by a strategy similar to that successfully applied for 6- and 8-
chlorooct-2-enoic acids failed. Spontaneous HCl elimination of the
desired product, leading to the corresponding octa-2,4-dienoic
acid is unavoidable.
Ethyl 3-chlorohexanoate : Benzotriazole (29.5 g) was added to a so-
lution of SOCl2 (18.06 mL) in dry CH2Cl2 (50 mL). More CH2Cl2 was
added until 165.4 mL of a 1.5m solution of SOCl2/benzotriazole
were obtained. This solution was added dropwise to a solution of
ethyl 3-hydroxyhexanoate (15.9 g, 99.2 mmol) in dry CH2Cl2
(500 mL), and the mixture was stirred at RT overnight. The solid
formed was removed by filtration and the filtrate was washed with
water (2200 mL), aq. Na2CO3 (10%, 150 mL), and NaHCO3
(150 mL). The organic layer was dried over MgSO4 and concentrat-
ed to dryness. The product was purified by flash column chroma-
tography (silica gel, cyclohexane/ethyl acetate) to give the target
compound (5.5 g). Starting ethyl 3-hydroxyhexanoate (10 g) was
recovered (yield 83%, conversion 37%).
3-Chlorohexanal : A solution of DIBAL-H in CH2Cl2 (1m, 33.8 mL) was
added at 78 8C to a solution of ethyl 3-chlorohexanoate (5.5 g,
30.8 mmol) in dry CH2Cl2 (28 mL). The reaction mixture was stirred
at this temperature for 1 h, after which it was poured into 40 g ice/
7.5 mL conc. HCl solution. The aqueous layer was extracted with
CH2Cl2 (220 mL). The combined organic layer was dried over
MgSO4 and the solvent was removed under reduced pressure. The
desired product (5 g, theory: 100%=4.14 g) was obtained and
used without further purification.
(E)-5-Chlorooct-2-enoic acid/(2E,4E)-octa-2,4-dienoic acid : A mixture
of 3-chlorohexanal (4.1 g, about 30 mmol) and malonic acid
(4.54 g, 43.4 mmol) in dry pyridine (10 mL) was stirred at 30 8C for
4 d, at 60 8C for 1 h, and finally at 95 8C for 1 h. The reaction mix-
ture was poured into ice/6m HCl solution (100 mL) and extracted
with Et2O (325 mL). The organic layer was extracted with NaOH
solution (3m, 215 mL). The aqueous layer was acidified with HCl
(10%) to pH 2 and extracted with Et2O (325 mL). The new organ-
ic layer was dried over MgSO4 and the solvent was removed under
reduced pressure. The crude reaction product was purified by flash
column chromatography (silica gel, cyclohexane/ethyl acetate) to
yield (2E,4E)-octa-2,4-dienoic acid as reaction product. Any at-
tempts to avoid HCl elimination and to obtain the desired (E)-5-
chlorooct-2-enoic acid failed (Figures S2 and S3).
Analytical methods and structure elucidation : HPLC-MS was per-
formed with a HPLC-DAD system (Agilent 1100) coupled to an HCT
ultra ESI-MS ion trap apparatus (Bruker Daltonics) operating in pos-
itive ionization mode. Separation was achieved by use of a Luna
RP-C18 column with a solvent system consisting of a water to ace-
tonitrile gradient. For separation of cinnabaramides and their deriv-
atives and of oct-2-enoyl-SNAC and 2-carboxyl-octenoyl-SNAC
esters, a solvent system based on water (A)/acetonitrile (B) contain-
ing formic acid (0.1%) was used. Gradient: 0–2 min 5% B; 2–
22 min linear from 5% to 95% B; 22–25 min isocratic at 95% B;
25–27 min linear from 95–5% B.
High-resolution measurements were performed with an Accela
UPLC-system (Thermo-Fisher) coupled to an LTQ-Orbitrap (linear
trap-FT-Orbitrap combination) operating in positive ionization
mode with a Waters BEH-C18 column with a solvent system con-
sisting of a water (A)/acetonitrile (B) gradient containing formic
acid (0.1%).
NMR spectra were recorded in [D6]DMSO with a Bruker DRX 500
spectrometer at 303 K, operating at 500.13MHz proton frequency.
The solvent peak was used as internal reference (dH=2.50 ppm,
dC=39.5 ppm). Chemical shifts are given in ppm, coupling con-
stants in Hertz. In the cases of the synthetic precursors used for
the mutasynthesis projects, NMR spectra were obtained with a
Bruker AVANCE spectrometer at 293 K in CDCl3 (300MHz proton
frequency), which was also used as internal reference (dH=
7.26 ppm). Analytical HPLC-MS was performed with an Agilent 1100
HPLC system coupled with an Agilent DAD detector, an evaporat-
ing light scattering detector (ELSD), and an LCT mass spectrometer
(Micromass, Manchester, UK) operating in positive and negative ESI
modes. A Waters Symmetry C18 column (3.5 mm, 1502.1 mm)
and a linear gradient from 0 to 100% MeCN (0.1% HCOOH, flow
rate 0.4 mLmin1) in 21 min were used. HR-ESIMS data were ob-
tained with a Bruker MicroTOF instrument, coupled with an HPLC
system as described above and with use of sodium formate as in-
ternal reference. Optical rotation values were measured in MeOH
with a Schmidt+Haensch Polartronic HH8 polarimeter; concentra-
tions are given in g per 100 mL. Structure elucidation of the novel
cinnabaramide derivatives was achieved by thorough interpreta-
tion of 1D and 2D NMR spectra, combined with LC-MS data includ-
ing extracted UV as well as positive and negative mode ESI spectra.
Cinnabaramide A was used for comparison. Additionally, the mo-
lecular formulas and elemental compositions of all cinnabaramide
derivatives were confirmed by high-resolution ESI-MS. The NMR
dataset used consisted of 1D proton and carbon, 1H,1H gCOSY,
1H,13C gHSQC, and 1H,13C gHMBC spectra (Figures S3 and S4).
Inhibition assay with human 20S proteasome : All chemicals were
of reagent grade and buffers were made with deionized distilled
water. Inhibition experiments were performed in HEPES buffer
(25 mm, pH 7.5) containing EDTA (0.5 mm), Triton-X100 (0.05%, v/
v), and SDS (0.001%, w/v). Inhibition was monitored by measuring
the release of AMC-coupled substrate peptides for the C-L, CT-L,
and T-L activities, respectively. Compounds were pre-incubated for
15 min at 37 8C in serial dilutions from 0.03 to 3000 nm with
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human 20S proteasome (2 nm, Biomol) dissolved either in buffer A
(HEPES (pH 8.0, 20 mm), EDTA (0.5 mm), SDS (0.035%, w/v)) for CT-L
and C-L activities or in buffer B (HEPES (pH 8.0, 20 mm), EDTA
(0.5 mm)) for T-L activity. Boc-LRR-AMC·2HCl, suc-LLVY-AMC, and Z-
LLE-AMC (Bachem) were made up to 50 mm DMSO stocks in order
to monitor T-L, CT-L, and C-L activities, respectively. Reactions were
initiated by addition of AMC substrates to final concentrations of
2 mm. The emission at 460 nm (5 nm cutoff; excitation at 380 nm)
was measured with a Spectramax M5 fluorescence reader (Molecu-
lar Devices) in black 96-well plates (BD Falcon) at 37 8C over
90 min. The measured AMC production was in the linear range of
an AMC standard curve.
MTT assay : Cells were seeded at 6103 cells per well on 96-well
plates (Corning CellBind) in complete medium (180 mL) and
directly treated with compounds dissolved in methanol in a serial
dilution. After 5 d incubation, MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl tetrazolium bromide, 20 mL of 5 mgmL1 stock] in PBS
(phosphate-buffered saline, pH 7.4) was added to each well and
further incubation at 37 8C was carried out for 2 h. The medium
was then discarded and cells were washed with PBS before addi-
tion of propan-2-ol/10n HCl (250:1, 100 mL) in order to dissolve
formazan granules. The absorbance at 570 nm was measured with
a microplate reader (EL808, Bio-Tek Instruments, Inc.), and cell via-
bility was expressed as percentage relative to the corresponding
methanol control. IC50 values were obtained by sigmoidal curve
fitting.
Cytotoxicity assay (propidium iodide staining): Cells were har-
vested from exponential phase cultures, counted, and plated in 96-
well microtiter plates at cell densities of 10000 to 80000 for hema-
tological cancer cell lines. After a 24 h recovery period to allow
cells to resume exponential growth, culture medium (four control
wells/plate) or culture medium with the test compound (10 mL)
was added with use of a liquid handling robotic system and treat-
ment was continued for 4 d. Compounds were applied in half-log
increments at ten concentrations in duplicate. For hematological
cancer cell lines (growing in suspension), 30 min after addition of
PI (propidium iodide, 7 mgmL1), fluorescence (FU1) was measured
to quantify dead cells. Triton X-100 (0.1%, v/v) was added next,
resulting in permeability of all cells (viable+dead cells). After a
second fluorescence measurement (FU2), the amount of viable
cells was calculated by subtraction of FU1 from FU2. Growth inhib-
ition/cytotoxicity is expressed as Test/Control100 (% T/C). IC50
values were calculated by nonlinear regression (log [inhibitor] vs re-
sponse (% T/C)) with the aid of the analysis software GraphPad
Prism, Prism 5 for Windows, version 5.01 (GraphPad Software, Inc.).
For calculation of mean IC50 values the geometric means were
used.
Determination of antifungal activities : Minimal inhibitory concen-
trations (MICs) in the serial dilution assay were determined in 96-
well microtiter plates in a manner similar to that described previ-
ously,[43] with use of Botrytis cinerea (DSM 5144), Pyricularia oryzae
(DSM 62938), and Mucor plumbeus (MUCL 49355) as test organ-
isms. Spore suspensions of the fungi were prepared from well-
grown YMG (glucose 0.4%, malt extract 1%, yeast extract 0.4%,
pH 6.3) agar plates and the initial titer for the biological assay was
adjusted to initial titers of 105 spores per mL YMG medium.
The chlorinated cinnabaramides arising from the precursor feeding
experiments and the cyclopentyl analogue of cinnabaramide A
were tested for comparison with cinnabaramide A, salinospora-
mide A, and actinomycin C complex. All test compounds were dis-
solved in methanol and supplied to the microtiter plates in serial
dilutions (100, 50, 25, 12.5, 6.3, 3.1, 1.6, and 0.8 mgmL1). The MICs
were determined after 24 h of incubation by OD measurement.
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Precursor-Directed Biosynthesis with Streptomyces JS360 and Isolation of 
Novel Cinnabaramid Derivatives 
A) General methods 
Precultures of cinnabaramide producer JS360 were done in YM medium (D-glucose 4 g/L; malt extract 
10 g/L, yeast extract 4 g/L; pH 7.2). 150 mL medium 150 mL in 500 mL Erlenmeyer flasks (without 
baffles) were inoculated with 2 mL spore suspension of JS 360. The precultures were grown for 80 h 
at 28 °C on a rotary shaker at 240 rpm. 
Main cultures were done in Q6 medium (D-Glucose 5 g/L, glycerine 20 g/L, cottonseed flour 10 g/L, 
CaCO3 1 g/L; no pH adjustment) supplemented with the precursor as described below. 150 mL 
medium in 500 mL Erlenmeyer flasks (without baffles) were inoculated with 2 mL of well-grown 
precultures. The main cultures were grown at 28 °C for 40 h on a rotary shaker at 240 rpm. 
Workup and extraction: Mycelium and supernatant were separated by centrifugation. The wet 
mycelium was extracted twice with 300 mL acetone each (30 min, ultrasound). The combined and 
filtered organic phases were concentrated in vacuo until an aqueous residue (ca. 150 mL) was 
obtained. The aqueous residue was extracted twice with 300 mL ethyl acetate each. The combined 
organic phases were dried over Na2SO4 and concentrated to dryness under reduced pressure to 
obtain a crude extract. 
Preparative HPLC was done with an Inertsil ODS-3 column (10 m, 30 x 250 mm) using a water (A) / 
acetonitril (B) gradient with 0.1% TFA (40-50% B in 15 min. 50-65% B in 10 min, 65% B isocratic for 
10 min, 65-75% B in 10 min, 75% B isocratic for 10 min, 75-100% B in 30 min; flow rate 10 mL/min). 
The UV signal was detected at 210 and 254 nm. 
B) Production and isolation of cyclopentyl-cinnabaramide A 
Q6 medium was supplemented with 0.5 mM 3-cyclopentyl-DL-alanine. After 12 h of growth, the cultures 
(20 flasks with 150 mL) were fed with additional 0.5 mM 3-cyclopentyl-DL-alanine. The crude mycelium 
extract (812 mg) obtained as described above was split into 5 aliquots, which were successively 
subjected to preparative HPLC to yield 2.3 mg of cyclopentyl-cinnabaramide A. 
C) Production and isolation of 15-chlorocinnabaramide A 
The strain JS360 was cultivated in Q6 medium (15 flasks with 150 mL). After 14 h, the medium was 
supplemented with 0.75 mM (E)-6-chloro-oct-2-enoic acid (addition of 100 L / flask of a solution of 
264 mg precursor dissolved in 1 mL MeOH). After another 4 h, additional 0.75 mM of precursor were 
added to the growing culture. The crude mycelium extract (1830 mg) obtained as described above 
was split into 5 aliquots, which were successively subjected to preparative HPLC to yield 6.3 mg of 15- 
chlorocinnabaramide A. 
D) Production and isolation of 17-chlorocinnabaramide A 
The strain JS360 was cultivated in Q6 medium (10 flasks with 150 mL). After 14 h, the medium was 
supplemented with 1.0 mM (E)-8-chloro-oct-2-enoic acid (addition of 100 L / flask of a solution of 264 
mg precursor dissolved in 1 mL MeOH). The crude mycelium extract (737 mg) obtained as described 
above was subjected to preparative HPLC to yield 4.3 mg of 17-chlorocinnabaramide A.
II
E) Feeding of (E)-4-chlorooct-2-enoic acid 
With the aim to obtain 13-chlorocinnabaramide A, strain JS360 was cultivated as described above but 
with Q6 nutrient medium supplemented with 1.5 mM (E)-4-chloro-oct-2-enoic acid, which was added 
after 4 h of growth. No chlorinated cinnabaramide derivatives could be detected by analytical HPLC-
MS after 9, 24, 33, 48, and 57 h cultivation time. 
 
 
Figures and Tables
Table S1: A) Comparison of the amino acid sequences of acyltransferase (AT) domains from the 
cinnabaramide gene cluster (CinA-AT1 and AT2, salinosporamide Sal-AT1, and AT2, and thuggacin 
TgaC-AT). The first two columns show the region around the active site Ser, and the conserved 
arginine implicated in binding of the dicarboxylated extender units, respectively. B) The table shows 
the active site and additional conserved residues which have been shown to correlate with domain 
specificity.[1-3] 
Table S2: HR-ESIMS data for cinnabaramide A and its novel derivatives. 
 
 Formula m/z, found m/z, calcd. for 
[M+H]+ 
Error [ppm] 
Cinnabaramide A C19H29NO4 336.2178 336.2171 2.1 
Cyclopentyl-Cinnabaramide A C18H29NO4 324.2313 324.2311 0.9 
15-Chlorocinnabaramide A C19H28ClNO4 370.1783 370.1780 0.9 
17-Chlorocinnabaramide A C19H28ClNO4 370.1782 370.1780 0.7 
Table S3: Minimal inhibitory concentrations (MICs) of cinnabaramide A, its novel derivatives, and 
reference compounds against fungi. 
 MIC [μg/mL] 
 Botrytis cinerea Mucor plumbeus Pyricularia oryzae
Cinnabaramide A >100 0.8 0.8
17-Chlorocinnabaramide A >100 6.3 3.1
15-Chlorocinnabaramide A >100 6.3 1.6
Cyclopentyl-Cinnabaramide A >100 6,3 0.8
Salinosporamide A >100 25 6.3
CinA-AT1 G Q S I G L A V A R S R L I
SalA-AT1 Q Q S V G V A A T H A R L V
CinA-AT2 G H S L G I A V A R S R L I
SalA-AT2 G H S I G V T I A R S R L I
TgaC-AT G N S Q G V V A R R S R L L
Domain 11 63 90 91 92 93 94 117 200 201 231 250 255 15 58 59 60 61 62 70 72 197 198 199
CinA-AT1 T Q G Q S I G H A H T N S W D M E V V Q A G Y A
SalA-AT1 T Q G Q S V G H S H T N S W D M E I V Q A G Y A
CinA-AT2 S Q G H S L G R G H T N V W E G D I Q H S E R A
SalA-AT2 G Q G H S I G R G H T N V W A T D I Q Q S D R P
TgaC-AT3 Q Q G N S Q G R T H T N V W R I D V M M S G D A
B)
A)
III
Figure S1: Structures of the cyclopentyl-cinnabaramides obtained by mutasynthesis. A) Cyclopentyl-
cinnabaramide A: R1 = OH, R2 = H, cyclopentyl-cinnabaramide B: R1 = R2 = OH, and cyclopentyl-
cinnabaramide C: R1 = R2 = H. B) Cyclopentyl-cinnabaramide D: R1 = R2 = OH, cyclopentyl-
cinnabaramide E: R1 = OH, R2 = H 
 Cinnabaramide A Cyclopentyl-
Cinnabaramide[a] 
15-Chlorocinnabaramide 17-Chlorocinnabaramide 
atom C. Mult. H. ( in Hz) C. Mult. H. ( in Hz) C. Mult. H. ( in Hz) C. Mult. H. ( in Hz) 
1 175.9, qC - 175.9, qC - 175.8. qC - 175.9, qC - 
2 47.7, CH 2.41, dd (7.6, 
5.8) 
47.7, CH 2.42, t(6.0) 47.5, CH 2.46, m 47.6, CH 2.44, t (6.5) 
3 86.1, qC - 86.6, qC - 86.0, qC - 86.1, qC - 
4 78.6, qC - 78.6, qC - 78.6, qC - 78.6, qC - 
5 69.1 CH 3.67, dd (9.0, 
7.8) 
69.4, CH 3.75, t (7.6) 69.1, CH 3.67, t (8.2) 69.1, CH 3.68, d (9.8) 
6 37.7, CH 2.29, m 42.1, CH 1.98, m 37.7, CH 2.29, m 37.7, CH 2.29, m 
7 128.5, 
CH 
5.81, m 29.8, CH2 1.29, 1.78, m 128.5, CH 5.80, m 128.5, CH 5.81, m 
8 127.7, 
CH 
6.73, m 24.1, CH2 1.44, 1.54, m 127.7, CH 5.72, m 127.7, CH 5.73, m 
9 24.6, CH2 1.92, m 25.2, CH2 1.46, 1.58, m 24.5, CH2 1.91, m 24.5, CH2 1.92, m 
10 21.0, CH2 1.41, 1.70, m 28.9, CH2 1.23, 1.69, m 21.0, CH2 1.41, 1.70, 
m 
21.0, CH2 1.41, 1.70, 
m 
11 25.3, CH2 1.24, 1.82, m - - 25.3, CH2 1.24, 1.81, 
m 
25.3, CH2 1.24, 1.82, 
m 
12 24.7, CH2 1.49, 1.60, m 24.7, CH2 1.48, 2.58, m 24.1, CH2 1.57, 1.77, 
m 
24.5, CH2 1.51, 1.60, 
m 
13 27.0, CH2 1.45, 1.53, m 27.0, CH2 1.44, 1.52, m 24.1, CH2 1.54, 1.59, 
m 
26.9, CH2 1.46, 1.55, 
m 
14 28.8, CH2 1.29, m 28.8, CH2 1.28, m 37.4, CH2 1.69, 1.76, 
m 
28.3, CH2 1.33, m 
15 31.0, CH2 1.28, m 31.0, CH2 1.28, m 66.0, CH 4.01, m 25.9, CH2 1.40, m 
16 22.0, CH2 1.28, m 22.0, CH2 1.28, m 30.9, CH2 1.66, 1.82, 
m 
31.9, CH2 1.72, m 
17 13.9, CH2 0.87, t (6.7) 13.9, CH3 0.87, t (6.3) 10.6, CH3 0.97, t (7.2) 45.3, CH2 3.64, m 
18 20.0, CH2 1.74, s 20.0, CH3 1.74, s 19.9, CH3 1.75, s 20.0, CH3 1.74, s 
19 168.9, qC - 169.3, qC - 168.8, qC - 168.9, qC - 
NH - 8.91, s - 8.79, s - 8.92, s - 8.92, s 
OH - 5.49, d (7.9) - 5.34, d (7.1) - 5.50, d (7.6) - n.d. 
[a] The same atom numbering was used for the cyclopentyl derivatives as for other cinnabaramides. Consequently, C-11 is lacking here. 
Table S4: NMR data assignment for cinnabaramide A and its novel derivatives 
IV
 
 
Figure S2: Synthesis of precursors for feeding experiments. 
 
 A) Scheme of (E)-4-chloro-2-octeonoic acid synthesis. 
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C) Scheme of (E)-8-chloro-2-octenoic acid and its corresponding SNAC derivative synthesis. 
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D) Scheme of (E)-5-chloro-2-octenoic acid synthesis. 
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Figure S3: 1H NMR spectra of the cinnabaramide hexyl side chain analog precursors. 
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1H NMR spectrum (CDCl3, 300 MHz) of (E)-6-chloro-2-octenoyl-SNAC 
VI
 
 
 
1H NMR spectrum (CDCl3, 300 MHz) of (E)-8-chloro-2-octenoic acid 
 
 
 
 
 
 
1H NMR spectrum (CDCl3, 300 MHz) of (E)-8-chloro-2-octenoyl-SNAC 
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1H NMR spectrum (CDCl3, 300 MHz) of (2E,4E)-2,4-octadienoic acid 
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Figure S4: 1H and 13C NMR spectra of the novel cinnabaramides.  
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Microbial polyketides represent a major class of secondary metabolites formed by tremendously large multimodu-lar enzymatic machineries termed polyketide synthases1. 
Their importance is best demonstrated by referring to the large 
number of polyketides applied in the clinic, many of which are 
regarded as blockbuster drugs2. The enormous structural variety 
shown by natural products of the polyketide is regarded as the 
major reason why these molecules can evolve to interact with a large 
number of targets.
Much of the chemical diversity stems from the multimodularity 
of each assembly line in which each module not only determines 
the choice of the starter or extender unit but also selectively speci-
fies the oxidation status (keto, hydroxyl or enoyl) of each position 
in the structure, selectively3. Additional diversity is generated by the 
methylation of hydroxyl groups or carbon atoms to form methoxy, 
methyl or gem-dimethyl partial structures as well as by the tailoring 
of reactions that occur after polyketide assembly such as glycosyla-
tions, carbamoylations or hydroxylations.
Acyltransferases are in charge of loading the extender dicar-
boxylic acid onto the carrier protein, and thus each acyltransferase 
domain in every module of the polyketide synthase (PKS) has the 
potential to incorporate malonyl-CoA derivatives with any side 
chain (in theory, even two side chains) that metabolism can gener-
ate. For a long time, however, it seemed that the choice of extender 
units in polyketide biosynthesis was rather limited. Polyketides 
mostly incorporate malonyl-CoA from fatty acid metabolism and 
methylmalonyl-CoA, which in several secondary-metabolite pro-
ducers is derived from other well-established pathways such as the 
succinyl-CoA mutase-epimerase pathway. Owing to the limited 
choice of extender units available from primary metabolism, side 
chain variability in polyketides seemed hardly possible.
The origins of methoxymalonyl-CoA giving rise to methoxy 
branches, as found in soraphen and ansamitocin, has been eluci-
dated. It turns out that a glycerol-derived precursor is bound to a 
carrier protein and is further processed to form this extender unit4,5. 
It was later reported that hydroxymalonyl-CoA and aminomalonyl-
CoA can be formed and used in a similar fashion6.
However, the literature describes numerous polyketides with 
side chains that cannot be explained retrobiosynthetically using 
any of the mechanisms described above (Fig. 1). Their formation 
remained enigmatic until the recent report of the biochemistry of 
the CCRs7. These enzymes reductively carboxylate crotonyl-CoA7,8 
to ethylmalonyl-CoA within the acetyl-CoA assimilation pathway, 
involving an unprecedented reaction mechanism. It was further 
suggested that crotonyl-CoA homologs may be involved in the gen-
eration of polyketide extender units such as ethylmalonyl-CoA.
Indeed, homologs of CCRs have been found to be closely asso-
ciated with a growing number of secondary-metabolite biosyn-
thetic pathways. The occurrence of these homologs can be logically 
connected to the structure of the respective compounds in a way 
that enables the prediction of the biochemistry of several of these 
enzymes. To date, CCRs were found in the pathways of cinnabar-
amides9, thuggacins10, salinosporamides11, FK506 (refs. 12,13), san-
glifehrins14, leupyrrins15, germicidins16, divergolides17, ansalactams18 
and filipin19,20 (Fig. 1 and Supplementary Results, Supplementary 
Fig. 1). In addition, CCRs have been predicted to be involved in 
the biosynthesis of other secondary metabolites for which no bio-
synthetic genes have been reported yet (for example, icumazole). 
However, most of the enzymes lack biochemical characterization, 
and no structural information is available for them. So far, only 
SalG, an enzyme involved in the formation of chloroethylmalonyl-
CoA from chlorocrotonyl-CoA in salinosporamide biosynthesis11, 
and PteB, an 2-octenoyl-CoA reductase-carboxylase involved in 
filipin biosynthesis, have been biochemically characterized19,20. We 
were intrigued by the fact that the myxobacterial metabolite thug-
gacin as well as the actinomycete-derived cinnabaramide (Fig. 1) 
contain hexyl side chains. Both biosynthetic gene clusters turned 
out to have CCR homologs (CinF and TgaD), which, interestingly, 
had very low sequence homology9,10 despite their assumed identi-
cal function. Both enzymes were hypothesized to be involved in the 
formation of hexylmalonyl-CoA from 2-octenoyl-CoA.
In this report, we biochemically characterized CinF and solved 
the crystal structure of the enzyme in complex with NADP+ and its 
substrate 2-octenoyl-CoA at high resolution. We were able to show 
1Department of Molecular Structural Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany. 2Department of Microbial Natural 
Products, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland 
University, Saarbrücken, Germany. 3Faculty of Science and Health, University of Koya, Koya, Kurdistan, Iraq. 4These authors contributed equally to this 
work. *e-mail: dirk.heinz@helmholtz-hzi.de or rom@helmholtz-hzi.de
Unusual carbon fixation gives rise to diverse 
polyketide extender units
Nick Quade1,4, Liujie Huo2,4, Shwan Rachid2,3, Dirk W Heinz1* & Rolf Müller2*
Polyketides are structurally diverse and medically important natural products that have various biological activities. During 
biosynthesis, chain elongation uses activated dicarboxylic acid building blocks, and their availability therefore limits side chain 
variation in polyketides. Recently, the crotonyl-CoA carboxylase-reductase (CCR) class of enzymes was identified in primary 
metabolism and was found to be involved in extender-unit biosynthesis of polyketides. These enzymes are, in theory, capable of 
forming dicarboxylic acids that show any side chain from the respective unsaturated fatty acid precursor. To our knowledge, we 
here report the first crystal structure of a CCR, the hexylmalonyl-CoA synthase from Streptomyces sp. JS360, in complex with 
its substrate. Structural analysis and biochemical characterization of the enzyme, including active site mutations, are reported. 
Our analysis reveals how primary metabolic CCRs can evolve to produce various dicarboxylic acid building blocks, setting the 
stage to use CCRs for the production of unique extender units and, consequently, altered polyketides. 
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that two residues in the active site are critical for the carboxylation 
reaction catalyzed by CinF. Additionally, the structure allowed us to 
identify residues important for substrate specificity. By point muta-
genesis of these residues, it was possible to change the substrate 
specificity of the protein. To our knowledge, the structure of CinF 
provides the first structural model for the CCR class of enzymes, 
allowing insight into a unique way to establish structural diversity 
in polyketides.
RESULTS
CinF contains two distinct domains and forms a tetramer
We solved the structure of the apo-2-octenoyl-CoA carboxylase-
 reductase CinF at 2.25-Å resolution and in complex with NADP+ 
and 2-octenoyl-CoA at 1.9-Å resolution. The asymmetric unit 
contains four CinF monomers (chains A–D) (Fig. 2a). For the apo 
structure, residues 1–347 were modeled with some gaps due to weak 
electron density, which is probably brought about by flexibility in 
the absence of the ligands. These parts were well defined in the 
structure of the ligand-bound complex, which comprises residues 
1–445. Both structures align quite well, with an average r.m.s. devia-
tion of 0.63 Å for CA atoms. Unless stated otherwise, we refer to the 
structure of the complex in the remainder of the text.
CinF can be divided into two domains: the catalytic domain pres-
ent at the N and C termini (residues 1–201 and 361–445, respec-
tively) and the central cofactor-binding domain (residues 202–360) 
(Fig. 2b). The latter has a Rossmann fold, which contains two mono-
nucleotide-binding BABAB motifs and an additional strand, B14. The 
catalytic domain consists of a seven-stranded antiparallel B-sheet, 
a separate three-stranded antiparallel B-sheet and eleven A-helices.
In the asymmetric unit, four CinF monomers were found in a 
dimer-of-dimers assembly (Fig. 2a). Size-exclusion chromatogra-
phy of CinF suggests a molecular mass of 176 kDa (calculated mass, 
48 kDa), corresponding to a tetramer (Supplementary Fig. 5). 
Analysis of the most probable assembly using the protein inter-
faces, surfaces and assemblies (PISA) server (http://www.ebi.ac.uk/
msd-srv/prot_int/pistart.html) also suggests a tetramer covering an 
interface area of 25,410 Å2 (Supplementary Fig. 6)21. The strongest 
interaction between two monomers is between the cofactor bind-
ing domains of chains A and D as well as between chains B and C, 
with an average dimer interface area of 1,475 Å2 (Fig. 2a). This 
interaction is mainly mediated by B15 of both subunits, thus creat-
ing the continuous 12-stranded B-sheet B14 that interacts with the 
same B-strand from the other chain, and helix A16, which is inserted 
between the two domains of the other chain. The two dimers interact 
via two interfaces to form the tetramer. The first tetramer interface is 
between the catalytic domains of chains A and B and chains C and D, 
covering an average area of 1,252 Å2, whereas the second is located 
between the cofactor binding domains of chains A and C and chains 
B and D and is relatively weak, covering an area of only 629 Å2.
Structure and activity define NADP(H) as the cofactor
Well-defined electron density between the two domains of CinF 
allowed unambiguous placement of the NADP+ molecule in all 
four subunits. The NADP+ molecule assumes an extended con-
formation and is only slightly bent around the loop preceding B14 
and the loop between B12 and A15 (Fig. 3a). These loops make 
several interactions with the NADP+ molecule and are disordered 
in the apo structure. The adenine group is bound mostly via 
Figure 1 | Unusual alkylmalonyl thioester building blocks generated by reductive carboxylation and incorporated into bacterial polyketide metabolites. 
CinF homologs are circled in dark yellow and their likely products are framed in black: 1, hexyl-malonyl-CoA; 2, chloroethyl-malonyl-CoA; 3, 2-carboxyl-5-
methylhexanoyl-CoA.
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water-mediated contacts and hydrophobic interactions with Ser338 
and Ser339. The 2`-phosphate group is involved in hydrogen bonds 
with Lys257 and with the OH group and the backbone nitrogen 
of Ser253 as well as by several water-mediated interactions, for 
example with Arg272 and Ser230. This shows that NADPH is 
indeed the cofactor, not NADH, as the use of NADH instead of 
NADPH abolished any activity in the reaction assay (data not 
shown). The pyrophosphate group is tightly bound via hydrogen 
bonds with Gln405 and with the backbone nitrogens of Gly232 and 
Leu233 as well as through several water-mediated interactions. The 
last two residues are located at the N-terminal end of helix A10. 
On the other hand, the nicotinamide group, which assumes an anti 
conformation, is inserted in a hydrophobic pocket lined by Leu201, 
Thr205, Leu233 and Cys335 and is held in position by hydrogen 
bonds with Thr205 and His361.
CinF positions 2-octenoyl-CoA for catalysis
Density for the 2-octenoyl-CoA was much clearer in monomers A 
and B than in C and D, suggesting only partial occupancy of the 
ligand in the latter two. This results in a high B factor for chains 
C and D and is probably due to subtle differences caused by crys-
tal packing. 2-Octenoyl-CoA was built into the monomer with the 
best defined density (chain A) and was then placed in the other 
monomers using noncrystallographic symmetry. The mode of 
2-octenoyl-CoA binding is thus described for chain A. The long 
and flexible ligand is bound in an extended conformation in which 
the acyl group is buried within the catalytic domain, whereas the 
CoA is bound on the surface of the monomer and held in place by 
interactions with the dimer partner of chain A (chain D) (Fig. 3b). 
The acyl group is accommodated by a hydrophobic pocket created 
by residues Pro141, Ala142, Met156, Ala163, Leu201, His361 and 
Gly362 as well as by the nicotinamide group of the NADP+ molecule 
(Fig. 3c). This places the C3 of the octenoyl chain in perfect posi-
tion for the hydride transfer from an NADPH molecule.
The pantetheine part of the CoA is bound in the interface between 
the catalytic domain of chain A and A14 and A16 of chain D (Fig. 3b). 
It makes most of its contacts through hydrophobic interactions with 
Trp80, Pro86, Leu87, Phe92 and Phe166 from chain A as well as with 
Tyr349 and Met352 from chain D. Additionally, there is a hydrogen 
bond from Arg348, and there are some water-mediated interactions. 
The remainder of the CoA molecule winds around helix A6 and the 
preceding loop. The CoA phosphates make contact with His91 from 
chain A, Arg286 and Arg293 from A14, and Tyr349 from A16 of 
chain D. These residues are not visible in the apo structure.
The ribose and the adenine parts of the CoA molecule are posi-
tioned on the surface of monomer A. They are only held in place 
by hydrophobic interactions with Leu87, Pro88 and His91 and by a 
water bridge to Asp36.
In silico docking suggests a CO2 binding site
CCRs use CO2 to carboxylate their substrates from the re face, in 
a position anti to the hydride transfer8. We aimed to confirm this 
by solving the structure of CinF in complex with CO2. However, 
cocrystallization with as much as 100 mM Na2CO3 or CS2, to act as 
CO2 mimics, or aeration of the crystals with up to 40 bar CO2 in a 
pressure chamber for 15 min right before freezing did not result in 
detectable CO2 (or CS2) binding. Therefore, we docked CO2 into the 
structure in silico22. Several very similar solutions were found, and 
all of them had relatively low affinities (Fig. 3d and Supplementary 
Fig. 7). The CO2 molecule is held in place by hydrogen bonds with 
residues Asn77 and Glu167 as well as by hydrophobic interactions 
with the underlying Phe166. The CO2 is in an anti position relative 
to the NADP+, and the distance from the C atom of the CO2 to the 
C2 of 2-octenoyl-CoA is about 3.3 Å. Therefore, we deem this a 
very probable orientation as the CO2 is optimally positioned for a 
nucleophilic attack from C2 of 2-octenoyl-CoA.
A comparison with other protein structures in complex with 
CO2 notably showed a similar CO2 binding site as proposed for 
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Figure 2 | Structure of CinF. (a) Image of the quaternary structure of CinF showing the dimer-of-dimers fold. The monomers are shown as cartoons, and 
the transparent surface is depicted in orange, blue, yellow and red. The ligands are shown as sticks. (b) Cartoon representation of the interface of the CinF 
monomer and dimer. Helices of one monomer are colored in blue, B-sheets in red and loops in white. The ligands are shown as sticks, NADP+ is in green, 
2-octenoyl-CoA in pink and the other monomer in yellow.
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CinF in an Rh protein (PDB code 3B9Z; Nitrosomonas europaea)23 
(Supplementary Fig. 8). In this structure, the CO2 is bound by 
an  asparagine on one side and an aspartate on the other, whereas 
a phenylalanine residue is found below the CO2. This further cor-
roborates our hypothesis that the CO2 is bound as suggested by our 
docking results.
CCRs show several insertions compared to other reductases
The results from size exclusion chromatography and PISA analysis 
suggest that CinF forms a tetramer. The closest homologous struc-
tures of CinF, two putative CCRs (unpublished data; PDB codes: 
3HZZ and 3KRT, both with 51% sequence identity), appear to form 
a similar tetramer. Tetrameric assemblies have also been shown for 
related proteins such as SsADH (PDB code 1R37, 24% sequence 
identity)24, whereas others, such as PIG3 (PDB code 2J8Z, 25% 
sequence identity)25, are dimeric. These dimers correspond to the 
strong dimer interface observed in CinF, which creates the continu-
ous B-sheet between the cofactor binding domains.
Comparison of CinF to reductases such as PIG3 reveal some 
remarkable differences between the otherwise similar structures 
(Fig. 4a). The insertion of several amino acids in the cofactor bind-
ing domain of CinF leads to an elongation and twist of helix A14 
in CinF compared to the same helix in PIG3. This twist places the 
residues (Arg286 and Arg293 in CinF and PIG3, respectively) in 
proximity to the CoA of the dimer partner. Another insertion in 
CinF exists between helix A5 and sheet B5, forming the two addi-
tional helices A6 and A7 as well as another short sheet, B4. This 
insertion also has an important role in substrate binding. Another 
short insertion involved in CoA binding can be found after sheet 
B1, leading to the formation of a helix, A3. CinF contains addi-
tional amino acids at its N and C termini, which form two helices 
each; neither helix, however, is involved in ligand binding or in 
tetramer formation.
Two residues define the substrate specificity
The three structures of the carboxylase-reductase family are overall 
very similar, with r.m.s. deviations of 1.3 Å and 1.5 Å for common 
CA atoms of chain A when CinF is compared with the CCRs from 
Streptomyces coelicolor (PDB code 3KRT) and Streptomyces collinus 
(PDB code 3HZZ), respectively (Fig. 4b). These two proteins are 
proposed to catalyze the reductive carboxylation of crotonyl-CoA, 
whereas CinF catalyzes the reaction with 2-octenoyl-CoA, which 
has a longer acyl chain. CinF has an elongated hydrophobic pocket 
for the binding of the octenoyl chain, whereas in the other mem-
bers of the carboxylase-reductase family no such pocket is detect-
able. Instead, the potential pocket is blocked by the large residues 
Phe370 and Ile171 in the CCR from S. coelicolor, whereas in CinF 
the corres ponding residues Gly362 and Ala163 are small (Fig. 4c). 
Trp80
Ser337
Ser338
NADP+
NADP+
His313
Arg272 Arg286
Arg293
Tyr349
Lys353
Arg348 Met352
Trp80Asp167
Phe166Phe92
Leu87
Pro86
His91
Pro88
Asp36
Trp351
Ser253
Lys257
Ser403
Gly232
Asn405
Leu233Thr205
His361
Octenoyl-CoA
NADP+
Gly362
Met156
Pro141
Leu201
Ala142
His361
Ala163
Octenoyl-CoA
NADP+
Asn77
Phe166
Glu167
CO2
Octenoyl-CoA
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a b
c d
Figure 3 | Ligand binding by CinF. CinF is shown as a cartoon and in sticks; chain A is colored blue and chain D is yellow. NADP+ and 2-octenoyl-CoA are shown 
as green and pink sticks, respectively. The electron density is shown at 1.0 S as gray mesh. (a) Interactions between NADP+ and CinF showing the residues 
responsible for cofactor specificity. (b) Binding of 2-octenoyl-CoA at the interface between chains A and D. (c) Close-up of the hydrophobic substrate binding 
pocket of the 2-octenoyl-chain. (d) Model of CO2 docked into the structure of CinF. CO2 is shown as cyan sticks. Dashed lines indicate hydrogen bonds.
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Thus, these two positions seem to determine the substrate specificity 
in carboxylases and reductases.
A putative CCR from Streptomyces hygroscopicus (GenBank 
Protein accession number AAR32675), which has 90% sequence 
identity with CinF, is probably also able to use 2-octenoyl-CoA as a 
substrate as none of the differing amino acids are involved in ligand 
binding (Fig. 4d and Supplementary Fig. 9).
A recent report describes PteB from Streptomyces avermitilis as a 
2-octenoyl-CoA carboxylase-reductase with relaxed substrate speci-
ficity19. In its ligand-binding site it shares the small alanine with CinF 
(Ala163). However, instead of also sharing a glycine with CinF, PteB 
has the large amino acid tyrosine (Fig. 4d). Therefore, it is probable that 
the geometry of the substrate binding pocket of PteB deviates slightly 
from that of CinF because it has several insertions and deletions rela-
tive to CinF that accommodate the relatively long 2-octenoyl-CoA.
Another protein with a substrate other than crotonyl-CoA is 
SalG (70% sequence identity) from Salinispora tropica, which is 
involved in the production of salinosporamides11. SalG also deviates 
in the two positions previously described to be important for sub-
strate specificity (Fig. 4d and Supplementary Fig. 9). SalG also has 
an alanine in the same position as CinF (Ala163), but instead of the 
Gly362 in CinF or the Phe370 in the CCR from S. coelicolor, it has 
an isoleucine. In silico modeling of this mutation shows that the size 
of the substrate binding pocket of CinF is reduced, so that instead of 
2-octenoyl-CoA only pentenoyl-CoA will fit into the pocket (Fig. 4c). 
This agrees well with the data of Eustaquio et al. (2009)11 that show 
chlorocrotonyl-CoA is the native substrate and is the same size as 
pentenoyl-CoA.
Recently, it has also been proposed that branched extender units 
can be introduced into polyketides by the CCR DivR (GenBank 
Table 1 | Apparent kinetic constants of CinF, CinFG362F and CinFA163I for reductive carboxylation activity
Enzymes Substrates kcat (min−1) KM (mM) kcat/KM (min−1 mM−1)
Relative catalytic 
efficiency (%)
CinF Crotonyl-CoA 82.6 o 4.4 0.954 o 0.050 86.6 100
2-Octenoyl-CoA 17.4 o 1.1 0.230 o 0.010 75.7 75.7
2-Octenoyl-SNAC 16.6 o 1.1 0.387 o 0.030 42.9 42.9
CinFG362F Crotonyl-CoA 24.1 o 2.2 0.728 o 0.046 33.1 38.3
CinFA163I Crotonyl-CoA 23.2 o 1.8 0.998 o 0.058 23.25 26.8
Original kinetic data are shown in Supplementary Figure 11. Each measurement was performed in three independent experiments. Data represent mean values o s.d.
Insertion 1
(helix 14)
a
d
b c
Insertion 2
(helix 6 and 7)
Insertion 3
(helix 3)
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helices at
termini
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C
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Ala163
NADP+
Phe370
Ile171
Octenoyl-CoA
Octenoyl-CoA
CCR_S. hygroscopicus
CCR_S. collinus
PteB
SalG
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Figure 4 | Comparison of CinF with other structures. (a) Comparison of CinF (blue) with PIG3 (yellow) showing the insertions of CinF. (b) Superposition 
of CinF (blue) with the CCRs from S. collinus (green; PDB code 3HZZ) and S. coelicolor (maroon; PDB code 3KRT). The ligands of CinF are shown as 
blue sticks. (c) Comparison of the substrate binding sites of CinF (blue) and the CCR from S. collinus (gray). The binding site of CinF is lined by small 
residues (Gly362 and Ala163), whereas this binding site is blocked by Ile171 and Phe370 in the CCR from S. collinus. This explains why CinF is able to 
use 2-octenoyl-CoA as a substrate whereas the other CCRs are not. In SalG, instead of the glycine residue an isoleucine is found. This residue was 
modeled into the ligand-binding site of CinF (purple). It explains why SalG is able to use the longer Cl−−crotonyl-CoA instead of the usual crotonyl-CoA. 
(d) Truncated structure-based sequence alignment of CinF with other carboxylase-reductase proteins. The sequences of CinF (S. coelicolor), a putative 
2-octenoyl-CoA carboxylase-reductase (S. hygroscopicus), SalG (S. tropica), DivR (Streptomyces sp. HKI0576) and a putative CCR (S. collinus, PDB code 
3KRT) and the 2-octenoyl-CoA carboxylase-reductase PteB (S. avermitilis) were aligned with ClustalW1 and displayed with ESPript2.22. The positions of 
the residues determining the substrate specificity are marked in yellow and with an asterisk.
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Gene accession number NP_824066, 68% sequence identity)17. 
DivR deviates from the typical CCRs in the positions that are 
responsible for substrate specificity (Fig. 4d and Supplementary 
Fig. 9). Instead of a phenylalanine, DivR has an alanine, Ala363, but 
it has an isoleucine at position 164 as in typical CCRs. Therefore, 
it should be possible for DivR to accept larger aliphatic chains in 
the substrate, such as the isobutenoyl moiety it has been proposed 
to use.
CinF converts 2-octenoyl-CoA to hexylmalonyl-CoA
It has been proposed that CinF is responsible for providing hexyl-
malonyl-CoA for the synthesis of cinnabaramides9. To test this 
hypothesis, we incubated purified protein with 2-octenoyl-CoA, 
crotonyl-CoA and 2-octenoic acid N-acetylcysteamine thioester 
(2-octenoyl-SNAC) in the presence of hydrogen carbonate 
and NADPH and analyzed the corresponding products. High-
Resolution MS (HRMS) analysis (Supplementary Fig. 10) showed 
that after incubation of crotonyl-CoA with CinF, a new compound 
with a retention time of 4.9 min and a m/z [M+H]+ of 882.155 could 
be detected, corresponding to the expected product ethylmalonyl-
CoA (calculated m/z: 882.150). After incubation with 2-octenoyl-
CoA, CinF generated a new compound with a retention time of 
11.4 min and a m/z [M+H]+ of 938.194 corresponding to the 
expected mass of hexylmalonyl-CoA (calculated m/z: 938.193). 
Incubation of 2-octenoyl-SNAC yielded a new substance with a 
retention time of 5.2 min and a m/z [M+H]+ of 290.142 correspond-
ing to hexyl malonyl-SNAC (calculated m/z: 290.141).
To determine the specificity of CinF toward different substrates, 
we conducted kinetic studies with CinF (Supplementary Fig. 11). 
Comparison of the kcat and KM values for the different substrates 
showed that CinF is able to process all three substrates with simi-
lar efficiency. However, it has a higher substrate specificity for 
crotonyl-CoA than for the other substrates. CinF had a lower KM 
value and thus a higher affinity for 2-octenoyl-CoA and 2-octenoyl-
SNAC than for crotonyl-CoA (Table 1). It is interesting to note that 
2-octenoyl-CoA and 2-octenoyl-SNAC are converted at nearly the 
same rate. It therefore seems that the CoA only increases affinity for 
the protein by establishing further interactions, whereas the reac-
tion velocity is mostly determined by the acyl of the substrate.
CinF mutants show altered substrate specificity
To investigate the importance of the Gly362 located within the 
ligand-binding pocket for substrate specificity, we mutated this 
residue to phenylalanine as found in typical CCRs or to isoleucine 
as found in SalG11. Another residue, Ala163, was also mutated to 
isoleucine as can be found in typical CCRs. Kinetic studies were 
performed with these three CinF variants using the preferred CinF 
substrate 2-octenoyl-CoA, 2-octenoyl-SNAC and the native CCR 
substrate crotonyl-CoA. All variants lost their ability to carboxylate 
2-octenoyl-CoA and 2-octenoyl-SNAC completely, revealing the 
crucial role of these amino acids for substrate specificity (Table 1). 
CinFG362F and CinFA163I had weak catalytic activity toward crotonyl-
CoA (Table 1), whereas CinFG362I was found inactive in this assay 
against all of the applied substrates. It was therefore possible to 
suppress the 2-octenoyl-CoA–converting activity with one single 
mutation in the active site while retaining some of its crotonyl-CoA– 
converting activity.
Docking of CO2 into the structure of CinF suggested that resi-
dues Glu167 and Asn77 are involved in the binding and activa-
tion of CO2. To verify this hypothesis, we tested several mutants 
of these residues (CinFE167A, CinFE167K, CinFE167Y, CinFN77A, CinFN77E 
and CinFN77Y) for their ability to perform the reduction and car-
boxylation reactions. The activity assays showed that all six of these 
mutated CinF variants completely lost their reductive carboxylation 
activity but partially retained their reductive activity for 2-octenoyl-
CoA (Supplementary Fig. 12). In the absence of CO2, the reductive 
activity of all variants was kinetically characterized with 2-octenoyl-
CoA only (Table 2). Remarkably, CinFG362F showed 117% catalytic 
efficiency in comparison to native CinF. It is possible that CinFG362F, 
owing to flexibility in the active site, is still able to bind the substrate 
2-octenoyl-CoA, albeit with reduced affinity. The resulting shorter 
residence time of the substrate in the protein may be sufficient to 
allow transfer of the hydride from the NADPH but not addition of 
the CO2, which seems to bind only weakly to the protein. Therefore, 
a decrease in CinF’s affinity for the substrate may abolish carboxyla-
tion but not reduction.
These data strongly support our hypothesis regarding the CO2 
binding site as determined by in silico analysis on the basis of the 
crystal structure. All CinF mutants seemed to be properly folded as 
tested by CD spectroscopy (Supplementary Fig. 13).
DISCUSSION
Intrigued by the chemical diversity nature generates in secondary 
metabolism, we set out to analyze the molecular basis for struc-
tural diversity found in the side chains of polyketides. Recent 
studies suggest that, in addition to known ways to biosynthesize 
the building blocks required for Claisen ester condensation, there 
must exist another common way to generate activated malonic 
acid derivatives that vary in their C2 substituents. The key step 
on this route is reminiscent of the crotonyl-CoA carboxylase-
reductase found in primary metabolism. As this enzyme has not 
been structurally described, we set out to study CinF and present 
here, to our knowledge, the first detailed structure analysis of a 
carboxylase-reductase.
Our structures of CinF showed how its substrate is bound in the 
active site and allowed the identification of two residues (Gly362 
and Ala163) that are responsible for the substrate specificity of this 
class of enzymes. Mutations (G362F, G362I and A163I) of these 
Table 2 | Apparent kinetic constants of CinF and its mutated variants for reductive activity versus 2-octenoyl-CoA
Enzymes kcat (min−1) KM (mM) kcat/KM (min−1 mM−1) Relative catalytic efficiency (%)
CinF 19.4 o 1.3 0.883 o 0.050 30.0 100.0
CinFE167A 20.1 o 1.8 0.796 o 0.09 25.3 84.1
CinFE167K 20.5 o 1.1 0.807 o 0.12 25.4 84.2
CinFE167Y 21.0 o 2.3 0.812 o 0.04 25.9 85.8
CinFN77A 22.5 o 1.4 1.200 o 0.10 18.8 62.1
CinFN77E 24.1 o 1.3 1.200 o 0.08 20.1 66.6
CinFN77Y 22.7 o 1.1 0.980 o 0.08 23.2 76.9
CinFG362F 18.8 o 1.2 0.532 o 0.030 35.3 117.6
CinFA163I 19.4 o 0.5 0.621 o 0.020 31.2 104.0
Original kinetic data are shown in Supplementary Figure 11. Each measurement was performed in three independent experiments. Data represent mean values o s.d.
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residues render CinF unable to use 2-octenoyl-CoA as a substrate, 
underlining their importance. It thus seems that by varying the 
size of the substrate-binding pocket, different substrates can be 
accommodated, leading to different substrate specificities of these 
enzymes. These findings are highly interesting for the generation 
of engineered CCRs to produce drugs incorporating uncommon 
extender units (described further below).
It has been demonstrated that CCRs carboxylate the substrate 
on the re side to yield a product with (2S) stereochemistry, whereas 
the hydride transfer from the NADPH is pro-(4R) specific to the 
re face of the substrate8. The arrangement of the substrates in the 
CinF structure clearly agrees with these findings, suggesting a com-
mon evolutionary origin of the carboxylase-reductase family and 
medium-chain reductases. However, CCRs have evolved to bind 
CO2, and reductive carboxylation is preferred over sole reduction of 
the substrate8. We used in silico docking to identify a potential CO2 
binding site. CO2 is bound by hydrogen bonds to a glutamate and an 
asparagine and by hydrophobic interactions with a phenylalanine 
(Fig. 3d). The hydrogen bonds would increase the electrophilicity 
of the molecule, thus making it more susceptible to nucleophilic 
attack from the 2-octenoyl-CoA double bond. The hydrophobic 
phenylalanine, on the other hand, probably reduces the binding of 
water in this pocket to prevent the reduction of the 2-octenoyl-CoA 
without carboxylation. This hypothesis is strongly corroborated by 
the results of our mutational analysis, leading to the discovery of 
enzymes that do not carboxylate but can still reduce.
In conclusion, to our knowledge we have for the first time solved 
a structure of a protein from the CCR family in complex with 
NADP+ and its substrate 2-octenoyl-CoA, of which until now only 
two apo structures were available. We have been able to show that 
two residues in the active site are critical for binding and activation 
of CO2. In addition, we have demonstrated that CinF is responsible 
for providing the unusual polyketide building block hexylmalonyl-
CoA. Furthermore, we have identified important residues that 
determine the size of the ligand-binding pocket and thereby the 
substrate specificity of these proteins. In light of the increasing rec-
ognition that polyketide compounds incorporate unusual building 
blocks, these findings provide a solid basis for attempts to modify 
the substrate specificity of CCR enzymes toward the generation of 
new polyketide extender units and, therefore, eventually the pro-
duction of altered polyketide structures.
However, incorporation of those extender units into polyketides 
is dependent on acyl-transferase domains required for recognition 
and loading onto the corresponding carrier protein of the PKS. This 
issue could be addressed by swapping the respective acyl- transferase 
domains found in the native PKS to change its specificity, an experi-
mental approach that has increasingly met with success in recent 
years26. In addition, the subsequent PKS elongation modules need 
to be capable of processing the altered intermediate, and the unsatu-
rated substrate for the CCR reaction needs to be available. Given 
these obstacles, the success of biosynthetic engineering may seem 
unlikely at first sight. However, as has been shown for the cinnabar-
amide biosynthetic pathway, such engineering approaches are indeed 
likely to result in the expected altered structures9. Acceptance of the 
unnatural dicarboxylic acid by the PKS and subsequent processing 
to produce chlorinated analogs was successful, thus demonstrating 
the validity of the approach.
On the basis of the structural insight presented in this manu-
script, the stage is now set for directed engineering of CCRs to 
accept additional substrates. In the future, identification of even 
more CCR homologs can be expected in the course of character-
izing biosynthetic pathways for polyketides with various side chains 
(Fig. 1). The knowledge gained will pave the way for learning more 
about this intriguing class of enzymes and will eventually enable 
advanced biosynthetic engineering of polyketide pathways to 
produce new drugs.
METHODS
Amplification, cloning and heterologous expression of cinF and its variants. cinF 
and its variants were cloned into the pSTW42 expression vector (a version of the 
pGEX-6P-1 vector in which the GST tag was replaced by SUMO3 tag from the 
pSUMO3 vector and the ampicillin resistance gene was replaced by the kanamycin 
resistance gene) (S. Werner, Helmholtz Institute for Pharmaceutical Research, and 
R.M., unpublished) and heterologously expressed in Escherichia coli BL21 (DE3) 
cells as described in Supplementary Methods.
Cell lysis, protein purification and characterization. The cells were harvested 
by centrifugation (7,000g, 10 min) and resuspended in binding buffer (50 mM 
Tris, 200 mM NaCl, 10% glycerol and 10 mM imidazole, pH 7.8). Cell lysis was 
performed using a cold French Press cell (SLM-Aminco) for two times at 900 p.s.i. 
Immediately after the lysis, 1/50 volume of 50× protease inhibitor (Roche) was 
added to the suspension, which was then centrifuged at 4 °C and 12,000g for  
30 min.
The soluble fraction was filtered using a 1.2-Mm pore filter (Sartorius) and 
was applied to a 5-ml Histrap (GE Healthcare) column equilibrated with binding 
buffer. The column was washed with binding buffer and eluted with elution buffer 
(50 mM Tris, 200 mM NaCl, 10% glycerol and 500 mM imidazole, pH 7.8). The 
purity of the elution fractions was determined by SDS gel electrophoresis. After 
immobilized metal-ion affinity chromatography, the buffer of the fractions with the 
recombinant protein was exchanged with 20 mM Tris pH 8 containing 150 mM  
NaCl using a PD-10 desalting column (GE Healthcare). To remove the SUMO 
tag from the recombinant fusion proteins, the samples were treated with SUMO-
protease 2 (LifeSensor) according to manufacturer protocol (LifeSensor). After the 
cleavage, the protein was purified by nickel-nitrilotriacetic acid affinity chromato-
graphy. Both fusion protein (SUMO-CinF) and cleaved protein (CinF) were  
verified by MALDI-TOF-MS (Supplementary Fig. 2).
Finally, a calibrated Superdex 200 16/60 size exclusion chromatography column 
(GE Healthcare), pre-equilibrated with 20 mM Tris pH 8, 100 mM NaCl and 5 mM 
DTT, was used. The calibration using the gel-filtration calibration kits (GE health-
care) also allowed an estimation of the oligomeric state of the protein. The purity 
of the CinF fractions was analyzed by SDS-PAGE, and pure fractions were pooled 
and concentrated up to 10 mg ml−1 with Vivaspin 30-kDa molecular-weight cutoff 
concentrators (Sartorius). Further characterization of the protein was performed as 
described in Supplementary Methods.
In vitro activity assay. The catalytic activity of CinF was tested in vitro with three  
different substrates: crotonyl-CoA, 2-octenoyl-CoA and 2-octenoyl-SNAC. 
Crotonyl-CoA (purity ~90%, HPLC) was purchased from Sigma-Aldrich;  
2-octenoyl-CoA and 2-octenoyl-SNAC were chemically synthesized 
(Supplementary Methods), their structures were confirmed by NMR spectroscopy 
(Supplementary Figs. 3 and 4), and their purity was determined as >90% via HPLC 
as described in Supplementary Methods. The reactions were performed using a 
mixture of 2 mM of each substrate, 33 mM NaHCO3, 4 mM NADPH, 100 mM Tris 
pH 7.4 and 0.43 nM CinF (control: heat-inactivated CinF). The reactions were  
incubated at 30 °C overnight, and the detection of the products was done via 
HPLC-MS analysis (analytical procedures are detailed in Supplementary Methods). 
The protein was denatured by addition of 0.1 vol trichloroethane and heating  
at 95 °C for 5 min, and it was removed by centrifugation at 12,000g for 5 min.
Kinetic studies of CinF. Kinetic studies of CinF were performed with three dif-
ferent substrates: crotonyl-CoA, 2-octenoyl-CoA and 2-octenoyl-SNAC. Gradient 
concentrations from 0.2 mM to 2.0 mM were used for each substrate. The kinetic 
study was followed spectrophotometrically at 340 nm using a 96-well plate. The 
reaction mixture (60 Ml) contained 100 mM Tris-HCl buffer pH 8, 4 mM NADPH, 
33 mM NaHCO3 and the corresponding substrates at varying concentrations. 
The reaction was started by adding approximately 0.1 nM of purified CinF. The 
measurement was performed for 1 h. In addition, a standard curve of NADPH was 
made from 0.125 mM to 4 mM. This allowed us to follow the NADPH consump-
tion, from which the velocity of the reaction and Michaelis-Menten curves can be 
calculated and generated via the software SigmaPlot Enzyme kinetics 1.3.
CD spectroscopy. The correct folding of CinF and its mutants was verified by 
CD using 0.2 mg ml−1 protein in 10 mM Na2HPO4 pH 8, 10 mM NaCl and 2 mM 
dithiothreitol. Spectra were recorded from 190 nm to 260 nm and showed that 
CinF and all mutants were most likely properly folded.
Crystallization of CinF. 96-well sitting-drop crystal screens were set up at 
291 K. Initial thin plate-like crystals were found with 0.1 M N-cyclohexyl-2-
aminoethanesulfonic acid (CHES) buffer pH 9.5 and 10% PEG 3000. Reproduction 
of the plate-like crystals was only made possible by increasing the PEG concentra-
tion to 20% and streak seeding from the initial crystals. Streak seeding into the 
drops of the initial screen that remained clear produced several new crystallization 
conditions. Of these conditions, 0.1 M Tris pH 7, 20% glycerol and 12% PEG 8000 
was chosen for reproduction of crystals in hanging-drop vapor-diffusion plates. 
To obtain large crystals, a mixture of 1 Ml protein solution (10 mg ml−1 in 20 mM 
Tris pH 8, 100 mM NaCl and 5 mM DTT) and 1 Ml reservoir was used. The drop 
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containing the protein reservoir mixture was equilibrated against 500 Ml of reser-
voir solution. After 1 d, the drops were streak seeded using a horse-tail hair. Initial 
crystals grew after 1 d and reached their final size within 3 d. The crystals of CinF 
in complex with its substrates were produced by cocrystallization using a solution 
containing 7 mg ml−1 CinF, 10 mM NADP+, 10 mM 2-octenoyl-CoA and 50 mM 
NaHCO3.
Data collection, processing and structure determination. For data collection, the 
crystals were flash cooled in liquid nitrogen. An apo-CinF X-ray diffraction dataset 
up to 2.0 Å was collected at 100 K with the European Synchotron Radiation Facility 
(Grenoble, France) beamline ID 29, equipped with an ADSC Q315R detector at a 
wavelength of 0.97 Å. A Micromax-007 HF rotating copper anode X-ray generator 
(Rigaku) with a Saturn 944+ CCD detector (Rigaku) was used to measure the  
dataset of CinF with NADP+ and 2-octenoyl-CoA diffracting to 1.9 Å. The struc-
ture was solved by molecular replacement using the unpublished structure of a 
CCR (PDB code 3KRT, submitted by V.N. Malashkevich, Y. Patskovsky, R. Toro, 
M.J. Sauder, S.K. Burley, S.C. Almo) as a model.
Detailed data collection and refinement methods are described in the 
Supplementary Methods, and statistics are listed in Supplementary Table 2.  
The final R values were 21.8%/27.6% (Rwork/Rfree) for the apo form and 19.9%/24.6% 
for the ligand-bound form.
Accession codes.  Protein Data Bank: the structures for apoCinF and CinF with 
ligands are deposited under accession codes 4A10 and 4A0S. The previously pub-
lished structures of the Rh protein from N. europaea, a CCR from S. coelicolor, a 
CCR from S. collinus, SsADH and PIG3 are deposited under accession codes 3B9Z, 
3KRT, 3HZZ, 1R37 and 2J8Z, respectively. 
Received 16 May 2011; accepted 21 September 2011;
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Supplementary Results 
 
Supplementary Tables 
 
Supplementary Table 1 Schematic display of CinF and its functional homologs 
Protein Residues 
(aa) 
Proposed function Sequence 
similarity, identity 
to CinF* 
Accession 
nummber 
CinF 449 2-Octenoyl-CoA reductase/carboxylase - CBW54676 
TgaD 388 2-Octenoyl-CoA reductase/carboxylase 30%, 16% ADH04642 
Leu10 399 2-methylhexenoyl-CoA reductase/carboxylase 5%,10% ADZ24994 
SalG 461 Chlorocrotonyl-CoA reductase/caraboxylase 81%, 67% ABP73651 
TcsC 445 Pentenoyl-CoA reductase/carboxylase 63%, 51% ADU56308 
SfaR 454 Crotonyl-CoA reductase/carboxylase 66%, 53% ACY06299 
*: Geneious alignment (cost matrix: BLOSUM62, Gap open penalty: 11, Gap extension penalty: 3) 
 
 
 
Supplementary Table 2 CinF data collection and refinement statistics 
 Apo 2-Octenoyl-CoA/NADP complex 
Data collection   
Space group P21 P21 
Unit cell dimensions    
a, b, c (Å) 101.6, 85.2, 113.9 96.0, 83.3, 122.7 
,, (°) 90, 107.4, 90 90, 110.9, 90 
Resolution (Å) 48.5-2.25 (2.4-2.25) 47.2-1.9 (2.0-1.9) 
Rmerge (%) 14.48 (47.7) 8.7 (42.6) 
I/I 9.97 (5.49) 13.85 (3.6) 
Completeness (%) 98.76 (98.85) 98.8 (94.1) 
Redundancy 3.3 (3.2) 3.6 (3.2) 
Refinement   
Rwork/ Rfree (%) 20.9/27.3 19.9/24.6 
Unique reflections 87221 (15214) 140724 (18977) 
Atom numbers   
- Protein 12550 13389 
- Ligand - 400 
- Solvent 1515 1905 
Average B-factor (Å2)   
- Protein (chains A, B, C,D) 5.7, 6.4, 9.5, 6.9 3.4, 4.3, 4.1, 4.9 
- NADP - 15.3, 16.4, 25.2, 22.8 
- Oct-CoA - 33.6, 39.1, 75.9, 55.8 
-Solvent 18.4 14.2 
R.m.s.d. from ideal geometry   
- Bond lengths (Å) 0.0103 0.0106 
- Bond angles (°) 1.31 1.61 
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Supplementary Figures 
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Supplementary Figure 1: Complementary examples of unusual alkylmalonyl thioester building blocks 
generated by reductive carboxylation and incorporated into bacterial polyketide metabolites. CinF 
homologues are circled in dark yellow and their likely products are framed in black: 1: hexyl-malonyl-CoA; 
2: 2-(2-methylbutyl)-malonyl-CoA; 3: 2-isobutyryl-malonyl-CoA; 4: propyl-malonyl-CoA; 5: ethyl-malonyl-
CoA; 6: 2-(2-oxobutyl)-malonyl-CoA. 
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*
*
Supplementary Figure 2: Results of MALDI-TOF-MS measurements for both fusion protein (SUMO-
CinF) and cleaved protein (CinF). Both proteins were identified with a high score.  
*The name of CinG has been changed to CinF due to changes in the annotation.  
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Supplementary Figure 3: 1H-NMR spectrum of 2-octenoyl-CoA (blue) compared to the spectrum of 
commercially available crotonyl-CoA (red). 
Supplementary Figure 4: 1H-NMR spectrum of 2-octenoyl-SNAC ester. 
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Supplementary Figure 5: Chromatogramm of size exclusion chromatography of CinF using a Superdex 
200 16/60 column (GE healthcare). Absorption at 280nm is shown in blue, absorption at 260nm in red. 
Supplementary Figure 6: Monomer interfaces of CinF as determined by the PISA server1. Shown are 
only the most relevant interactions. 
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Supplementary Figure 7: In silico modelling results for CO2 binding by CinF. CinF is shown in blue, the 
CO2 in cyan. 
 
Supplementary Figure 8: CO2 binding by Rh protein (pdb code: 3B9Z, Nitrosomonas europaea)2. Rh protein 
is shown in purple, CO2 in yellow. 
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Supplementary Figure 9: Structure based sequence alignment of CinF with other carboxylase/reductase 
proteins. The sequences of CinF (Streptomyces coelicolor), a putative 2-octenoyl-CoA carboxylase/reductase 
(Streptomyces hygroscopicus), SalG (Salinospora tropica), DivR (Streptomyces sp. HKI0576) and a putative 
CCR (Streptomyces collinus, pdb code: 3KRT) and the 2-octenoyl-CoA carboxylase/reductase PteB 
(Streptomyces avermitilis) were aligned with ClustalW3 and displayed with ESPript2.24. The positions of the 
residues determining the substrate specificity are marked in yellow and with an asterisk. 
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Supplementary Figure 10: High-resolution UPLC-MS analysis of CinF-catalyzed reductive 
carboxylation of different substrates. 
A: I: Shown is the extracted ion chromatogram (EIC) of m/z [M+H]+ = 836 and of m/z [M+H]+ = 882. II: 
Shown is the EIC of of m/z [M+H]+ = 836 and of m/z [M+H]+ = 882. III: Shown is the EIC of m/z [M+H]+ = 
892.2 and m/z [M+H]+ = 938.2. IV: Shown is the EIC of  m/z [M+H]+ = 892.2 and m/z [M+H]+ = 938.2. V: 
Shown is the EIC of m/z [M+H]+ = 244.2 and m/z [M+H]+ = 290.2. VI: Shown is the EIC of m/z [M+H]+ = 
244.2 and m/z [M+H]+ = 290.2. 
B: Shown is the high-resolution mass spectrum corresponding to substrate and products. VII shows the mass 
spectrum at r.t. 5.4 min of I, where the m/z [M+H]+ = 836.148 corresponds to crotonyl-CoA. VIII shows the 
mass spectrum at r.t. 4.9 min of II, where the m/z [M+H]+ = 882.155 corresponds to ethylmalonyl-CoA. IX 
shows the mass spectrum at r.t. 12.7 min of III, where the m/z [M+H]+ = 892.189 corresponds to 2-octenoyl-
CoA. X shows the mass spectrum at r.t. 11.4 min of IV, where the m/z [M+H]+ = 938.194 corresponds to 
hexylmalonyl-CoA. XI shows the mass spectrum at r.t. 5.9 min of V, where the m/z [M+H]+ = 244.136 
corresponds to 2-octenoyl-SNAC. XII shows the mass spectrum at r.t. 5.2 min of VI, where the m/z [M+H]+ 
= 290.142 corresponds to hexylmalonyl-SNAC. 
All compounds were identified by known molecular weight through high-resolution UPLC-MS.  
Nature Chemical Biology: doi:10.1038/nchembio.734
- 10 - 
 
Supplementary Figure: 11 Results of in vitro biochemical characterisation of CinF and its variants. 
A): Determination of steady-state kinetic parameters of CinF for different thioester substrates in the presence 
of NADPH and NaHCO3. B) Determination of steady-state kinetic parameters of CinF_A163I and 
CinF_G362F variants for crotonyl-CoA in the presence of NADPH and NaHCO3. C) Determination of steady-
state kinetic parameters of CinF and its different variants only for their reductive activities versus octenoyl-
CoA in the presence of NADPH and in the absence of NaHCO3. 
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Supplementary Figure: 12 High-resolution UPLC-MS analysis of CinF and its variants-catalysed reductive 
carboxylation of 2-octenoyl-CoA. A: Shown is the extracted ion chromatogram (EIC) of m/z [M-H]- = 890.2, 
892.2 and 936.2, respectively. In the negative control (I) only the deprotonated mass m/z [M-H]- = 890.1890 
corresponding to 2-octenoyl-CoA could be observed. In the positive control (II) only the deprotonated mass m/z 
[M-H]- = 936.194 corresponding to the carboxylated product hexyl-malonyl-CoA could be observed. In assays 
incubated with all other variants (III-X) only the deprotonated mass m/z [M-H]- = 892.207 corresponding to the 
reduced product octanoyl-CoA could be observed.  
B: Shown is the high-resolution mass spectrum at different retention times corresponding to substrate and 
products. XI shows the mass spectrum at r.t. 11.09 min of I, where the deprotonated mass m/z [M-H]- = 890.189 
corresponds to 2-octenoyl-CoA. XII shows the mass spectrum at r.t. 11.03 min of III-X, where the deprotonated 
mass m/z [M-H]- = 892.207 corresponds to reduced product octanoyl-CoA. XIII shows the mass spectrum at r.t. 
9.14 min of II, where the deprotonated mass m/z [M-H]- = 936.194 corresponds to carboxylated product 
hexylmalonyl-CoA. 
All compounds were identified by known molecular weight through high-resolution UPLC-MS.  
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Supplementary Figure 13: Circular dichroism spectra of CinF and its 
variants. 
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Supplementary Methods 
Cloning and heterologous expression of cinF and its variants. 
Polymerase chain reaction was performed with primers CinF-up (5’-
TTTAAACGGGAGGTAGCAGCTTGTCCCGAGCC-3’) and CinF-dn (5’- CTCGAGTCA 
CCGGGAGGTGGCGGTGAG-3’; inserted restriction sites are highlighted in bold) to 
generate cinF PCR products with DraI/XhoI restriction site overhangs. To generate cinF 
variants’ fragments with DraI/XhoI restriction site overhangs, a three-step PCR strategy was 
performed as following: firstly with primer CinF-up and CinF-part1 (5’-
GACGATCTTCTTGAGCTTCATCCACA-3’) to amplify fragment 1 containing partial 
sequence of cinF, concurrently using primers CinF-part2 (for Gly362Phe: 5’-
TGTGGATGAAGCTCAAGAAGATCGTCGGCAGCCACTTCGCCAACCACGA-3’, for 
Gly362IIe: 5’-TGTGGATGAAGCTCAAGAAGATCGTCGGCAGCCACATCGCCAACCAC 
GA-3’; for A163I: ACGGCGACGGCATGCTCGGCACCGAACAGCGGATCTGGGG 
CTTCGAGACCA; for E167A: AGGAGCCCGCCACCCACGGCGACGGCATGCTCGGCAC 
CGCCCAGCGGGCCT; for E167K: AGGAGCCCGCCACCCACGGCGACGGCATGCTC 
GGCACCAAGCAGCGGGCCT; for E167Y: AGGAGCCCGCCACCCACGGCGACGGCAT 
GCTCGGCACCTACCAGCGGGCCT; for N77A: TCGTCGCGGTGATGGCCAGCTCCAT 
CAACTACGCCACGGTCTGGTCGGCGA; for N77E: TCGTCGCGGTGATGGCCAGCT 
CCATCAACTACGAGACGGTCTGGTCGGCGA; for N77Y: TCGTCGCGGTGATGGCCA 
GCTCCATCAACTACTACACGGTCTGGTCGGCGA; mutations are highlighted in bold) 
containing the corresponding mutation points for different cinF variants respectively, and 
CinF-dn to generate fragment 2, another partial sequence of cinF sharing a 26 bp homolog 
arm with fragment 1 (shown in italic in primers CinF-part2). Finally, using these two 
fragments mixture as template and CinF-up and CinF-dn as primers, a third PCR was 
performed to generate the different full-length cinF variants’fragments repectively. All PCR 
products were ligated into cloning vector pJET and transformed into E. coli HS966. Correct 
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construct of  pJET_cinF and pJET_ cinF_variants were confirmed by DraI/XhoI restriction 
digest and subsequent sequencing. 
To generate the expression construct pSTW42_cinF and pSTW42_cinF_variants expression 
vector pSTW42 (derived from pGEX-6P-1, GST-tag sequences was replaced by SUMO-tag 
from pSUIMO3 vector, resistance gene was exchanged from ampicillin to kanamycin) 
containing XhoI/Eco47III restriction sites was used. An N-terminal SUMO-tag containing 
poly-histidine was utilized for facilitating the subsequent purification. Ligation products were 
transformed into E.coli HS966. Correct constructs were confirmed by XhoI/NdeI restriction 
digest and sequencing. 
For heterologous expression of CinF and its variants correct constructs were transformed into 
the expression strain E. coli BL21 (DE3) by electroporation. Correct clones were transferred 
into 5 ml LB-medium with 50 g/ml kanamycin and grown overnight at 37 ºC. On the next 
day the overnight culture was used for inoculation of LB-medium with 50 g/ml kanamycin. 
The expression culture was incubated at 37 ºC to an OD600 of 0.6, and expression was induced 
by addition of 1mM IPTG. Subsequently, the culture was incubated at 16 ºC overnight.  
 
Verification of CinF using Matrix MALDI-TOF-MS 
The desired protein band was excised from the SDS-PAGE gel and washed three times with 
water. 500 l of a 50% acetonitrile (ACN) mixture in H2O were added until the gel piece was 
destained. The gel piece was then air dried and 500 l ACN were added for 10 min. The gel 
piece was air dried again and 20 l trypsin were added to each sample. After complete 
rehydration of the gel piece, 20 l 40 mM NH4HCO3 were added and the gel piece was 
incubated overnight at 30 ºC. TFA was added to a final concentration of 0.1%. The sample 
was then stored at -20 ºC prior to analysis by MALDI-MS. 0.7 l desalted protein sample was 
mixed with 0.4 l CCA matrix solution. The sample was co-crystallized with matrix on the 
metal plate and sent to the analysis in positive modus with MALDI-TOF-MS/MS. 
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Identification of the target protein was done by peptide mass-fingerprint (PMF) and peptide 
fragment-fingerprint (PFF) analysis.  
The results of the MALDI-TOF-MS were compared to the theoretical fragments after tyrosine 
digestion and uploaded to protein data bank to perform the evaluation. This analysis was able 
to identify 99.99% of the amino acid sequence and therefore confirmed correct CinF 
expression. Both fused protein (SUMO-CinF) and cleaved protein (CinF) were successfully 
identified (See Supplementary Figure 2).  
 
Synthesis and purification of 2-octenoyl-CoA/-SNAC 
Synthesis of 2-octenoyl-CoA/-SNAC was conducted by following procedures as described 
previously5. Crude, synthetic 2-octenoyl-CoA/-SNAC were purified using a Waters auto-
purification system operating in positive ionization mode. Separation was achieved using an 
XBridgePrep C18 column (Waters; 19 × 150 mm, 5 μm partical size, flow 25 mL min-1) with a 
solvent system consisting of solvent A (20 mM ammonium formiate (pH 6.0)) and solvent B 
(1:1 solvent A: MeOH). The following gradient was applied: 40% B for 4 min, 40–60% B 
over 4 min, 60–100% B over 0.5 min, 100% B for 3 min, 100 - 40% B over 0.5 min, and 4 
min 40% B. Compounds were detected by diode array and ESI-MS analysis. The purified 
product was subsequently desalted using a Sephadex column. The structure of the product 
was verified by NMR and purity was calculated according to HPLC measurement. 
 
NMR spectroscopy 
2-Octenoyl-SNAC-ester 
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1H-NMR (700 MHz, MeOD):  6.92 (dt, J = 15.5, 7.1 Hz, 1H, 3-H), 6.16 (d, J = 15.5 Hz, 1H, 
2-H), 3.34 (t, J = 6.7 Hz, 2H, 10-H), 3.06 (t, J = 6.7 Hz, 2H, 9-H), 2.24 - 2.20 (m, 2H, 4-H), 
1.92 (s, 3H, 12-H), 1.51 – 1.46 (m, 2H, 5-H), 1.38 – 1.29 (m, 4H, 6-H and 7-H), 0.92 (t, 
J = 7.1 Hz, 8-H) ppm; 13C-NMR (175 MHz, MeOD):  191.2 (1-C), 173.4 (11-C), 147.7 
(3-C), 129.4 (2-C), 40.2 (10-C), 33.1 (4-C), 32.6 (6-C), 28.8 (9-C), 28.8 (5-C), 23.4 (7-C), 
22.4 (12-C), 14.1 (8-C) ppm. HRMS (m/z): [M+H]+ calcd. for C12H21NO2S, 244.1367; found, 
244.1363: analysis (calcd., found for C12H21NO2S): C (59.22, 59.23), H (8.70, 8.68), N (5.76, 
5.76), O (13.15, 13.16), S (13.18, 13.17).  
 
2-Octenoyl-CoA 
 
 
1H-NMR (700 MHz, MeOD):  8.59 (bs, 1H, 23-H), 8.22 (s, 1H, 24-H), 6.91 (dt, J = 15.4, 7.0 
Hz, 1H, 3-H), 6.14 (d, J = 15.4 Hz, 1H, 2-H), 6.12 (d, J = 4.9 Hz, 1H, 22-H), 4.99 (m, 1H, 20-
H), 4.79 (m, 1H, 21-H), 4.48 (bs, 1H, 19-H), 4.29 (bs, 2H, 18-H), 4.08 (bs, 1H, 15-H), 4.01 
(bs, 1H, 17-Ha), 3.63 (bs, 1H, 17-Hb), 3.50 – 3.44 (m, 2H, 13-H), 3.35 – 3.32 (m, 2H, 10-H), 
3.05 (t, J = 6.8 Hz, 2H, 9-H), 2.43 (t, J = 7.1 Hz, 2H, 12-H), 2.23 - 2.18 (m, 2H, 4-H), 1.50 – 
1.44 (m, 2H, 5-H), 1.36 – 1.28 (m, 4H, 6-H and 7-H), 1.06 (s, 3H, 16-Me), 0.91 (t, J = 7.0 Hz, 
8-H), 0.85 (s, 3H, 16-Me) ppm. HRMS (m/z): [M+H]+ calcd. for C29H49N7O17P3S, 892.1907; 
found, 892.1890: analysis (calcd., found for C29H49N7O17P3S): C (39.06, 39.08), H (5.43, 
5.44), N (11.00, 10.98), O (30.50, 30.51), P (10.42, 10.42), S (3.60, 3.61). 
1H-NMR shifts of Coenzyme A moiety are according to those from commercially available 
Crotonyl-CoA ester. 
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Analysis of in vitro reaction assay  
Measurements of CinF reaction assays with different substrates were accomplished via 
chromatography conducted using an Ultimate3000 RSLC system (Dionex, Idstein, Germany) 
equipped with a Waters BEH C18 100 x 2.1 mm, 1.7 μm dp column (Waters, Milford, USA). 
The separation was carried out at 600 μl/min and 45 °C. Solvent A was 0.1 % formic acid 
(v/v) and solvent B was acetonitrile with 0.1 % formic acid (v/v). Solvent B initially remained 
at 5 % B for 2 min before increasing to 20 % during a 7 min gradient. UV spectra were 
acquired at 260 nm. The HPLC flow was splitted to 450 nl/min to allow positive nanoESI 
using a TriVersa Nanomate (Advion Biosciences, Ithaca, USA). Line spectra ranging from 
200 – 2000 m/z (R = 30000) were measured using a linear iontrap–orbitrap hybrid mass 
spectrometer (LTQ-Orbitrap, ThermoFisher Scientific, Bremen, Germany). 
Measurements of CinF and its variants in assays with 2-octenoyl-CoA were conducted using 
an Ultimate3000 RSLC system (Dionex, Idstein, Germany) equipped with a Luna HILIC 100 
x 2 mm, 3 μm dp column (Phenomenex, Torrance, USA). The separation was carried out at 
400 μl/min and 40 °C. Solvent A was 20 mM ammonium formate adjusted to pH 8.5 by 
NH4OHaq. Solvent B was acetonitrile. Solvent B initially remained at 85 % B for 0.5 min 
before decreasing from 85 to 50 % during a 15 min gradient. UV spectra were acquired at 260 
nm. The HPLC flow was splitted to 50 μl/min before ionization in (-)-ESI mode using a 
Maxis 3G mass spectrometer (Bruker Daltonics, Bremen, Germany). Line spectra were 
acquired ranging from 300 – 1200 m/z at 2 Hz.  
 
Data collection and refinement 
The CinF crystals belong to the space group P21 with unit cell dimensions a= 96.01 Å, b= 
83.30 Å and c= 122.74 Å and == 90° and = 110.96°.  The data processing was carried out 
using XDS6 and scaling was done with XSCALE. A set of 5% of randomly chosen reflections 
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were set aside for the calculation of the free R factor (Rfree). The Matthews coefficient7 of 
VM = 2.39 Å3 Da-1 indicated four monomers per asymmetric unit corresponding to a solvent 
content of 48%. To obtain initial phases molecular replacement by MOLREP8 was performed 
using the putative crotonyl-CoA carboxylase/reductase (3KRT) as a search model, finding 
four monomers in the asymmetric unit (initial FOM=0.34). One round of manual model 
building and repositioning drastically increased the FOM to 0.76. The structure was refined 
with REFMAC58 and completed in Coot9. For the data set of CinF in complex with its 
substrates the model of the apo-structure was used for molecular replacement. Clear density 
for NADP was visible in all monomers and also for 2-octenoyl-CoA in two monomers, 
whereas in the other two monomers the density was much weaker. Structure and restraint files 
for 2-octenoyl-CoA were generated using the Dundee Prodrg server10. The 2-octenoyl-CoA 
was build into the monomer with the best density (chain A) and, by applying the symmetry, 
placed in the other monomers as well. Water molecules were added and edited manually as 
well as using the water find tool in Coot with a cutoff of 1 sigma within hydrogen bonding 
distance to protein residues. A final TLS refinement11 step using five TLS groups per 
monomer as determined by the TLS Motion Determination Server 12 was carried out with 
REFMAC5. 
MolProbity13,14 validation indicated a good quality model. Nearly all residues fall within the 
allowed regions of the Ramachandran plot15 (>99%). Only in the complex structure H313, 
which is involved in substrate binding, is an outlier in all chains. The relevance of the crystal 
contacts was assessed using the PISA server1. 
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ABSTRACT
Dideuterated β-cyclohexenylalanines, proposed biosynthetic intermediates of the cinnabaramides, can be obtained from chiral alkynols via a
sequence of IrlandClaisen rearrangement, ring closing metathesis, and radical decarboxylation. Feeding experiments indicate that both (2S)-β-
cyclohexenylalanines can be incorporated into cinnabaramide, while the configuration at the cyclohexenyl ring does not restrict biosynthetic
processing.
The proteasome is a key player in the regulation of a
wide range of cellular processes by degradation of proteins,
mediating processes such as amino acid recycling, cell
differentiation, and apoptosis.1 Therefore, proteasome
inhibitors are interesting candidates as antitumor drugs.2
Effective proteasome inhibitors are widespread in nature,
produced by a wide range of microorganisms. Many of
these inhibitors are peptide derived small molecules, such
as the group of γ-lactamβ-lactones.3
In 1991, Omura et al. isolated a potent inhibitor from
Streptomyces lactacystineus, called lactacystin.4 But actu-
ally, the active compound was not lactacystin itself, but its
clasto-form omuralide (Figure 1).5 A closely related family
of compounds are the salinosporamides,6 isolatedbyFenical
from themarine actinomyceteSalinospora tropica.7 Almost
the same structuralmotif was found in the cinnabaramides,
a secondarymetabolite of the terrestrial strainStreptomyces
JS 360.8
The cinnabaramides and salinosporamides only differ in
the side chain of the γ-lactam ring. Cinnabaramides and
salinosporamide A inhibit the 20S-proteasome in the low
nanomolar range.8,9 The strained β-lactone ring of these
† Saarland University.
‡Helmholtz Institute for Pharmaceutical Research Saarland.
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compounds interacts with a threonine in the active center
of theproteasome, inactivating the enzymeby ringopening
andcovalent blockingof the active center.9 Salinosporamide
is found to trigger apoptosis and is inphase 1of clinical trials
for the treatment of multiple myeloma.10 Not surprising,
these natural products arouse interest in the community of
synthetic organic chemists, and a wide range of interesting
syntheseshavebeendeveloped inrecentyears foromuralide,11
cinnabaramide,12 and especially salinosporamide13 and
derivatives.14 The recent developments in this field are
nicely covered in reviews by Moore3a and Potts.15
Besides the development of straightforward protocols
for the synthesis of these compounds, much effort has
also been focused toward investigating their biosynthesis.
While Moore et al. are involved in the biosynthesis of the
salinosporamides,3b,16 we are mainly interested in the
cinnabaramides.17
In principle, the molecule can be divided into two major
parts. In the case of the salinosporamides, the lower part of
the molecule is the product of a polyketide synthase (PKS)
leading to an activated β-ketothioester A (Scheme 1). The
upper part, the unusual amino acid β-hydroxy cyclohex-
enylalanine, is formed via a shunt in the phenylalanine
biosynthetic pathway, leading primarily to β-cyclohexeny-
lalanineB.16a After coupling to the peptidyl carrier protein
and oxidation by a cytochrome P450 hydroxylase (C), the
two building blocks are coupled on a nonribosomal pep-
tide synthetase (NRPS) to give D. Subsequent cyclization
gives rise to salinosporamide.16
In principle, onemight expect a very similar biosynthetic
pathway also for the cinnabaramides, which should differ
mainly in the PKS-subunit. To study the cinnabaramide
biosynthesis, we were interested in obtaining deuterium-
labeled building blocks which can be used for feeding
experiments. Recently, we described the stereoselective
synthesis of dideuterated (2R,3S,4S)-β-cyclohexenyl-
serine,18 a postulated intermediate in an early biosynthetic
proposal.16aLater, the configuration of the amino acidwas
determined to be (2S).16b Therefore, it was not so surpris-
ing that no incorporation of this amino acid itself, or in
the activated form, was observed in feeding experiments.
Recent biosynthetic studies by the M€uller group indicate
that, in the case of the cinnabaramides, B is probably
coupled to the corresponding β-ketoester and that the
cyclochrome P-450 oxidation at the β-position proceeds
later on in the biosynthesis.19
To prove this proposal, we developed a stereoselective
synthesis of the two isomeric dideuterated (2S)-β-cyclo-
hexenylalanines. So far, the absolute configuration of the
cinnabaramide intermediates is not yet determined, but the
(2S) configuration seems reasonable, based on the analogy
to the salinosporamide biosynthesis. In the natural prod-
uct, the (4S)-configuration is found, and therefore the
(2S,4R)-β-cyclohexenylalanine 1 should be the correct
Scheme 1. Biosynthesis of Salinosporamide A according to
Moore16a
Figure 1. Naturally occurring γ-lactamβ-lactones.
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intermediate. Interestingly, the biosynthetic enzyme re-
sponsible for the activation of the β-cyclohexenylalanine
seems to have a rather broad substrate spectrum, allowing
also the incorporation of other amino acids.16b,20 There-
fore, we were interested to see if the configuration of the
4-position does play any role.
Our retrosynthetic plan toward the (2S,4R)-1 is shown
in Scheme 2.D2-labeled β-cyclohexenylalanine 1 should be
accessible via radical decarboxylation of the corresponding
aspartate derivative E, while the cyclohexenyl ring should
be the result of a ring closing metathesis (RCM). The key
step of the synthesis is a stereoselective Claisen rearrange-
ment providing the diene F from the allyl ester G. In this
step the stereogenic center at C-4 is incorporated. Depend-
ing on the configuration of the allyl alcohol used, both
isomers can be obtained stereoselectively. The configura-
tion at C-3 of F does not play any role, because this
stereogenic center is removed later on. The required di-
deuterated trans allyl alcohol should be available from the
corresponding propargyl alcohol (R)-2 via reduction using
LiAlD4.
We began our synthesis with the coupling of 5-bromo-
pentene with butyn-3-ol (Scheme 3). Although this reac-
tion is described in the literature,21wewere able to improve
the yield of 2 significantly by using LiNH2 as a base
(instead of BuLi). The racemic alkynol 2was subsequently
subjected to an enzymatic kinetic resolutionusingNovozym
435. The reaction stops after 50% conversion, and both
enantiomeric compounds were obtained with high yield
and ee. Unfortunately, we were not able to determine the
ee-value of the unreacted alcohol directly by GC (no
separation) and therefore, for analytical purposes, the
remaining alcohol (S)-2 was also converted into the acetate
(S)-3. Upon saponification, both enantiomers of alkynol 2
were obtained.
For the synthesis of the deuterated (2S,4R)-cyclohex-
enylalanine 1, (R)-2 was reduced with LiAlD4 (Scheme 3).
The in situ formed vinylalumoxane was quenched by
the addition of D2O giving rise to the trans-configured
dideuterated allyl alcohol (R)-4. Coupling to semipro-
tected aspartate22 using the Steglich protocol provided
the required allylester 5, the substrate for the subsequent
Claisen rearrangement. Our group was investigating
Claisen rearrangements of amino acids for a long time.23
While the best results are obtained for R-amino acid esters
with chelated enolates,24 this protocol is not really suitable
for β-amino acid esters, such as 5. Here the IrelandClaisen
rearrangement25 is the method of choice,26 providing 6 in
high yield and diastereoselectivity. While the stereogenic
center at C-2 remains unchanged, the configuration at
C-4 is determined by the stereogenic center of the allyl
alcohol (chirality transfer almost perfect). The configura-
tion at C-3 is the result of the enolate formation in the
deprotonation step. This center is formed as a 9:1 mixture,
according to NMR. But this center is negligible, because
it is removed later on. The diastereomeric rearrangement
products could be separated by flash chromatography.
Diastereomerically pure 6 was subjected to ring closing
metathesis providing cyclohexenyl aspartate 7 in high
yield. In case the diastereomeric mixture was subjected
to RCM also at this stage, a separation of the isomers was
possible.
The next step, the radical decarboxylation, was found to
be the most critical one of the whole sequence.We decided
to apply the Barton protocol using the corresponding
N-hydroxythiopyridone esters.27 Unfortunately, this ester
was found to be very sensitive, undergoing fast decom-
position. Attempts to isolate and purify it were unsuccess-
ful. Therefore, we had to carry out the activation and
decarboxylation in a one-pot protocol. We investigated
a wide range of coupling reagents for the initial step, the
formation of the active ester. No ester formation was
observed by using chloroformates, carbonyldiimidazole,
or T3P as coupling reagents. DCC at20 C provided the
required ester, but in impure form, and therefore, the
decarboxylated productwas very difficult to separate from
the byproducts formed. The best results were obtained
using PhPOCl2/NEt3 in the activation step, and the very
mild BEt3/O2 protocol
28 for the radical formation. t-BuSH
was used as aH-source.Under these optimized conditions,
the required product 8 could be obtained in 49%yield. The
final steps toward 1proceededquantitatively. The isomeric
(2S,4S)-derivative was obtained from (S)-2 in an analo-
gous fashion and comparable yield.
Scheme 2. Retrosynthesis of (2S,4R)-Dideuterated Cyclohexe-
nylalanine 1
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Subsequent feeding experiments were conducted using
compound 1, which was stepwise administrated to the
culture broth of Streptomyces sp. JS360 (see Supporting
Information). Organic extracts of the culture supernatants
were analyzed using HPLC-MS, which unambiguously
demonstrated incorporation of 1 into cinnabaramide re-
sulting in the production of dideuterated cinnabaramides
in a yield comparable to that of native cinnabaramides.
Based on this efficient incorporation we can conclude that
(2S,4R)-β-cyclohexenylalanine 1 most likely serves as the
native substrate of the cinnabaramide peptide synthetase.
Interestingly, while the salinosporamide pathway shows
a broad substrate tolerance allowing for the incorporation
of alternative amino acids, no cinnabaramides derived
from incorporation of proteinogenic amino acids have
been detected in extracts of the wild type producer. But
interestingly, the diastereomeric (2S,4S)-cyclohexenylala-
ninewas incorporated aswell. Thismay indicate that either
(1) the free amino acids cannot be activated for further
incorporation or (2) in vivo insufficient quantities of amino
acids are available for secondary metabolite biosynthesis.
As the latter scenario is unlikely we assume that it should
be possible to incorporate alternative amino acids in the
respective position of cinnabaramides. Ongoing work in
our laboratories is addressing this question. After con-
ducting a bioactivity screening, we expect to discovermore
cytotoxic novel cinnabaramides.
In conclusion, we have shown that the IrlandClaisen
rearrangement of β-amino acid allylic esters is a highly
suitable tool for the stereoselective synthesis of β-substi-
tuted aspartates. Subsequent ring closing metatheses and
decarboxylations give rise to deuterated β-cyclohexenyla-
lanine derivatives. Feeding experiments indicate that (2S)-
β-cyclohexenylalanine is an intermediate in thebiosynthesis
of cinnabaramide. The configuration at the cyclohexenyl
ring doesnot play any role, as obviouslyboth stereoisomers
are accepted by the peptidyl carrier protein. Further bio-
synthetic studies are currently under investigation.
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1) General remarks 
All air- or moisture-sensitive reactions were carried out in dried glassware (>100 °C) 
under an atmosphere of nitrogen. Dried solvents were distilled before use: THF was 
distilled from LiAlH4, CH2Cl2 was dried with CaH2 before distillation and DMF was 
purchased from Sigma-Aldrich. The products were purified by flash chromatography 
on silica gel columns (Macherey-Nagel 60, 0.063-0.2 mm). Mixtures of ethyl acetate 
and hexane were generally used as eluents. Analytical TLC was performed on pre-
coated silica gel plates (Fluka). Visualization was accomplished with UV-light and 
KMnO4 or Ninhydrin solution. Melting points were determined with a Laboratory 
Devices  MEL-TEMP II melting point apparatus and are uncorrected. 1H and 13C 
NMR spectra were recorded with a Bruker AC-400 [400 MHz (1H) and 100 MHz (13C)] 
spectrometer in CDCl3, unless otherwise specified. Chemical shifts are reported in 
ppm relative to TMS, and CHCl3 was used as the internal standard. Multiplicities are 
reported as (br) broad, (s) singlet, (d) doublet, (t) triplet, (q) quartet and (m) multiplet. 
The diastereomeric ratios were determined by NMR and GC. Enantiomeric ratios 
were determined by GC using chiral columns (Chirasil-Dex-CB or Chirasil-Val-CB).
Mass spectra were recorded with a Finnigan MAT 95 spectrometer using the CI 
technique.  
 
2) Synthesis of (2S,4R)-1
Non-8-en-3-yn-2-ol (2)1
 
Lithium (700 mg, 101 mmol) was added in small portions to liquid ammonia (250 mL) 
at –40 °C. After addition was complete, a small amount of Fe(NO3)3 · 9H2O was 
added. When the blue color had disappeared completely, a solution of 3-butyn-2-ol 
(3.50 g, 50.0 mmol) in dry THF (5 mL) was added dropwise at –40 °C and stirred for 
one hour. Then, a solution of 5-bromo-1-pentene (5.00 g, 33.5 mmol) in THF (5 mL) 
was added dropwise and the reaction mixture was allowed to warm up to rt slowly 
overnight. The resulting mixture was quenched with water (50 mL) and the aqueous 
phase was extracted with Et2O (3 x 50 mL). The combined organic layers were dried 
over Na2SO4 and the solvent was evaporated in vacuo. The residue was purified by 
flash chromatography on silica gel (pentane/Et2O, 8:2) to give racemic alcohol 2 
(4.35 g, 31.5 mmol, 94%) as a colorless liquid. Rf 0.21 (pentane/Et2O, 8:2) 
1H NMR (400 MHz, CDCl3): 1.39 (d, 3J9,8 = 6.8 Hz, 3 H, 9-H), 1.57 (m, 2 H, 4-H), 
1.96 (bs, 1 H, OH), 2.13 (tdd, 3J3,4 = 14.4 Hz, 3J3,2 = 7.1 Hz, 4J3,1cis = 1.5 Hz, 2 H, 
3-H), 2.20 (td, 3J5,4 = 7.2 Hz, 5J5,8 = 1.9 Hz, 2 H, 5-H), 4.50 (m, 1 H, 8-H), 5.00 (m, 
1 H, 1-Htrans), 5.02 (ddt, 3J1cis,2 = 17.2 Hz, 2J1cis,1trans = 4J1cis,3 = 1.5 Hz, 1 H, 1-Hcis), 
                                             
1 Roush, W. R.; Spada, A. P. Tetrahedron Lett. 1982, 23, 3773–3776. 
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5.77 (ddt, 3J2,1cis = 17.2 Hz, 3J2,1trans = 10.2 Hz, 3J2,3 = 7.1 Hz, 1 H, 2-H). 13C NMR 
(100 MHz, CDCl3):17.9 (t, C-5), 24.6 (q, C-9), 27.7 (t, C-4), 32.6 (t, C-3), 58.4 (d, 
C-8), 82.6 (s, C-6), 84.0 (s, C-7), 115.1 (t, C-1), 137.7 (d, C-2).  
GC: Chirasil-Dex-CB, T0 [5 min] = 75 °C, 0.5 °C/min - 120 °C, 8.0 °C/min - 180 °C, 
(S)-2: tR = 43.04 min, (R)-2: tR = 45.86 min. 
 
(S)-Non-8-en-3-yn-2-ol [(S)-2]1 and (R)-Non-8-en-3-yn-2-yl acetate [(R)-3] 
             
To a solution of racemic alcohol 2 (2.75 g, 19.9 mmol) in vinyl acetate (30 mL) 
Novozym® 435 (150 mg) was added at rt. The mixture was shaken for 16 h. After the 
reaction was completed (NMR), the enzyme was filtered off and the solvent was 
evaporated in vacuo. The residue was purified by flash chromatography 
(pentane/Et2O 8:2 to 6:4) to give alcohol (S)-2 (1.30 g, 9.41 mmol, 47%, 96% ee) and 
acetate (R)-3 (1.75 g, 9.68 mmol, 49%, 98% ee) as colorless liquids. 
(S)-2: Rf 0.21 (pentane/Et2O, 8:2); []D20 = – 19.5 ° (c = 1.9, CHCl3, 96% ee). 
(R)-3: Rf 0.46 (pentane/Et2O, 8:2); []D20 = + 137.5 ° (c = 1.1, CHCl3, 98% ee); 1H 
NMR (400 MHz, CDCl3): 1.46 (d, 3J9,8 = 6.7 Hz, 3 H, 9-H), 1.57 (m, 2 H, 4-H), 
2.06 (s, 3 H, 11-H), 2.13 (tdd, 3J3,4 = 14.4 Hz, 3J3,2 = 7.2 Hz, 4J3,1cis = 1.7 Hz, 2 H, 
3-H), 2.21 (td, 3J5,4 = 7.2 Hz, 5J5,8 = 1.9 Hz, 2 H, 5-H), 4.99 (m, 1 H, 1-Hcis), 5.03 (ddt, 
3J1cis,2 = 17.2 Hz, 2J1cis,1trans = 4J1cis,3 = 1.7 Hz, 1 H, 1-Hcis), 5.44 (qt, 3J8,9 = 6.7 Hz, 
5J8,5 = 1.9 Hz, 1 H, 8-H), 5.78 (ddt, 3J2,1cis = 17.2 Hz, 3J2,1trans = 10.2 Hz, 3J2,3 = 7.2 Hz, 
1 H, 2-H); 13C NMR (100 MHz, CDCl3):18.0 (t, C-5), 21.2 (t, C-11), 21.8 (q, C-9), 
27.6 (t, C-4), 32.7 (t, C-3), 60.8 (d, C-8), 78.9 (s, C-6), 85.1 (s, C-7), 115.2 (t, C-1), 
137.8 (d, C-2), 170.0 (s, C-10).  
GC: Chirasil-Dex-CB, T0 [5 min] = 60 °C, 1.0 °C/min - 120 °C, 6.0 °C/min - 180 °C, 
(S)-3: tR = 45.60 min, (R)-3: tR = 45.97 min. 
HRMS (C11H19O3 [M+H2O+H]+): calculated 199.1329, found 199.1256. 
 
(R)-Non-8-en-3-yn-2-ol [(R)-2]1
1 3
2 4
5 6
7
8 9
OH
 
To a solution of acetate (R)-3 (3.10 g, 17.2 mmol) in methanol (80 mL) 1 M aq. NaOH 
(19.0 mL, 19.0 mmol) was added at rt and stirred overnight. After removal of the 
methanol in vacuo, the residue was diluted with Et2O (30 mL) and the aqueous phase 
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was extracted with Et2O (3 x 30 mL). The combined organic layers were washed with 
brine (20 mL) and dried over Na2SO4. The solvent was evaporated in vacuo and the 
residue was purified by flash chromatography on silica gel (pentane/Et2O 7:3) to give 
alcohol (R)-2 (2.36 g, 17.2 mmol, 100%) as colorless liquid. Rf 0.21 (pentane/Et2O, 
8:2); []D20 = + 30.5 ° (c = 1.0, CHCl3).  
 
(R,E)-3,4-Dideuteronona-3,8-dien-2-ol [(R)-4]1
 
To a suspension of lithium aluminium deuteride (609 mg, 14.5 mmol) in dry THF (10 
mL) a solution of alcohol (R)-4 (880 mg, 6.37 mmol) in THF (8 mL) was added at 0 
°C. The reaction mixture was allowed to warm to rt overnight and quenched with 
deuterium oxide (5 mL). A 2 M solution of Na2CO3 (20 mL) was added to the reaction 
mixture and stirring was continued for 10 min. The layers were separated and the 
aqueous phase was extracted with Et2O (3 x 50 mL). The combined organic layers 
were dried over Na2SO4 and the solvent was removed in vacuo. After purification by 
column chromatography on silica gel (pentane/Et2O, 6:4), the deuterated alcohol (R)-
4 (860 mg, 6.05 mmol, 95%) was obtained as colorless liquid. Rf 0.16 (pentane/Et2O, 
8:2); []D20 = + 12.7 ° (c=1.0, CHCl3).  
1H NMR (400 MHz, CDCl3): 1.24 (d, 3J8.9 = 6.4 Hz, 1 H, 9-H), 1.46 (m, 2 H, 4-H), 
1.55 (bs, 1 H, OH), 2.00–2.08 (m, 4 H, 3-H, 5-H), 4.24 (q, 3J9.8 = 6.4 Hz, 1 H, 8-H), 
4.94 (ddt, 3J1trans,2 = 10.4 Hz, 2J1trans,1cis = 2.0 Hz, 4J1trans,3 = 1.2 Hz, 1 H, 1-Htrans), 4.99 
(dtd, 3J1cis,2 = 16.8 Hz, 4J1cis,3 = 2J1cis,1trans = 2.0 Hz, 1 H, 1-Hcis), 5.79 (ddt, 3J2,1cis = 
16.8 Hz, 3J2,1trans = 10.4 Hz,  3J2,3 = 6.7 Hz, 1 H, 2-H). 13C NMR (100 MHz, 
CDCl3):23.4 (q, C-9), 28.3 (t, C-4), 31.3 (t, C-3 oder C-5), 33.1 (t, C-3 oder C-5), 
68.7 (d, C-8), 114.5 (t, C-1), 130.1 (t, J7,D = 22.8 Hz, C-7), 134.0 (t, J7,D = 23.0 Hz, C-
6), 138.6 (d, C-2). 
HRMS (C9H15D2O [M+H]+): calculated 143.1399, found 143.1398. 
 
(S)-4-[(R,E)-3,4-Dideuteronona-3,8-dien-2-yl] 1-methyl 2-(tert-butoxycarbonyl-
amino)succinate [(2S,R)-5] 
 
To a solution of (L)-1-methyl-N-boc-aspartate (1.22 g, 4.93 mmol), alcohol (R)-4 (705 
mg. 4.93 mmol) and 4-(dimethylamino)pyridine (49.0 mg, 0.40 mmol) in Et2O (30 mL) 
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N,N-dicyclohexylcarbodiimide (1.12 g, 5.42 mmol) was added at 0 °C. The reaction 
mixture was allowed to warm to rt overnight and filtered. The filtrate was washed with 
1 M KHSO4 (10 mL), sat. NaHCO3 (10 mL) and brine (20 mL). After drying over 
Na2SO4, the solvent was removed in vacuo and the residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc 8:2). The allylic ester (2S,R)-5 
(1.67 g, 4.50 mmol, 91%) was obtained as colorless oil. Rf 0.32 (petroleum 
ether/Et2O, 8:2); []D20 = + 70.2 ° (c=1.0, CHCl3).  
1H NMR (400 MHz, CDCl3): 1.26 (d, 3J9,10 = 6.5 Hz, 3 H, 9-H), 1.43 (s, 9 H, 1-H), 
1.45 (m, 2 H, 14-H), 2.00–2.05 (m, 4 H, 13-H, 15-H), 2.77 (dd, 2J7a,7b = 16.8 Hz, 
3J7a,4 = 4.4 Hz, 1 H, 7-Ha), 2.94 (dd, 2J7b,7a = 16.8 Hz, 3J7b, 4 = 4.4 Hz, 1 H, 7-Hb), 3.72 
(s, 3 H, 6-H), 4.54 (m, 1 H, 4-H), 4.94 (ddt, 3J17trans,16 = 10.0 Hz, 2J17trans,17cis = 1.6 Hz, 
4J17trans,15 = 1.2 Hz, 1 H, 17-Htrans), 4.99 (ddt, 3J17cis,16 = 17.2 Hz, 2J17cis,17trans = 4J17cis,15 
 = 1.6 Hz, 1 H, 17-Hcis), 5.30 (q, 3J10,9 = 6.5 Hz, 1 H, 10-H), 5.45 (d, 3JNH,4 = 8.0 Hz, 1 
H, N-H), 5.77 (ddt, 3J16,17cis  = 17.2 Hz, 3J16,17trans = 10.0 Hz, 3J16,15 = 6.7 Hz, 1 H, 16-
H). 13C NMR (100 MHz, CDCl3): 20.2 (q, C-9), 28.0 (t, C-14), 28.2 (s, C-1), 31.3 
(t, C-13 oder C-15), 33.0 (t, C-13 oder C-15), 37.1 (t, C-7), 50.0 (d, C-4), 52.5 (q, C-
6), 71.9 (d, C-10), 80.0 (s, C-2), 114.6 (t, C-17), 128.9 (t, J7,D = 23.4 Hz, C-11), 132.9 
(t, J7,D = 22.8 Hz, C-12), 138.4 (d, C-16), 155.3 (s, C-3), 170.0 (s, C-8), 171.5 (s, C-
5).  
HRMS (C14H22D2NO4 [M–Boc+H]+): calculated 272.1825, found 272.1826. 
 
(2S,3S)-2-[(S)-1-(tert-Butoxycarbonylamino)-2-methoxy-2-oxoethyl]-3-deutero-3-
((Z)-1-deuteroprop-1-enyl)oct-7-enoic acid [(2S,3S,4S)-6] 
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Freshly distilled HMDS (1.67 mL, 8.08 mmol) was dissolved in dry THF (8 mL) in a 
Schlenk tube and cooled to –30 °C. N-Butyllithium (2.5 M in hexanes, 2.15 mL, 5.38 
mmol) was added dropwise and stirring was continued for 5 min. The mixture was 
allowed to warm to rt and was cooled again to –78 °C. In a second Schlenk tube, 
ester (2S,R)-5 (1.00 g, 2.69 mmol) was dissolved in THF (10 mL) and cooled to –78 
°C. The LHMDS solution was transferred dropwise to the second flask via a double-
ended needle and stirred for 30 min at –78 °C. TMSCl (1.72 mL, 13.5 mmol) was 
added and stirring was continued for 1 h. The reaction mixture was then quickly 
warmed up to 60 °C. This temperature was maintained for 2 h while stirring. The 
mixture was quenched with 1 M HCl (15 mL) and the organic layer was extracted with 
Et2O. The combined organic layers were washed with 1 M KHSO4 and brine. After 
drying over Na2SO4, the solvent was removed in vacuo. Column chromatography on 
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silica gel (petroleum ether/EtOAc 9:1, 1% HOAc) afforded (2S,3S,4S)-6 as the major 
diastereomer (784 mg, 2.10 mmol, 78%) and (2S,3R,4S)-6 as the minor diastereo-
mer (109 mg, 0.29 mmol, 11%) als colorless solids; mp. 137-138 °C. 
GC (methyl ester of crude reaction mixture) Chirasil-Val-CB, T0 [5 min] = 145 °C, 1.0 
°C/min - 180 °C, 6.0 °C/min - 180 °C (2S,3S,4S)-6: tR = 34.66 min. (2S,3R,4S)-6: = 
43.63 min. 
(2S,3S,4S)-6: Rf 0.15 (petroleum ether/Et2O, 8:2, 1% HOAc); []D20 = + 8.6 ° (c=1.0, 
CHCl3). Rotameric ratio at rt: 3:1.  
Major rotamer: 1H NMR (400 MHz, CDCl3): 1.28–1.46 (m, 3 H, 11-H, 10-Ha), 1.43 
(s, 9 H, 1-H), 1.57 (m, 1 H, 10-Hb), 1.66 (d, 3J17,16 = 6.2 Hz, 3 H, 17-H), 2.02 (m, 2 H, 
12-H), 2.93 (d, 3J7,4 = 6.8 Hz, 1 H, 7-H), 3.73 (s, 3 H, 6-H), 4.55 (dd, 3J4,7 = 3J4,NH = 
7.4 Hz, 1 H, 4-H), 4.93 (ddt 3J14trans,13 = 10.0 Hz, 2J14trans,14cis = 2.0 Hz, 3J14trans,12 = 1.2 
Hz, 1 H, 14-Htrans), 4.98 (ddt, 3J14cis,13 = 17.2 Hz, 2J14cis,14trans = 5J14cis,12 = 2.0 Hz, 1 H, 
14-Hcis), 5.23 (d, 3JNH,4 = 7.4 Hz, 1 H, NH), 5.47 (m, 1 H, 16-H), 5.78 (ddt, 3J13,14cis = 
17.2 Hz, 3J13,14trans= 10.0 Hz, 3J13,12 = 6.7 Hz, 1 H, 13-H), 9.35 (bs, 1 H, OH). 13C NMR 
(100 MHz, CDCl3): 17.9 (q, C-17), 26.6 (t, C-11), 28.3 (q, C-1), 32.0 (t, C-10), 
33.4 (t, C-12), 51.7 (d, C-7), 52.5 (q, C-6), 53.4 (d, C-4), 80.3 (s, C-2), 114.5 (t, C-14), 
128.5 (d, C-16), 130.1 (t, J15,D = 16.7 Hz, C-15), 138.7 (d, C-13), 155.0 (s, C-3), 171.5 
(s, C-5), 176.9 (s, C-8).  
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.26 (m, 1 H, 4-H), 
5.80 (bs, 1 H, NH).  
(2S,3R,4S)-6: Rf 0.17 (petroleum ether/Et2O, 8:2, 1% HOAc).  
1H NMR (selected signals) (400 MHz, CDCl3): 1.44 (s, 9 H, 1-H), 3.71 (s, 3 H, 6-
H). 13C NMR (100 MHz, CDCl3):18.0 (q, C-17), 28.3 (q, C-1), 32.1 (t, C-10), 33.5 
(t, C-12), 41.9 (d, C-9), 50.5 (d, C-7), 52.7 (d, C-6), 79.9 (s, C-2), 138.6 (d, C-13), 
155.4 (s, C-2), 172.4 (s, C-5).  
HRMS (C19H30D2NO6 [M+H]+): calculated 372.2350, found 372.2311. 
 
(2S,3S)-3-(tert-Butoxycarbonylamino)-2-[(S)-1,2-dideuterocyclohex-2-enyl]-4-
methoxy-4-oxobutanoic acid [(2S,3S,4S)-7] 
 
To a solution of acid (2S,3S,4S)-6 (100 mg, 0.27 mmol) in dry dichloromethane (3 
mL) benzylidene-bis(tricyclohexylphosphine)dichlororuthenium (2.7 mg, 0.003 mmol) 
was added at rt and stirring was continued for 2 h. The solvent was evaporated in 
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vacuo and the residue was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc 9:1, 1% HOAc). The metathesis product (2S,3S,4S)-7 (78 mg, 0.24 
mmol, 89%) was obtained as colorless foam. 
Rf 0.06 (petroleum ether/Et2O, 9:1, 1% HOAc); []D20 = – 8.1 ° (c=1.2, CHCl3); Rota-
meric ratio at rt: 4:1.  
Major rotamer: 1H NMR (400 MHz, CDCl3): 1.44 (s, 9 H, 1-H), 1.41–1.59 (m, 2 H, 
14-Ha, 13-Ha), 1.78 (m, 1 H, 13-Hb), 1.88–2.01 (m, 3 H, 14-Hb, 12-H), 2.76 (d, 3J7,4 = 
6.0 Hz, 1 H, 7-H), 3.75 (s, 3 H, 6-H), 4.71 (m, 1 H, 4-H), 5.38 (d, 3JNH,4 = 8.0 Hz, 1 H, 
NH), 5.75 (m, 1 H, 11-H), 10.13 (bs, 1 H, OH). 13C NMR (100 MHz, CDCl3): 21.5 
(t, C-13), 24.9 (t, C-12), 26.6 (t, C-14), 28.3 (q, C-1), 33.9 (t, J9,D = 19.3 Hz, C-9), 
52.5 (d,q, C-4, C-6), 53.5 (d, C-7), 80.3 (s, C-2), 127.3 (t, J9,D = 23.5 Hz, C-10), 129.0 
(d, C-11), 155.1 (s, C-3), 171.4 (s, C-5), 177.4 (s, C-8).  
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.53 (m, 1 H, 4-H), 
6.13 (bs, 1 H, NH). 13C NMR (100 MHz, CDCl3): 26.7 (t, C-14), 52.8 (d,q, C-4, C-
6), 53.7 (d, C-7), 81.8 (s, C-2), 128.5 (d, C-11), 155.6 (s, C-3), 171.2 (s, C-5), 170.9 
(s, C-5), 176.7 (s, C-8).  
HRMS (C16H24D2NO6 [M+H]+): calculated 330.1880, found 330.1853. 
 
(S)-Methyl 2-(tert-butoxycarbonylamino)-3-[(R)-1,2-dideuterocyclohex-2-enyl]-
propanoate [(2S,4R)-8]  
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To a solution of acid (2S,3S,4S)-7 (191 mg, 0.578 mmol) in dry THF (1 mL) triethyl-
amine (500 μL, 3.57 mmol) and phenylphosphonic acid dichloride (90%, 100 μL, 
643 μmol) was added at 0 °C. After stirring for 15 min at 0°C and 15 min at rt, the 
reaction mixture was cooled to –10 °C. Mercaptopyridine-N-oxide (189 mg, 1.49 
mmol) was added and stirring was continued for 1.5 h in the dark. To the resulting 
mixture subsequently tert-butylmercaptane (670 μL, 5.95 mmol) and triethylborane 
(1M in THF, 200 μL, 200 μmol) were added at –10 °C. After 3h, the reaction mixture 
was diluted with Et2O (10 mL) and washed with 1 N KHSO4 (5 mL), sat. NaHCO3 (5 
mL) and brine (5 mL). After drying over Na2SO4, the solvent was evaporated in 
vacuo, and the residue was purified by column chromatography on silica gel 
(petroleum ether/EtOAc, 95:5). The deuterated cyclohexenyl alanine (2S,4R)-8 (80.2 
mg, 281 μmol, 49%) was obtained as colorless solid. Rf 0.35 (petroleum ether/Et2O, 
8:2). []D20 = – 31.3 ° (c=1.1, CHCl3); rotameric ratio at rt: 85:15.  
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Major rotamer: 1H NMR (400 MHz, CDCl3): 1.24 (m, 1 H, 13-Ha), 1.42 (s, 9 H, 1-
H), 1.48–1.58 (m, 2 H, 7-Ha, 12-Ha), 1.68 (m, 1 H, 12-Hb), 1.73–1.81 (m, 2 H, 7-Hb, 
13-Hb), 1.95 (m, 2 H, 11-H), 3.71 (s, 3 H, 6-H), 4.38 (m, 1 H, 4-H), 4.96 (d, 3JNH,4 = 
7.8 Hz, 1 H, NH), 5.70 (m, 1 H, 10-H). 13C NMR (100 MHz, CDCl3): 21.0 (t, C-12), 
25.1 (t, C-11), 28.3 (q, C-1), 29.0 (s, C-13), 30.9 (t, J8,D = 19.0 Hz, C-8), 39.3 (t, C-7), 
51.6 (d, C-4), 52.2 (q, C-6), 79.9 (s, C-2), 127.9 (d, C-10), 129.5 (t, J9,D = 23.5 Hz, C-
9), 155.3 (s, C-3), 173.8 (s, C-5).  
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.22 (m, 1 H, 4-H), 
4.74 (bs, 1 H, NH).  
HRMS (C15H24D2NO4 [M+H]+): calculated 286.1982, found 286.2002 
 
(S)-2-(tert-Butoxycarbonylamino)-3-[(R)-1,2-dideuterocyclohex-2-enyl]propan-
oic acid [(2S,4R)-9] 
 
To a solution of ester (2S,4R)-8 (65.0 mg, 228 μmol) in methanol (0.5 mL) was added 
1 M aq. NaOH (250 μL, 250 μmol). The reaction mixture was heated to 60 °C for 1 h. 
The solvent was evaporated in vacuo and the residue was acidified with 1 M KHSO4. 
The mixture was extracted with EtOAc (3 x 10 mL) and dried over Na2SO4. The 
solvent was removed again in vacuo and the resulting product (61.5 mg, 228 μmol, 
100%) was used without further purification. []D20 = – 55.0 ° (c = 1.1, CHCl3); 
rotameric ratio at rt: 2:1. 
Major rotamer: 1H NMR (400 MHz, CDCl3): 1.27 (m, 1 H, 12-Ha), 1.44 (s, 9 H, 1-
H), 1.50–1.61 (m, 2 H, 6-Ha, 11-Ha), 1.70 (m, 1 H, 11-Hb), 1.77–1.87 (m, 2 H, 6-Hb, 
12-Hb), 1.97 (m, 2 H, 10-H), 4.40 (m, 1 H, 4-H), 4.99 (d, 3JNH,4 = 8.0 Hz, 1 H, NH), 
5.72 (t, 3J9,10 = 3.4 Hz, 1 H, 9-H), 9.66 (bs, 1 H, OH). 13C NMR (100 MHz, CDCl3): 
21.0 (t, C-11), 25.1 (t, C-10), 28.3 (q, C-1), 29.0 (s, C-12), 30.9 (t, J7,D = 20.3 Hz, 
C-7), 38.9 (t, C-6), 51.6 (d, C-4), 80.2 (s, C-2), 128.0 (d, C-9), 129.4 (t, J8,D = 21.4 Hz, 
C-8), 155.6 (s, C-3), 178.1 (s, C-5). 
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.23 (m, 1 H, 4-H), 
6.37 (bs, 1 H, NH). 13C NMR (100 MHz, CDCl3): 39.3 (t, C-6), 52.7 (d, C-4), 81.7 
(s, C-2), 156.6 (s, C-3), 177.5 (s, C-5).  
HMRS (C14H22D2NO4 [M+H]+): calculated 272.1825, found 272.1847.  
 
 S9
(S)-2-Amino-3-[(R)-1,2-dideuterocyclohex-2-enyl]propanoic acid hydrochloride 
[(2S,4R)-1] 
H3N 12
3
OH
4
6
O
7
9
8
5
D
D
Cl
 
HCl (4 M in Dioxane, 380 μL, 2.40 mmol) was added dropwise to the Boc-protected 
amino acid (2S,4R)-9 (41.5 mg, 151 μmol) at rt. After stirring for 1 h, the solvent was 
evaporated in vacuo to yield the HCl-salt (2S,4R)-1 (31.3 mg, 151 μmol, 100%) as 
white crystalline solid; mp. 200 °C (decomp.). []D20 = – 19.3 ° (c = 1.1, MeOH). 
1H NMR (400 MHz, CD3OD): 1.31 (m, 1 H, 9-Ha), 1.58 (m, 1 H, 8-Ha), 1.73–1.79 
(m, 2 H, 3-Ha, 8-Hb), 1.90–1.96 (m, 2 H, 3-Hb, 9-Hb), 2.01 (m, 2 H, 7-H), 4.03 (dd, 
3J2,3a = 3J2,3b = 7.0 Hz, 1 H, 2-H), 5.78 (t, 3J6,7 = 3.4 Hz, 1 H, 6-H). 13C NMR (100 
MHz, CD3OD): 21.9 (t, C-8), 26.1 (t, C-7), 29.6 (t, C-9), 31.9 (t, J4,D = 19.2 Hz, C-
4), 38.3 (t, C-3), 52.0 (d, C-2), 129.6 (d, C-6), 129.9 (t, J5,D = 23.7 Hz, C-5), 172.2 (s, 
C-1). 
HRMS (C9H15D2NO2 [M+H]+): calculated 172.1301, found 172.1304. 
 
3) Synthesis of (2S,4S)-1 
(S,E)-3,4-Dideuteronona-3,8-dien-2-ol [(S)-4] 
1
2
3
4
5
6
7 8 9
OHD
D  
(S)-Non-8-en-3-yn-2-ol (S)-2 (1.00 g, 7.24 mmol) was reduced with LiAlD4 (609 mg, 
14.5 mmol) according to the procedure described for (R)-4, yielding alcohol (S)-4 
(808 mg, 5.69 mmol, 79%) as a colorless oil. Rf 0.16 (pentane/Et2O, 8:2); []D20 = –
9.7 ° (c=1.0, CHCl3); NMR according to (R)-4. 
 
(S)-4-[(S,E)-3,4-dideuteronona-3,8-dien-2-yl] 1-methyl 2-(tert-butoxycarbonyl-
amino)succinate [(2S,S)-5]  
 
 S10
(S)-4 (687 mg, 4.83 mmol) was esterified with (L)-1-methyl-N-boc aspartate (1.22 g, 
4.93 mmol), using 4-(dimethylamino)pyridine (59.0 mg, 0.84 mmol) and 
N,N-dicyclohexylcarbodiimide (1.09 g, 5.28 mmol), according to the procedure 
described for (2S,R)-5. Ester (2S,S)-5 (1.52g, 4.09 mmol, 85%) was obtained as 
colorless oil. Rf 0.27 (petroleum ether/EtOAc, 9:1). []D20 = – 17.6 ° (c=1.0, CHCl3); 
rotameric ratio at rt 9:1. 
Major rotamer: 1H NMR (400 MHz, CDCl3): 1.26 (d, 3J9,10 = 6.5 Hz, 1 H, 9-H), 1.42 
(s, 9 H, 1-H), 1.44 (m, 2 H, 14-H), 1.99–2.05 (m, 4 H, 13-H, 15-H), 2.75 (dd, 2J7a,7b = 
16.8 Hz, 3J7a,4 = 4.8 Hz, 1 H, 7-Ha), 2.94 (dd, 2J7b,7a = 16.8 Hz, 3J7b, 4 = 4.5 Hz, 1 H, 7-
Hb), 3.72 (s, 3 H, 6 H), 4.54 (m, 1 H, 4-H), 4.92 (ddt, 3J17trans,16 = 10.4 Hz, 2J17trans, 17cis 
= 2 Hz, 4J17trans,15 = 1.2 Hz, 1 H, 17-Htrans), 4.97 (ddt, 3J17cis,16 = 17.2 Hz, 2J17cis,17trans = 
4J17cis,15  = 2.0 Hz, 1 H, 17-Hcis), 5.29 (q, 3J10,9 = 6.4 Hz, 1 H, 10-H), 5.46 (d, 
3JNH,4 = 8.5 Hz, 1 H, N-H), 5.76 (ddt, 3J16,17cis  = 17.2 Hz, 3J16,17trans = 10.4 Hz, 
3J16,15 = 6.7 Hz, 1 H, 16-H). 13C NMR (100 MHz, CDCl3): 20.2 (q, C-9), 27.9 (t, C-
14), 28.2 (q, C-1), 31.2 (t, C-13 oder C-15), 33.0 (t, C-13 oder C-15), 37.1 (t, C-7), 
49.9 (d, C-4), 52.5 (q, C-6), 71.9 (d, C-10), 80.0 (s, C-2), 114.6 (t, C-17), 128.8 (t, J7,D 
= 23.3 Hz, C-11), 132.9 (t, J7,D = 23.2 Hz, C-12), 138.4 (d, C-16), 155.3 (s, C-3), 
170.1 (s, C-8), 171.5 (s, C-8). 
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.40 (m, 1 H, 4-H), 
5.13 (bs, 1 H, NH). 
HRMS (C14H22D2NO4 [M–Boc+H]+): calculated 272.1825, found 272.1835. 
 
(2R,3R)-2-((S)-1-(tert-Butoxycarbonylamino)-2-methoxy-2-oxoethyl)-3-deutero-
3-((Z)-1-deuteroprop-1-enyl)oct-7-enoic acid [(2S,3R,4R)-6]
 
 
According to (2S,3S,4S)-6, (2S,3R,4R)-6 was prepared from (2S,S)-5 (1.43 g, 3.85 
mmol), hexamethyldisilazide (2.4 mL, 11.5 mmol), n-butyllithium (2.5 M in hexanes, 
3.08 mL, 7.69 mmol) and TMSCl (2.45 mL, 19.2 mmol), yielding the major 
diastereomer (2S,3R,4R)-6 (1.20 g, 3.22 mmol, 85%) and the minor diastereomer 
(2S,3S,4R)-6 (65.0 mg, 0.177 mmol, 4%) as colorless oils.   
(2S,3R,4R)-6: Rf 0.18 (pentane/EtOAc, 8:2, 1% HOAc); []D20 = + 24.7 ° (c = 1.0, 
CHCl3); 1H NMR (400 MHz, CDCl3):  = 1.21–1.32 (m, 2 H, 10-Ha, 11-Ha), 1.36–1.49 
(m, 10 H, 11-Hb, 1-H), 1.56 (m, 1 H, 10-Hb), 1.65 (d, 3J17,16 = 6.5 Hz, 3 H, 17-H), 2.01 
(m, 2 H, 12-H), 2.98 (d, 3J7,4 = 3.9 Hz, 1 H, 7-H), 3.72 (s, 3 H, 6-H), 4.65 (dd, 
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3J4,NH = 10.1 Hz, 3J4,7 = 6.5 Hz, 1 H, 4-H), 4.93 (m, 1 H, 14-Htrans), 4.98 (m, 1H, 
14-Hcis), 5.47 (q, 3J16,17 = 6.5 Hz, 1 H, 16-H), 5.63 (d, 3JNH,4 = 10.1 Hz, 1 H, NH), 5.77 
(ddt, 3J13,14cis = 16.9 Hz, 3J13,14trans = 10.2 Hz, 3J13,12 = 6.7 Hz, 1 H, 13-H); 13C NMR 
(100 MHz, CDCl3): 17.8 (q, C-17), 26.4 (t, C-11), 28.3 (q, C-1), 31.2 (t, C-10), 
33.4 (t, C-12), 50.8 (d, C-7), 52.3 (d, C-4), 52.6 (q, C-6), 80.1 (s, C-2), 114.4 (t, C-14), 
128.0 (d, C-16), 138.6 (d, C-13), 155.7 (d, C-3), 172.1 (s, C-5), 178.1 (s, C-8).  
(2S,3S,4R)-6: Rf 0.15 (pentane/EtOAc, 8:2, 1% HOAc); Selected Signals: 1H NMR 
(400 MHz, CDCl3):  = 1.44 (s, 9 H, 1-H), 1.60 (d, 3J16,17 = 6.5 Hz, 3 H, 17-H), 2.87 (d, 
3J7,4 = 3.3 Hz, 1 H, 7-H), 3.74 (s, 3 H, 6-H), 4.50 (dd, 3J4,NH = 9.9 Hz, 3J4,7 = 3.3 Hz, 1 
H, 4-H), 5.30 (m, 1 H, 16-H), 5.58 (bs, 1 H, NH). 13C NMR (100 MHz, CDCl3): 
17.9 (q, 17-C), 26.3 (t, C-11), 33.5 (t, C-12), 52.5 (d, C-4), 52.6 (q, C-6), 114.5 (t, 
C-14), 138.5 (d, C-13), 155.6 (d, C-3), 172.1 (s, C-5). 
HRMS (C19H30D2NO6 [M+H]+): calculated 372.2350, found 372.2342.  
 
(2R,3S)-3-(tert-butoxycarbonylamino)-2-[(R)-1,2-dideuterocyclohex-2-enyl]-4-
methoxy-4-oxobutanoic acid [(2S,3R,4R)-7] 
HN
1
2
3
O
4
5
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O
7
8
O
9
OH
10
11
O
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O
13
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D
 
According to (2S,3S,4S)-7, (2S,3R,4R)-7 was prepared from (2S,3R,4R)-6 (790 mg, 
2.13 mmol) and Grubbs I catalyst (21.0 mg, 25.5 μmol), yielding a colorless foam 
(550 mg, 1.55 mmol, 86%).  
(2S,3R,4R)-7: Rf 0.18 (pentane/EtOAc, 8:2, 1% HOAc); []D20 = + 53.3 ° (c = 1.0, 
CHCl3); rotameric ratio at rt 9:1. 
Major rotamer 1H NMR (400 MHz, CDCl3): 1.45 (s, 9 H, 1-H), 1.40–1.61 (m, 2 H, 
14-Ha, 13-Ha), 1.75 (m, 1 H, 13-Hb), 1.87 (m, 1 H, 14-Hb), 2.01 (m, 2 H, 12-H), 2.91 
(d, 3J7,4 = 3.6 Hz, 1 H, 7-H), 3.73 (s, 3 H, 6-H), 4.66 (dd, 3J4,NH = 10.7 Hz, 3J4,7 = 3.7 
Hz, 1 H, 4-H), 5.67 (d, 3JNH,4 = 10.7 Hz, 1 H, NH), 5.81 (t, 3J11,12 = 3.4 Hz, 1 H, 11-H), 
7.61 (bs, 1 H, OH). 13C NMR (100 MHz, CDCl3): 20.4 (t, C-13), 25.0 (t, C-12), 
26.3 (t, C-14), 28.3 (q, C-1), 33.3 (t, J9,D = 22.3 Hz, C-9), 50.9 (d, C-7), 52.6 (q, C-6), 
52.7 (d, C-4), 80.4 (s, C-2), 129.0 (d, C-11), 155.2 (s, C-3), 171.6 (s, C-5), 177.2 (s, 
C-8) 
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.46 (m, 1 H, 4-H), 
6.09 (bs, 1 H, NH). 
HRMS (C16H24D2NO6 [M +H]+): calculated 330.1880, found 330.1878. 
 
 S12
(S)-Methyl 2-(tert-butoxycarbonylamino)-3- [(S)-1,2-dideuterocyclohex-2-enyl]-
propanoate [(2S,4S)-8]  
 
According to the procedure described for (2S,4R)-8, the (2S,4S)-diastereomer was 
prepared from (2S,3R,4R)-7 (380 mg, 1.15 mmol), PhPOCl2 (90%, 196 μL, 1.24 
mmol), Et3N (970 μL, 6.92 mmol), mercaptopyridine N-oxide (365 mg, 2.88 mmol), 
tert-butyl mercaptane (1.30 mL, 11.5 mmol) and triethyl borane (1M in THF, 400 μL, 
400 μmol) yielding the cyclohexenyl alanine derivative (186 mg, 652 μmol, 57%) as 
colorless resin. Rf 0.33 (pentane/EtOAc, 8:2,); []D20 = + 47.0 ° (c=0.9, CHCl3); 
rotameric ratio at rt 9:1. 
Major rotamer 1H NMR (400 MHz, CDCl3): 1.24 (m, 1 H, 13-Ha), 1.43 (s, 9 H, 1-
H), 1.47–1.60 (m, 2 H, 7-Ha, 12-Ha), 1.65–1.74 (m, 2 H, 12-Hb, 7-Hb), 1.85 (m, 1 H, 
13-Hb), 1.95 (m, 2 H, 11-H), 3.71 (s, 3 H, 6-H), 4.36 (m, 1 H, 4-H), 4.92 (d, 3JNH,4 = 
8.1 Hz 1 H, NH), 5.69 (t, 3J10,11 = 3.4 Hz, 1 H, 10-H). 13C NMR (100 MHz, CDCl3): 
20.9 (t, C-12), 25.1 (t, C-11), 28.1 (s, C-13), 28.3 (q, C-1), 31.9 (t, J8,D = 18.8 Hz, 
C-8), 39.3 (t, C-7), 51.5 (d, C-4), 52.2 (q, C-6), 79.9 (s, C-2), 128.0 (d, C-10), 130.3 (t, 
J9,D = 23.6 Hz, C-9), 155.4 (s, C-3), 173.9 (s, C-5). 
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.22 (m, 1 H, 4-H), 
4.74 (m, 1 H, NH). 
HRMS (C15H24D2NO4 [M+H]+): calculated  286.1982, found 286.1986. 
 
(S)-2-(tert-Butoxycarbonylamino)-3-[(S)-1,2-dideuterocyclohex-2-enyl]propan-
oic acid [(2S,4S)-9] 
 
According to (2S,4R)-9, Ester (2S,4S)-8 (150 mg, 526 μmol) was saponified with 
NaOH (1.0 M, 580 μL, 580 μmol), yielding acid (2S,4S)-9 (138 mg, 510 μmol, 97%) 
as colorless resin. []D20 = + 77.9 ° (c=0.4, CHCl3); rotameric ratio at rt 2:1. 
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Major rotamer 1H NMR (400 MHz, CDCl3): 1.27 (m, 1 H, 12-Ha), 1.44 (s, 9 H, 1-
H), 1.52 (m, 1 H, 11-Ha), 1.60–1.79 (m, 3 H, 6-H, 11-Hb), 1.86 (m, 1 H, 12-Hb), 1.97 
(m, 2 H, 10-H), 4.38 (m, 1 H, 4-H), 4.94 (d, 3JNH,4 = 8.0 Hz 1 H, NH), 5.70 (t, 3J9,10 = 
3.5 Hz, 1 H, 10-H), 9.20 (bs, 1 H, OH). 13C NMR (100 MHz, CDCl3): 20.9 (t, C-
11), 25.1 (t, C-10), 28.0 (s, C-12), 28.3 (q, C-1), 31.0(t, J7,D = 20.6 Hz, C-7), 38.8 (t, 
C-6), 51.5 (d, C-4), 80.2 (s, C-2), 128.1 (d, C-9), 130.2 (t, J8,D = 22.4 Hz, C-8), 155.7 
(s, C-3), 178.1 (s, C-5). 
Minor rotamer (selected signals): 1H NMR (400 MHz, CDCl3): 4.20 (m, 1 H, 4-H), 
6.22 (bs, 1 H, NH); 13C NMR (100 MHz, CDCl3):  52.6 (d, C-4), 81.7 (s, C-2), 
127.9 (d, C-9), 156.6 (s, C-3), 177.7 (s, C-5). 
HRMS (C14H22D2NO4 [M+H]+): calculated 272.1825, found 272.1875. 
 
(S)-2-Amino-3-[(S)-1,2-dideuterocyclohex-2-enyl]propanoic acid hydrochloride 
(2S,4S)-1 
H3N 12
3
OH
4
6
O
7
9
8
5
D
D
Cl
According to (2S,4R)-1, (2S,4S)-9 (97.0 mg, 309 μmol) was deprotected with HCl (4 
M in dioxane, 750 μL, 3.00 mmol), giving the hydrochloride (64.1 mg, 309 μmol, 
100%) as white crystalline solid, mp. 205 °C (decomp.). []D20 = + 75.3 ° (c=1.0, 
MeOH). 
1H NMR (400 MHz, CD3OD): 1.30 (m, 1 H, 9-Ha), 1.59 (m, 1 H, 8-Ha), 1.75 (m, 
1 H, 8-Hb), 1.80–1.93 (m, 3 H, 3-H, 9-Hb), 2.01 (m, 2 H, 7-H), 4.01 (d, 3J2,3 = 6.8 Hz, 
1 H, 2-H), 5.76 (t, 3J6,7 = 3.4 Hz, 1 H, 6-H). 13C NMR (100 MHz, CD3OD): 21.7 (t, 
C-8), 26.1 (t, C-7), 29.3 (t, C-9), 31.8 (t, J4,D = 18.9 Hz, C-4), 38.2 (t, C-3), 52.0 (d, C-
2), 129.5 (d, C-6), 130.2 (t, J5,D = 24.2 Hz, C-5), 172.3 (s, C-1). 
HRMS (C14H22D2NO4 [M+H]+): calculated 172.1301, found 172.1304. 
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4) Supplemental informations on feeding experiment 
Materials 
YMG medium1 (D-glucose 20 g/L, meat extract 5 g/L, yeast extract 5 g/L, casein 
hydrolysate 3 g/L, sodium chloride 1.5 g/L, peptone 5 g/L) was used for Strepto-
myces sp. JS360 propagation. Q6 medium21 (D-glucose 0.5%, cotton seed meal 1%, 
glycerol 2%, calcium carbonate 0.1%, pH 7.2 adjusted with sodium hydroxide) was 
used for cinnabaramide production. 
Methods 
Feeding experiments: 
Streptomyces sp. JS360 was grown in 20 mL V6 medium at 30 °C for 48 h and was 
transferred to 25 ml Q6 medium in dilution factor 1:50 supplemented variously with D-
di-deuterated cyclohexenyl-alanine, L-di-deuterated cyclohexenyl-alanine in concen-
tration of 0.1 mM. These substances were added in three portions to the bacterial 
culture after 0, 6, and 12 h, respectively, and afterwards cultures were further incuba-
ted at 30 °C for 24 h. To investigate the production level of cinnabaramides and their 
derivatives, culture supernatant was extracted by ethyl-acetate three times in ratio 
1:1. After removal of the solvent in vacuo, the remainder was dissolved in methanol 
(1 ml) and 5 μL of the solution was injected for HPLC-MS analysis. 
 
Analytical procedure: 
High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) was 
performed with a HPLC-DAD system (Agilent 1100) coupled to an HCT ultra ESI-MS 
ion trap apparatus (Brucker Daltonics) operating in positive ionization mode. 
Separation was archived by use of a Luna RP-C18 column with a solvent system 
consisting of water to acetonitrile gradient. For separation of cinnabaramides and 
their derivatives, a solvent system based on water (A)/acetonitrile (B) containing 
formic acid (0.1%) was applied. Gradient: 0-2 min 5% B; 2-22 min linear from 5% to 
95% B; 22-25 min isocratic at 95% B; 25-27 min linear from 95-5% B. 
High-resolution LC-MS measurements were performed with an Accela UPLC-system 
(Thermo-Fisher) coupled to an LTQ-Orbitrap (linear trap-FT-Orbitrap combination) 
operating in positive ionization mode with a Waters BEH-C18 column with a solvent 
system consisting of a water (A)/acetonitrile (B) gradient containing formic acid 
(0.1%). 
 
                                             
2 Stadler, M.; Bitzer, J.; Mayer-Bartschmid, A.; Müller, H.; Benet-Buchholz, J.; Gantner, F.; Tichy, H.-
V.; Reinemer, P.; Bacon, K. B. J. Nat. Prod. 2007, 70, 246–252. 
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Figure S1: A) Left: HPLC-MS analysis of S. sp JS360 wild type extracts with extracted ion 
chromatogram (EIC) for m/z = 354.2 corresponding to cinnabaramide E (tR = 11.2 min). 
Right: mass spectrum at tR = 11.2 min showing isotopic pattern of cinnabaramide E. B) Left: 
HPLC-MS analysis of S. sp JS360 wild type extracts fed by D-di-deuterated cyclohexenyl-
alanine with extracted ion chromatogram (EIC) for m/z = 354.2 corresponding to 
cinnabaramide E (tR = 11.2 min). Right: mass spectrum at tR = 11.2 min showing isotopic 
pattern of cinnabaramide E and di-deuterated cinnabaramide E analogue (highlighted in 
gray), showing that feeding of the wildtype strain with D-di-deuterated cyclohexenyl-alanine 
resulted in production of respective di-deuterated cinnabaramides. 
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5) Copies of NMR spectra 
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(R)-Non-8-en-3-yn-2-yl acetate [(R)-3] 
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(R,E)-3,4-Dideuteronona-3,8-dien-2-ol [(R)-4] 
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(S)-4-[(R,E)-3,4-Dideuteronona-3,8-dien-2-yl] 1-methyl 2-(tert-butoxycarbonyl-
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(2R,3S)-3-(tert-Butoxycarbonylamino)-2-[(R)-1,2-dideuterocyclohex-2-enyl]-4-
methoxy-4-oxobutanoic acid [(2S,3R,4R)-7] 
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(S)-Methyl 2-(tert-butoxycarbonylamino)-3-[(S)-1,2-dideuterocyclohex-2-
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enyl]propanoic acid [(2S,4S)-9] 
ppm (t1)
1.02.03.04.05.06.0
6,
23
5,
71
5,
70
5,
69
5,
29
4,
96
4,
94
4,
38
4,
37
4,
20
1,
98
1,
97
1,
96
1,
86
1,
85
1,
74
1,
70
1,
54
1,
54
1,
53
1,
52
1,
44
1
26
1
24
1.00
0.29
0.66
1.03
2.06
1.11
3.26
1.18
9.28
1.44
0.97
HN
1
2
3
OH
4
6
O
7
11
O
12
O
8
9
10
5
D
D
 
 
 
ppm (t1)
050100150200
17
8,
10
17
7,
72
15
6,
64
15
5,
68
13
0,
47
13
0,
24
12
9,
99
12
8,
05
12
7,
86
81
,6
5
81
,6
2
80
,2
2
52
,5
9
51
,5
1
38
,8
2
31
,2
5
31
,0
4
30
,8
8
28
,2
7
28
,0
1
25
,1
3
20
,8
6
HN
1
2
3
OH
4
6
O
7
11
O
12
O
8
9
10
5
D
D
 
(2S ,4S)-9
(2S ,4S)-9 
 S30
 
(S)-2-Amino-3-[(S)-1,2-dideuterocyclohex-2-enyl]propanoic acid hydrochloride 
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SUMMARY
Bottromycins represent a promising class of anti-
biotics binding to the therapeutically unexploited
A-site of the bacterial ribosome. By inhibiting
translation they are active against clinically impor-
tant pathogens, such as vancomycin-resistant
Enterococci. Structurally, bottromycins are heavily
modiﬁed peptides exhibiting various unusual bio-
synthetic features. To set the stage for compound
modiﬁcation and yield optimization, we identiﬁed
the biosynthetic gene cluster, used synthetic bio-
technology approaches to establish and improve
heterologous production, and generated analogs
by pathway genetic engineering. We unambiguously
identiﬁed three radical SAM methyltransferase-
encoding genes required for various methylations
at unactivated carbons yielding tert-butyl valine,
methyl-proline, and b-methyl-phenylalanine resi-
dues, plus a gene involved in aspartate methyl-ester
formation. Evidence for the formation of the exo-
thiazole unit and for a macrocyclodehydration
mechanism leading to amidine ring formation is
provided.
INTRODUCTION
One of the most prominent global public health threats is caused
by antibiotic resistance in conjunction with new and reoccurring
infectious diseases. In addition, antimicrobial research in phar-
maceutical companies is challenged by a severe disproportion
between the degree of investment and the expected proﬁt in
the course of drug development. Therefore, access to new hit-
and-lead structures addressing novel targets and/or represent-
ing new chemical scaffolds exhibiting activity against multi-
drug-resistant bacteria is of utmost importance (Fischbach and
Walsh, 2009; Newman and Cragg, 2012; Li and Vederas, 2009).
Bottromycins were discovered as antibacterial peptides
with promising activity against Gram-positive bacteria and
mycoplasma from the fermentation broth of Streptomyces
bottropensis (Waisvisz et al., 1957a, 1957b, 1957c; Waisvisz
and van der Hoeven, 1958; Tanaka et al., 1968). Later on it
was shown that their antibacterial ability extends to methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resis-
tant Enterococci (VRE) (Shimamura et al., 2009). The structure
elucidation process involved several chemical revisions (Naka-
mura et al., 1965a, 1965b, 1965c, 1966, 1967; Takahashi et al.,
1976; Schipper, 1983) and ultimately led to the assignment of 1
(Figure 1), which was recently conﬁrmed by total synthesis (Shi-
mamura et al., 2009). Mode of action studies revealed the amino-
acyl-tRNA binding site (A site) on the 50S ribosome as the target
of bottromycins, ultimately leading to the inhibition of protein
synthesis (Otaka and Kaji, 1976, 1981, 1983). As this site is
currently not addressed by clinically used antibiotics, no cross-
resistance was observed, and bottromycins are regarded as
promising leads to be developed as novel anti-infectives, with re-
newed interest even in medicinal chemistry (Gouda et al., 2012).
Bottromycins represent octapeptides exhibiting an internal
tetrapeptide cycle formed via a unique amidine linkage. The
compound harbors an exo-thiazole and several unnatural amino
acids, which carry methyl-groups at nonactivated carbons,
posing additional challenges for total synthetic approaches
aimed toward drug development.
As a valid alternative to total synthesis, biosynthetic engi-
neering can be envisaged to improve structure and yield of any
microbial natural product eventually resulting in fermentative
production (Fischbach and Voigt, 2010). To achieve this goal
the underlying principles of compound production need to be
understood, and thus identiﬁcation of the biosynthetic genes is
mandatory. In principle, there are two natural ways for the
production of highly modiﬁed and bioactive peptide scaffolds:
biosynthesis can be achieved in a thiotemplated fashion on large
multienzymatic systems termed nonribosomal peptide synthe-
tases (NRPS), which were intensively studied in the past
decades (Finking and Marahiel, 2004; Schwarzer et al., 2003).
Alternatively, and only recently described as more common
than originally anticipated, complex peptides can also be bio-
synthesized starting from simple, ribosomally made precursor
peptides undergoing intriguing modiﬁcation steps (McIntosh
et al., 2009; Nolan and Walsh, 2009; Oman and van der Donk,
2010). Nonribosomally synthesized peptides (NRPs) and the
latter compounds of ribosomal origin (RPs) differ mainly in the
construction of the core-scaffold as RPs are limited in structural
diversity by incorporation of the canonical proteinogenic amino
acids only. However, they can be extensively posttranslationally
1278 Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved
modiﬁed, which is mostly performed on the precursor peptide
state (McIntosh et al., 2009; Oman and van der Donk, 2010).
NRPS, in contrast, incorporate during chain assembly numerous
‘‘unnatural’’ amino acids and are thought to undergo less exten-
sive post-NRPS modiﬁcations. However and despite their vastly
different core biosynthetic routes, RPs and NRPs share many
postassemblymodiﬁcations, which are often required for biolog-
ical activity. These include heterocyclizations, methylations, and
glycosylations, just to name a few (Walsh et al., 2001; McIntosh
et al., 2009; Oman and van der Donk, 2010). In NRPS the
required enzymatic functionalities are optionally incorporated
into the megasynthetases. As discussed above it is difﬁcult to
predict from the chemical structure whether modiﬁed peptides
are based on NRP and RP assembly logic. Therefore, retrobio-
synthetic analysis of bottromycin did not yield an assignment
of the type of biosynthetic pathway to be expected.
Motivated by the promising activity and the chemical
uniqueness of the bottromycin scaffold, we set out to identify
the biosynthetic gene locus in the terrestrial actinomycete
Streptomyces sp. BC16019, which was shown to produce
bottromycin A2, B2, and C2 (Lerchen et al., 2006). This work
identiﬁed a ribosomal locus required for bottromycin biosyn-
thesis and set the stage for synthetic biotechnology approaches
toward structure and yield improvement. We heterologously
expressed the biosynthetic pathway and optimized initially low
bottromycin production titers. Using pathway engineering we
were able to assign each of the ﬁve unusual methylation
reactions to speciﬁc genes, which in parallel enabled the
production of three, to our knowledge, novel derivatives. In
addition, work presented here provides evidence for a unique
‘‘macrocyclodehydration’’ reaction giving rise to the unique
amidine linkeage found in the bottromycin scaffold.
Figure 1. Maturation of the Ribosomal Bottromycin Peptide Scaffold
The bottromycin precursor peptide consists of the core peptide as well as a C-terminal extension (underlined) likely serving as recognition sequence. Maturation
of the bottromycin peptide scaffold requires a number of posttranslational modiﬁcations (highlighted in gray), the timing of which is currently unknown. These
include various methylations and proteolytic digestion as well as ‘‘macrocyclodehydration’’ and thiazole ring formation (proposed mechanisms for the latter two
are boxed, for explanations see subsection ‘‘In Silico Analysis of the Bottromycin Biosynthetic Pathway’’). R, H or Me; X, OH or MTADFLNDDPNNAELSALE
MEELESWGAWDGEATS.
Chemistry & Biology
Ribosomal Bottromycin Biosynthesis
Chemistry & Biology 19, 1278–1287, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1279
RESULTS AND DISCUSSION
Identiﬁcation of the Bottromycin Biosynthetic
Gene Cluster
Our initial attempts to identify the bottromycin biosynthetic
pathway were based on the assumption that the compound is
made via a nonribosomal peptide synthetase (NRPS) assembly
line, similar to most other cyclic peptide pathways analyzed to
date. Those systems usually exhibit a modular architecture, in
which each module incorporates one amino acid building block
to the growing peptide chain (Finking and Marahiel, 2004;
Schwarzer et al., 2003). Retrobiosynthetic analysis revealed
that the bottromycin peptide core almost certainly originates
from eight amino acids (Gly-Pro-Val-Val-Val-Phe-Asp-Cys),
which led us to predict an octamodular NRPS biosynthetic
machinery. In accordance with textbook biosynthetic logic, bot-
tromycin thiazole ring formation from a cysteine residue requires
the catalytic activity of a heterocyclization (HC) and an oxidation
(Ox) domain (Walsh et al., 2001; Schwarzer et al., 2003; Roy
et al., 1999; Walsh and Nolan, 2008), which should therefore
be included within the putative bottromycin assembly line. As
the identiﬁcation of heterocycle-forming peptide pathways using
homologous and heterologous probes for HC and/or Ox
domains is well established (Cheng et al., 2002), we considered
this strategy to screen for the bottromycin biosynthetic pathway.
A cosmid library of the bottromycin producer Streptomyces sp.
BC16019 was constructed and analyzed for HC/Ox harboring
NRPS pathways by hybridization experiments (S.R., L.H., and
R.M., unpublished data). However, these efforts did not lead to
the identiﬁcation of a genetic locus possibly involved in bottro-
mycin biosynthesis. To obtain comprehensive information about
all putative secondary metabolite pathways of S. sp. BC16019
whole-genome shotgun sequence data were generated using
the 454 technology. Detailed in silico analysis of the resulting
319 sequence scaffolds revealed no putative NRPS-dependent
bottromycin biosynthetic gene cluster, indicating that the com-
pound might rather derive from a ribosomal pathway. In this
case, one would expect a small precursor peptide-encoding
gene accompanied by a number of ‘‘modifying genes’’ for craft-
ing the complex and bioactive bottromycin scaffold from a rather
simple, linear peptide chain assembled from the canonical
20 proteinogenic amino acids. Indeed, we were able to identify
a small open reading frame (orf; botA) in the sequence data
encoding the bottromycin octapeptide sequence, plus some
C-terminal extension. In silico analysis of the ﬂanking regions
led to the identiﬁcation of a number of genes encoding enzymes
that are most likely involved in the various posttranslational
modiﬁcation (PTM) steps predicted for the maturation of the bot-
tromycin propeptide (see Figure 1 and Table 1). In order to
conﬁrm that the identiﬁed chromosomal region encodes the
bottromycin biosynthetic pathway, we established a genetic
modiﬁcation procedure for the producer strain to perform tar-
geted gene inactivation experiments. Using the suicide vector
pKC1132-botOMT-KO, one of the putative-modifying genes,
botOMT, was inactivated via homologous recombination, result-
ing in the mutant strain S. sp. BC16019::pKC1132-botOMT-KO.
High-performance liquid chromatography (HPLC)-mass spec-
trometry (MS) analysis in comparison to wild-type extracts
showed the abolishment of bottromycin production, conﬁrming
the involvement of botOMT in bottromycin biosynthesis. At this
point, polar effects on genes located downstream could not be
excluded using the applied insertion strategy. Further experi-
ments (see subsection ‘‘Establishment and Optimization of
Heterologous Bottromycin Production’’) clearly established the
bot locus as the bottromycin biosynthetic gene cluster.
In Silico Analysis of the Bottromycin Biosynthetic
Pathway
The gene locus responsible for bottromycin biosynthesis was
identiﬁed through in silico analysis of genome data coupled
with targeted insertion mutagenesis as described above as
well as via heterologous expression of the entire pathway (see
subsection ‘‘Establishment and Optimization of Heterologous
Bottromycin Production’’). The pathway consists of (at least)
13 genes (bot genes) and spans about 18 kb (see Figure 2).
The botA gene encodes a 44-amino acid peptide and is ﬂanked
Table 1. Proteins Involved in Bottromycin Biosynthesis
Protein Residues (aa) Annotation Proposed Function in Bottromycin Biosynthesis
BotRMT1 641 Radical SAM C-Methylation (of phenylalanine)
BotA 44 Structural gene Precursor peptide
BotC 434 Cyclodehydratase (YcaO-like family) Macrocyclodehydration (?)
BotCD 400 Cyclodehydratase (YcaO-like family
and docking_ocin superfamily)
Cyclodehydration during thiazole
ring formation (?)
BotRMT2 660 Radical SAM C-Methylation (of valines)
BotH 293 Putative a/b hydrolase Macrocycle or thiazole ring formation (?)
BotAH 465 Putative amidohydrolase Macrocycle or thiazole ring formation (?)
BotCYP 345 Cytochrome P450 enzyme Macrocycle or thiazole ring formation (?)
BotRMT3 681 Radical SAM C-Methylation (of proline)
BotR 184 Transcriptional regulator Pathway regulation
BotOMT 279 O-methyl transferase O-Methylation
BotT 441 Multidrug transporter Efﬂux pump, self-resistance
BotP 504 Leucyl-aminopeptidase Proteolytic cleavage
See also Figure S1 and Table S1.
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by a set of modifying genes required for maturation to an
8-residue highly modiﬁed macrocycle (see Figure 1). The BotA
precursor peptide is bipartite: it contains an N-terminal core
peptide as well as a C-terminal extension (the N-terminal methi-
onine is most likely cleaved off by a methionine aminopeptidase
during translation or by the putative peptidase BotP). This struc-
ture is unique among precursor peptides from ribosomal path-
ways described to date; in other precursors, the core peptides
are typically ﬂanked by N-terminal leader sequences, and in
some cases additional C-terminal extensions are found (Oman
and van der Donk, 2010). It is frequently postulated that the
N-terminal leader sequences serve as a recognition motif for
the PTM enzymes and that they are removed in the last step of
the maturation process (Oman and van der Donk, 2010). The
absence of an N-terminal leader sequence in BotA indicates
that the C-terminal extension—or parts of it—functions as PTM
enzyme recognition sequence. Furthermore, as discussed for
the N-terminal leaders, some other functions can be attributed
to the C-terminal BotA sequence, for example, serve as secre-
tion signal, act as chaperone (in cis) and assist with folding, stabi-
lize the precursor against degradation, and/or keep the peptide
inactive during biosynthesis inside the cell (Oman and van der
Donk, 2010). (Final) Proteolytic cleavage of the C-terminal exten-
sion is most likely catalyzed either by the putative a/b-hydrolase
BotH or by BotP, which shows homology to leucyl aminopepti-
dases (Matsui et al., 2006). For some members of this group, it
could be shown that they also prefer methionine as N-terminal
amino acid, which correlates well with the predicted cleavage
site in BotA (see Figure 1) (Herrera-Camacho et al., 2007). The
highly modiﬁed bottromycin scaffold results from various PTM
reactions, and a number of candidate genes involved in these
processes have been identiﬁed in the bot locus—although
most of the encoded proteins exhibit only very low sequence
identity to proteins found in the common databases. This ﬁnding
and the associated difﬁculties in predicting enzyme function
from low similarity scores on the protein level are currently
a general challenge for the analysis of ribosomal peptide biosyn-
thesis pathways, which complicates the in silico analysis and
Figure 2. Heterologous Bottromycin Production
(A) Inserts of the three expression constructs (pOJ436 derivatives) used for heterologous bottromycin production. The original cosmid DG2 was modiﬁed via
Red/ET recombineering to delete the 50-ﬂanking region (orf7–orf20) by insertion of kanR and, in the next step, to insert the PermE* promoter upstream of botT
together with specR.
(B) Quantiﬁcation of heterologous bottromycin production by HPLC-MS analysis of the culture extracts from different S. coelicolor mutant strains. Sections
of extracted ion chromatograms at m/z = 823.45 corresponding to the [M+H]+ ion of bottromycin A2 (1) are illustrated as representative readout of productivity.
The S. coelicolor A3(2) host strains contain one of the three expression constructs shown in (A). With S. coelicolor::DG2 and DG2-kan, ‘‘rifampicin-induced
mutagenesis’’ was performed (‘‘DG2-rif’’ and ‘‘DG2-kan-rif’’).
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functional gene annotation. However, a striking feature of the
bottromycin scaffold is its extensivemethylation pattern, and ac-
cording to our expectations a number of putativeS-adenosylme-
thionine (SAM)-dependent methyl transferases (MTs) could be
identiﬁed (BotRMT1, BotRMT2, BotRMT3, and BotOMT). Bo-
tOMT shows homologies to O-MTs and was therefore assumed
to be involved in O-methylation of the aspartate residue. The re-
maining three MTs (BotRMT1–BotRMT3) belong to the class of
radical SAM-dependent MTs (‘‘radical SAMs’’; Frey et al.,
2008; Atta et al., 2010) andwere expected to catalyze the various
C-methylations at the bottromycin scaffold. According to their
didomain protein architecture (N-terminal cobalamin binding
domain and C-terminal radical SAM domain), BotRMT1–
BotRMT3 belong to class B of the recently classiﬁed radical
SAM MTs (Zhang et al., 2012), which are indeed hypothesized
to contain members methylating unactivated sp3 carbons. This
ﬁnding is also in accordance with the proposedmethylation sites
of BotRMT1–BotRMT3 at proline, phenylalanine, and the two
valine residues. However, based on the in silico analysis, it is
clearly impossible to assign the exact function of each protein.
We therefore carried out further experiments to elucidate the
pathway (see subsection ‘‘Functional Studies on the Bottromy-
cin Methylation Pattern: A Suite of Hyperactive Methylases’’).
The thiazole ring is yet another structural feature of bottromycin,
occurring widespread in ribosomally made and nonribosomally
assembled peptide scaffolds (Walsh et al., 2001; Schwarzer
et al., 2003; Roy et al., 1999; McIntosh et al., 2009; Walsh and
Nolan, 2008; Nolan and Walsh, 2009). This heterocycle is typi-
cally installed by cyclodehydration starting from a cysteine
residue, the thiol of which attacks the carbonyl carbon of the
adjacent amino acid to form a thiazoline, which can subse-
quently undergo oxidation to form the thiazole. For the ribosomal
peptide microcin B17, it was shown that a three-protein
complex, consisting of a cyclodehydratase, a ‘‘docking protein,’’
and a ﬂavin mononucleotide (FMN)-dependent dehydrogenase,
is required for thiazole ring formation (Li et al., 1996). Whereas
the function of the cyclodehydratase (cyclodehydration reaction)
and the dehydrogenase (thiazoline oxidation) was clearly as-
signed, the precise function of the ‘‘docking protein’’ remained
elusive until recently, and a direct role in regulating cyclodehy-
dratase activity and assembly of an active complex was debated
(Melby et al., 2011). However, a recent study demonstrates that
the ‘‘docking protein,’’ which belongs to the YcaO-like protein
family, itself catalyzes the cyclodehydration under consumption
of ATP (Dunbar et al., 2012). This study not only provided ﬁrst
experimental evidence for the requirement of ATP-hydrolysis
for cyclodehydration reactions but also showed the dispens-
ability of the subunit formerly annotated as ‘‘cyclodehydratase’’
for the reaction. However, it could be shown that this protein can
increase the reaction rate by approximately three orders of
magnitude. When analyzing the bottromycin biosynthetic
pathway for enzyme candidates possibly involved in thiazole
ring formation, two putative ‘‘YcaO-like family proteins’’ (BotC
and BotCD) were identiﬁed, whereas genes encoding homologs
of the ‘‘cyclodehydratase’’ subunit could not be detected (see
below). Based on the above ﬁndings, we assume that BotC
and BotCD autonomously act as cyclodehydratases. Whereas
one of these enzymes is most likely involved in thiazoline ring
formation, the other candidate might play a role in the unique
‘‘macrocyclodehydration’’ reaction as discussed below (see Fig-
ure 1).We speculate that BotCD is the enzyme involved in bottro-
mycin thiazole formation, because it shows not only homology to
YcaO-like family proteins but also to the ‘‘docking_ocin super-
family’’ of proteins (TIGR03604; members of this protein family
include enzymes related to SagD; Lee et al., 2008), which
includes ‘‘docking proteins’’ involved in heterocyclization reac-
tions in other ribosomal pathways. BotC, on the other hand,
would thus be a likely candidate for the unique catalyst perform-
ing the macrocyclodehydration discussed below. After cycliza-
tion conversion of thiazoline moieties into thiazoles usually
occurs via dehydrogenation. However, a putative dehydroge-
nase activity could not be detected in the bot locus, suggesting
that thiazole ring formation in bottromycin biosynthesis
proceeds via a different mechanism. The absence of a dehydro-
genasemight be explained by the requirements to form an ‘‘exo-
thiazole’’ moiety, which probably results from an oxidative elim-
ination reaction (see Figure 1). One possible scenario is an oxida-
tive decarboxylation after proteolysis of the C-terminal extension
sequence. However, we cannot exclude other ‘‘elimination
hypotheses,’’ which might rely on further premodiﬁcations of
the thiazoline ring (e.g., hydroxylation or dehydrogenation). Alter-
natively, precursor peptide proteolysis and subsequent oxida-
tive decarboxylation of the C-terminal cysteine might occur
before cyclodehydration. Similar reactions have been described
for the biosynthesis of aminovinyl-cysteine-containing ribosomal
peptides, including the generation of reactive ‘‘thio-enol’’ inter-
mediates via oxidative decarboxylation of C-terminal cysteine
residues (Sit et al., 2011). The enzymes involved were character-
ized as homo-oligomeric ﬂavin-containing cysteine decarboxy-
lases, but no putative homolog of this enzyme family was found
encoded within the bottromycin biosynthetic gene locus. Appar-
ently, the underlying biochemistry for bottromycin ‘‘exo-thia-
zole’’ ring formation cannot be predicted based on the available
in silico data and requires further experimental studies.
Another intriguing modiﬁcation unique for ribosomal peptide
biosynthesis is the formation of the bottromycin macrocycle
established between the N-terminal glycine and the second
valine residue. Similar to textbook cyclodehydration chemistry,
we propose a nucleophilic attack of the glycine amino group to
the valine carbonyl carbon, followed by dehydration. This trans-
formation may be seen as ‘‘macrocyclodehydration’’ reaction,
resulting in the formation of an amidine group, which is—to the
best of our knowledge—unique among all ribosomal peptides
biosynthetically characterized so far and also very rare among
other natural products. Coformycin (Nakamura et al., 1974)
and ectonine (Inbar and Lapidot, 1988), also described as pyro-
statin B (Castellanos et al., 2006), are examples of natural prod-
ucts containing this structural feature. Studies on the genetics
and biochemistry of ectoine metabolism revealed that the cyclic
amidine moiety is formed via a ‘‘cyclodehydratase’’-like reaction
similar to the macrocyclization mechanism we postulate for the
bottromycin biosynthesis. The enzyme involved is described as
ectoine synthase (EctC) and belongs to the family of carbon-
oxygen lyases. It is encoded in the ectoine biosynthetic gene
locus, which is found widespread in microorganisms (Pastor
et al., 2010), and could also be identiﬁed in the bottromycin
producer as well as in Streptomyces coelicolor. However, no
homolog of the ectoine synthase family could be identiﬁed in
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the bottromycin biosynthetic gene cluster, and we assume that
one of the putative cyclodehydratases (BotC and BotCD) might
be involved in ‘‘macrocyclodehydration.’’ BotC is the favored
candidate enzyme because of the arguments provided above.
However, we cannot exclude the involvement of ectoine biosyn-
thetic pathway enzymes in this reaction, as they are encoded in
the chromosomes of both the native and the heterologous
bottromycin producers. Additionally, there are some bot genes
with yet unassigned biosynthetic function, like botH, botAH,
and botCYP, encoding a putative a/b hydrolase, an amidohydro-
lase, and a P450 enzyme, respectively, which might be involved
in this unusual ‘‘macrocyclodehydration’’ reaction or in the
‘‘exo-thiazole’’ ring formation discussed above. Besides the
discussed enzyme candidates involved in the maturation of
the bottromycin precursor peptide, the biosynthetic gene cluster
encodes a putative transcriptional regulator (BotR) as well as
a putative multidrug transporter (BotT). The latter might play an
important role for the self-resistance of the bottromycin
producer, which is underpinned by results from genetic engi-
neering studies based on a heterologous expression system
(see next subsection).
Establishment and Optimization of Heterologous
Bottromycin Production
As genetic manipulation of the native bottromycin producer
S. sp. BC16019 turned out to be rather difﬁcult and was
restricted to the established single-cross-over method with
very lowefﬁciency, we aimed to establish a heterologous expres-
sion system to further characterize and engineer bottromycin
biosynthesis. To mobilize the bottromycin pathway for expres-
sion in suitable host strains, the entire 18 kb biosynthetic
gene cluster was required to be subcloned on one physical
entity. We were able to identify a cosmid harboring the complete
target region plus some ﬂanking sequence when screening the
gene library of the bottromycin producer with suitable probes
(cosmid DG2, see Figure 2A). As the pOJ436 cosmid backbone
already contains genetic elements for conjugation (origin of
transfer, oriT) and site-speciﬁc integration into Streptomyces
chromosomes (phage FC31 integrase gene and attachment
site; Bierman et al., 1992), the related host strains Streptomyces
coelicolor A3(2) and Streptomyces albus J1074 were directly
transformed with this construct. Transconjugants were veriﬁed
by PCR and subsequently analyzed for heterologous bottromy-
cin production. Parallel cultivations of host strains with and
without the expression construct in comparison to the native bot-
tromycin producer were carried out followed by HPLC-MS anal-
ysis of the culture extracts. Successful heterologous bottromycin
production could be detected for both of the expression hosts,
S. coelicolor::DG2 and S. albus::DG2, demonstrating that the
putative bottromycin pathway was complete and active in the
foreign circuits under control of its native regulatory elements.
Because the heterologous production yields in both hosts
were much lower compared to the native producer (1 mg/l
in S. albus and 4 mg/l in S. coelicolor; 100 times lower than
in native host), optimization approaches focused on the
S. coelicolor expression system were initiated. In a preliminary
step, the bulky expression construct was simpliﬁed by deletion
of a 16 kb insert fragment at the 50 end of the bot gene cluster.
This modiﬁcation was performed via Red/ET recombineering
(Zhang et al., 1998, 2000), resulting in the integration of a kana-
mycin resistance gene to generate cosmid DG2-kan (see Fig-
ure 2A). As expected, subsequent heterologous expression in
S. coelicolor showed that this deletion does not signiﬁcantly
affect the bottromycin production titer (see Figure 2B), and it
also conﬁrmed our assumption that the excised genetic region
(orf7–orf20) is not required for bottromycin biosynthesis. Aiming
at improvement of bottromycin production titers, we next applied
an undirected approach based on the observation that certain
drug-resistance mutations in the rpoB gene (encoding the RNA
polymerase b-subunit), or the rpsL gene (encoding the ribosomal
S12 protein), may effectively enhance secondary metabolite
production in Gram-positive bacteria (Hu et al., 2002; Inaoka
et al., 2004; Shima et al., 1996; Hu and Ochi, 2001; Tamehiro
et al., 2003). Such mutations can be induced, for example, by
challenging the bacteria with rifampicin (mutations in rpoB) or
streptomycin (mutations in rpsL). After plating of the expression
strains S. coelicolor::DG2 and S. coelicolor::DG2-Kan on rifam-
picin-containing medium, spontaneous isolates resistant to the
antibiotic were obtained. Quantitative bottromycin production
analysis of clones from each ‘‘rifampicin mutagenesis’’ experi-
ment revealed mutant strains (S. coelicolor::DG2-rif and
S. coelicolor::DG2-Kan-rif) with a considerably higher production
titer (about ten times higher compared to the starting clones, see
Figure 2B). In parallel to this successful undirected approach, we
also considered targeted engineering strategies to improve bot-
tromycin production yields; because of the antibacterial activity
of bottromycin, we speculated that the self-resistance of the
host strain might be a limiting factor for the production titer.
Indeed we could show that the growth of S. coelicolor is already
heavily impaired at bottromycin concentrations of 2 mg/ml. In
light of this result, the putative efﬂux pump (BotT) encoded in
the bottromycin biosynthetic gene cluster represented a prom-
ising target for directed engineering approaches as we specu-
lated it to play a crucial role for self-resistance. To overexpress
the botT gene, its native promoter was replaced against the
strong PermE* promoter (Bibb et al., 1994) by insertion of a
spectinomycin resistance cassette via Red/ET recombineering
(see Figure 2A). S. coelicolor A3(2) wild-type was subsequently
transformed with the resulting construct DG2-kan-efﬂux-
ermE, and bottromycin production was quantiﬁed in com-
parison to S. coelicolor::DG2(-kan) and the corresponding ‘‘rif
mutants.’’ The HPLC-MS analysis revealed that, once more,
bottromycin production could be increased: the generated
S. coelicolor::DG2-kan-efﬂux-ermE expression host shows a
20 times higher production titer compared to S. coelicolor::
DG2(-kan) and an around two times higher production titer
compared to S. coelicolor::DG2(-kan)-rif. The generated data
on the successful enhancement of heterologous bottromycin
production for future experiments suggest combining both
strategies: the targeted approach (PermE* promoter insertion)
with the undirected approach (‘‘rifampicin mutagenesis’’). This
could potentially lead to a further increase of bottromycin
production yields.
Functional Studies on the Bottromycin Methylation
Pattern: A Suite of Hyperactive Methylases
A remarkable characteristic of the bottromycin scaffold is its
versatile methylation pattern, which can be attributed to a set
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of four putative MTs encoded in the bot gene cluster. Based on
the in silico analysis, it was quite obvious that BotOMT might
catalyze O-methylation of the aspartate residue, whereas the
action sites of the three radical SAMs (BotRMT1–BotRMT3)
could not be assigned (C-methylation at C-7, C-19, C-26, and/
or C-33, see Figure 1). The established heterologous expression
system provided an excellent opportunity to accomplish func-
tional studies on the four MTs by performing targeted gene dele-
tion experiments, followed by the heterologous expression of the
modiﬁed pathways to elucidate the resulting bottromycin meth-
ylation pattern. In order to achieve this goal, four orthogonal gene
deletions were performed on the expression construct DG2-kan-
efﬂux-ermE using the Red/ET recombineering technology
Figure 3. Engineering and Characterization
of theBottromycin ‘‘MethylationMachinery’’
(A) Modiﬁcation of the bottromycin biosynthetic
gene cluster. The four methyl transferase encod-
ing genes botRMT1, botRMT2, botRMT3, and
botOMT were deleted from the expression
construct DG2-kan-efﬂux-ermE in four orthogonal
Red/ET recombineering steps by insertion of
appropriate selection marker cassettes.
(B) Assigned fragment ions used for the com-
parison of the different bottromycin scaffolds
detected in (C)–(F). R1, R2, R3, and R4 = H or Me.
(C)–(F) High-resolution MS/MS fragmentation
analysis of bottromycin A2 reference substance
(C) and of bottromycin scaffolds detected in
extracts from the S. coelicolor A3(2) host strain
expressing modiﬁed versions of the bottromycin
biosynthetic gene cluster: botRMT3 deletion (D),
botRMT1 deletion (E), and botRMT2 deletion (F).
For the fragment spectrum from the botOMT
deletion experiment and a detailed comparison of
calculated and detected high-resolution masses
see Table S2 and Figure S1.
(Zhang et al., 1998, 2000). The respective
MT-encoding genes were replaced by an
antibiotic resistance gene (ampR, cmR, or
zeoR), and in case of botRMT1–botRMT3
the PermE* promoter was simultaneously
introduced in front of the downstream
genes to ensure proper transcription
(see Figure 3A). After S. coelicolor A3(2)
was transformed with the modiﬁed
constructs, the heterologous production
was studied by intensive HPLC-hrMS/
MS analysis on the culture extracts to
elucidate the methylation pattern of the
produced bottromycin derivatives. By
comparing the fragmentation pattern of
the detected bottromycin scaffolds, the
function of all four MTs could be unam-
biguously assigned (see Figure 3, Fig-
ure S1 [available online], and Table S2).
Three bottromycin derivatives can be
usually detected in extracts of the native
bottromycin producer, which differ in
the methylation pattern of the proline
residue: the monomethylated main product bottromycin A2 (1)
plus unmethylated (bottromycin B2 (2)) and bimethylated (bottro-
mycin C2) minor components (Nakamura et al., 1967). Deletion
of botRMT3 resulted in the (exclusive) production of a bottromy-
cin scaffold exhibiting a molecular mass as well as a fragmenta-
tion pattern identical to authentic bottromycin B2 (2) reference
substance. Consequently, we can draw the conclusion that
botRMT3 catalyzes radical C-methylation of the proline residue.
After deleting botRMT1, again a bottromycin derivative with
amolecular mass identical to bottromycin B2 could be detected,
but numerous differences in the fragmentation pattern are
obvious. The mass of all ‘‘phenylalanine-containing’’ fragments
(3a and 3e) is reduced by 14 Dalton (Da) in comparison to the
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corresponding fragments of bottromycin A2 and B2 (1a and 1e/
2e, 2a is also reduced by 14 Da as it contains the nonmethylated
proline residue). On the other hand, ‘‘non-phenylalanine-
containing’’ fragments (3b–3d) show the same mass as corre-
sponding fragments from bottromycin A2 (1b–1d), strongly
indicating that the three other relevant positions (proline and
two valine residues) are still methylated. Based on this, BotRMT1
was assigned to catalyze radical C-methylation of the phenylal-
anine residue. The deletion of the third radical SAM-encoding
gene (botRMT2) resulted in the production of a bottromycin scaf-
foldwith amolecular mass 28Da less than that of bottromycin A2
(1) and 14 Da less than that of bottromycin B2 (2), indicating the
presence of two unmethylated positions. The mass of fragment
4e veriﬁes the presence of the methyl group at the phenylalanine
residue, whereas fragments 4b–4d indicate the ‘‘loss’’ of methyl
groups at two valine sites. This suggests that BotRMT2 is
involved in radical C-methylation of two of the three valine resi-
dues and therefore acts twice during bottromycin biosynthesis.
A similar analysis was carried out for the botOMT deletion exper-
iment (not shown in Figure 3) and provided experimental
evidence for the assigned function: O-methylation of the aspar-
tate residue. The produced ‘‘free acid’’ bottromycin scaffold
cannot be detected in strains expressing the complete pathway,
and the same holds true for compounds 3 and 4 identiﬁed after
botRMT1 and botRMT2 deletion. Thus, in addition to the ﬁndings
on the functional role of the bottromycin MTs, these experiments
also led to the production of three, to our knowledge, novel
bottromycin derivatives. It will be very interesting to analyze
the bioactivity of the modiﬁed scaffolds, which is currently
impeded by the very low production yields that also prevented
us from characterizing all structures via NMR experiments. The
reason(s) for the heavily reduced production yields in the deletion
experiments currently remain elusive. Reduced conversion rates
of desmethyl precursors by subsequent biosynthetic enzymes or
breakdown of the immunity system in the deletion mutants are
two of numerous possible explanations. As no cross-comple-
mentation reactions could be observed in the mutants analyzed,
we conclude that the three radical SAMs act very speciﬁcally
when crafting the bottromycin scaffold.
SIGNIFICANCE
Bottromycins represent an intriguing family of natural
products exhibiting promising activity against methicillin-
resistant Staphylococcus aureus and vancomycin-resistant
Enterococci. As protein synthesis inhibitors, they are re-
garded as attractive lead compounds for the development
of novel antibiotics because bottromycins target the unique
aminoacyl-tRNA binding site of the 50S ribosomal subunit.
Here, we discovered the bottromycin biosynthetic pathway
from Streptomyces sp. BC16019, providing evidence that
the heavily modiﬁed peptide scaffold is of ribosomal origin.
Quite unusually, the bottromycin precursor peptide lacks an
N-terminal leader sequence,which is regarded as a common
structural feature of ribosomally made natural product
peptide precursors. Our data also highlight the bottromycin
biosynthetic pathway as an outstanding example for a
variety of posttranslational modiﬁcation reactions, which
in general are typical for ribosomal peptide biosyntheses.
Maturation of the bottromycin precursor peptide includes
macrocyclization via a unique amidine-forming ‘‘macrocy-
clodehydration,’’ a second cyclodehydration most likely
coupled to oxidative elimination building a thiazole ring,
proteolytic cleavage, and various unusual methylation reac-
tions. By use of synthetic biotechnology approaches, we
functionally elucidated the methylation steps involving the
action of an O-methyl transferase and three radical S-ad-
enosylmethionine (SAM)-dependent methyl transferases
required for alkylation of nonactivated carbons. The latter
enzyme class is currently not well characterized and thus
of special interest. These experiments also enabled the
production of three bottromycin derivatives based on a
heterologous expression system. Initial low yields were
addressed by application of targeted and undirected
approaches for production optimization. These resulted in
signiﬁcant increases of bottromycin production titers in
the heterologous host now providing an important basis
for advanced structure and yield improvements. In a broader
sense, the discovery and characterization of the ribosomal
bottromycin pathway revealed exciting insights into
the biosynthesis of ribosomally made peptides—a bio-
technologically hardly exploited class of natural products
of increasing importance for drug discovery.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Streptomyces sp. BC16019, originally obtained from a soil sample collected in
Germany (Lerchen et al., 2006), is maintained in the culture collection of
InterMed Discovery GmbH, Dortmund, Germany, under liquid nitrogen. For
the present study, it was revived and cultivated at 30C and 180 rpm in liquid
yeast and malt extract with glucose (YMG) medium (Stadler et al., 2007).
Streptomyces coelicolor A3(2) (Bentley et al., 2002) and Streptomyces albus
J1074 (Chater and Wilde, 1976) were grown at 30C and 180 rpm in liquid
Tryptone soya broth (TSB) medium (Kieser et al., 2000), and their mutants
were cultivated in liquid TSB medium containing 60 mg/ml apramycin at
30C and 180 rpm. S. sp. BC16019, S. coelicolor A3(2), and Streptomyces al-
bus J1074 were grown on solid MS agar plates (Kieser et al., 2000). In addition
toEscherichia coliHS996 (Invitrogen, Carlsbad, CA, USA) used as general host
for molecular biology experiments, E. coli GB05-red (Fu et al., 2012) was
employed in Red/ET recombineering experiments (Zhang et al., 2000), and
E. coli ET12567/pUZ8002 (Kieser et al., 2000) was used for conjugation
experiments. All E. coli strains were grown in Luria Broth (LB) medium at
37C. If necessary, the medium was supplemented with the following antibi-
otics for screening appropriate mutants: chloramphenicol 30 mg/ml, spectino-
mycin 100 mg/ml, ampicillin 100 mg/ml, zeocin 25 mg/ml, kanamycin sulfate
50 mg/ml, and apramycin 60 mg/ml.
Sequencing and In Silico Analysis of the Streptomyces sp. BC16019
Genome
Total genomic DNA of S. sp. BC16019 was isolated in accordance with the
Kirby mix procedure as described previously (Kieser et al., 2000) and
sequenced by applying the 454 technology (Rothberg and Leamon, 2008),
including 2 kb paired-end reads. The resulting sequence data (2,228 contigs
and 319 scaffolds) were subsequently screened for putative open reading
frames (orfs) encoding peptides that contain the amino acid sequence of the
bottromycin scaffold (GPVVVFDC). For this, the EMBOSS ‘‘getorf’’ tool was
applied to identify sequences of ORFs (deﬁned as region between two stop
codons), in accordance with the standard amino acid code. The output
sequence list of all possible, translated orfs was subsequently screened for
the GPVVVFDC-sequence using standard text editor software. A small orf
(later named botA) was identiﬁed, encoding this sequence plus some
C-terminal extension (see Figure 1).
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Sequence Analysis of the Bottromycin Biosynthetic Gene Cluster
Based on the data from the library screening (see Supplemental Experimental
Procedures), cosmid DG2 was chosen for further analysis, including whole
cosmid shotgun sequencing as described previously (Silakowski et al.,
1999). The obtained sequence of the 41 kb chromosomal fragment (insert
of cosmid DG2) was subsequently analyzed using bioinformatic tools. Predic-
tion of open reading frames was performed with FramePlot 4.0 (http://
nocardia.nih.go.jp/fp4/), and functional annotation was based on BlastP
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and Pfam (http://pfam.sanger.ac.uk/
search) searches. The Geneious 5.6.2 software packages (Biomatters, New
Zealand) was used for the analysis and annotation of DNA and protein
sequences. In addition to the putative 18 kb bottromycin biosynthetic gene
cluster (bot genes; see Figure 2 and Table 1) a number of ﬂanking orfs
(orf1– orf20; see Figure 2 and Table S1) were identiﬁed.
ACCESSION NUMBERS
The GenBank accession number for the bottromycin biosynthetic gene cluster
sequence fromStreptomyces sp. BC16019 reported in this paper is JX235926.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, one ﬁgure, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2012.08.013.
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Table S1, related to Table 1. Orfs encoded in the flanking regions of the proposed bot gene
cluster. 
Figure S1, related to Figure 3: Proposed chemical structures of detected fragments by high-
resolution MS-MS analysis. 
Table S2, related to Figure 3: Data for MS fragmentation analysis of bottromycin 
derivatives. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
SUPPLEMENTAL REFERENCES 
SUPPLEMENTAL DATA 
Table S1, related to Table 1. Orfs encoded in the flanking regions of the proposed bot gene cluster 
Protein Residues (aa) Annotation[a] 
Orf1 417 Putative sugar phosphotransferase system (PTS) IIC domain  
Orf2 250 Putative beta-lactamase B superfamily domain 
Orf3 174 Putative PemK-like protein 
Orf4 307 Putative CBS-like (Cystathionine beta-synthase (CBS) and Cysteine synthase) protein 
Orf5 92 Putative ThiS (thiaminS) family-like protein 
Orf6 368 Putative binding domain of LacI transcriptional regulator family 
Orf7 77 Putative sugar phosphotransferase system (PTS) IIB domain 
Orf8 245 Putative ribonuclease PH-like 3'-5' exoribonuclease 
Orf9 200 Putative deoxyribonucleotide triphosphate pyrophosphatase (HAM1-like protein) 
Orf10 268 Putative HNH endonuclease domain-containing protein 
Orf11 90 Hypothetical protein 
Orf12 181 Putative peroxiredoxin (PRX) family-like protein 
Orf13 113 Putative chaperonin 10kd subunit-like protein 
Orf14 807 Putative penicillin binding proteins (PBPs) 
Orf15 244 Putative ABC-2 family transporter 
Orf16 293 Putative ABC-2 family transporter 
Orf17 300 Putative ATP-binding domain of ABC family transporter 
Orf18 284 Hypothetical protein 
Orf19 503 Putative GDSL-link lipase/acylhydrolase  
Orf20 403 Hypothetical protein 
[a] Annotations was based on Protein Blast (Database: nonredundant protein sequences (nr)) and Pfam family search with E-value 1.0. 
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Figure S1, related to Figure 3. Proposed chemical structures of detected fragments by high-
resolution MS-MS analysis. 
Table S2, related to Figure 3. Data for MS fragmentation analysis of bottromycin derivatives. 
Substance ([M+H]+) Chemical fomular Calculated mass  (Da) 
Detected mass  
(Da) 
Bottromycin A2 (1) C42H63N8O7S+ 823.4496 823.4530 
Fragment 1a C35H53N6O5+ 637.4072 637.3992 
Fragment 1b C25H44N5O5+ 494.3337 494.3324 
Fragment 1c C25H42N5O4+ 476.3231 476.3201 
Fragment 1d C19H31N4O3+ 363.2391 363.2363 
Fragment 1e C16H17N3O2S 315.1041 315.0995 
Bottromycin B2 (2) C41H61N8O7S+ 809.4339 809.4385 
Fragment 2a C34H51N6O5+ 623.3915 623.3940 
Fragment 2b C24H42N5O5+ 480.3180 480.3136 
Fragment 2c C24H40N5O4+ 462.3075 462.3257 
Fragment 2d C18H29N4O3+ 349.2234 349.2240 
Fragment 2e C16H17N3O2S 315.1041 315.0995 
Bottromycin D2 (3) C41H61N8O7S+ 809.4339 809.4372 
Fragment 3a C34H51N6O5+ 623.3915 623.4012 
Fragment 3b C25H44N5O5+ 494.3337 494.3389 
Fragment 3c C25H42N5O4+ 476.3231 476.3201 
Fragment 3d C19H31N4O3+ 363.2391 363.2341 
Fragment 3e C15H15N3O2S 301.0885 301.0815 
Bottromycin E2 (4) C40H59N8O7S+ 795.4183 795.4121 
Fragment 4a C33H49N6O5+ 609.3759 609.3735 
Fragment 4b C23H40N5O5+ 466.3024 466.3051 
Fragment 4c C23H38N5O4+ 448.2918 448.3001 
Fragment 4d C18H29N4O3+ 349.2234 349.2363 
Fragment 4e C16H17N3O2S 315.1041 315.0995 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Construction and screening of a Streptomyces sp. BC16019 cosmid library 
For the construction of a 35-45 kb fragment library, 100 μg of the chromosomal DNA from S. sp.
BC16019 was partially digested with Sau3AI in 1 ml final volume. 150 l aliquots taken at 
various time points from the digestion were analyzed by electrophoresis using a 0.4% (w/v) 
agarose gel. After dephosphorylation with SAP, 2.5 g of the DNA was ligated with 1.0 g of the 
pOJ436 cosmid vector hydrolyzed with PvuII/SAP and BamHI. Packaging of the resulting 
ligation mixture was performed with the Gigapack® III gold packaging kit (Stratagene) and the 
extract was subsequently transformed into E. coli HS966 cells. After incubation in LB medium at 
37 °C for 60 min, aliquots were plated out on LB agar amended with apramycin 60 g/ml. A 
cosmid library consisting of 2304 clones was generated and automatically transferred twice onto 
a 22.2 x 22.2 cm nylon membrane (Biodyne B, Pall) with a Qbot robot (Genetix) as described 
previously (Dunham, 1997). 
For the identification of a cosmid carrying the putative bottromycin biosynthetic gene cluster 
including the putative precursor peptide gene (botA), which was identified in the genome 
sequence data (see above), a suitable probe was designed based on the available genome 
sequence information. The ~ 0.5 kb fragment was amplified from S. sp. BC16019 chromosomal 
DNA using the primers contig572-bot-for and contig572-bot-rev (see Table below). After DIG-
labelling (DIG DNA labeling and detection kit, Roche, Germany) and purification of the probe, 
overnight hybridization experiments were carried out at 42 °C, followed by stringent washing at 
68 °C and developing of the membrane using the anti-DIG polyclonal antibody and detection kit 
according to the manufacturer’s recommendations (Roche, Germany). Hybridizing cosmids were 
isolated, pre-analyzed by BamHI digestion in order to verify their size and to identify putative 
duplicates and then subjected to end-sequencing using the primers pOJ436-T3 and pOJ436-T7 
(see Table below).  
Inactivation of botOMT in Streptomyces sp. BC16019 
Inactivation of botOMT gene in S. sp. BC16019 was accomplished by homologous recombination 
in the encoding region. Primers botK-KO-up and botK-KO-dn (see Table below) were used to 
amplify a 0.6 kb fragment homologous to an internal region of the target gene botOMT. The 
amplified DNA fragment was cloned into the suicide vector pKC1132 (Kieser et al., 2000) to 
generate the inactivation construct pKC1132-botOMT-KO. The botOMT inactivation mutant 
S. sp. BC16019::pKC1132-botOMT-KO was obtained by conjugation as follows: pKC1132-
botOMT-KO was electroporated into E. coli ET12567/pUZ8002. Transformants were selected on 
LB agar plates supplemented with apramycin (60 μg/ml). Spores of S. sp. BC16019 were 
prepared from 7 day-old MS agar plates according to published procedures (Kieser et al., 2000). 
Conjugation was performed between the E. coli ET12567/pUZ8002/pKC1132-botOMT-KO and 
spores of the S. sp. BC16019. Conjugants were selected after incubation for 7 days on MS agar 
plates supplemented with 25 μg/ml nalidixic acid and 60 μg/ml apramycin. Chromosomal DNA 
of selected conjugants was isolated according to the Kirby mix procedure (Kieser et al., 2000). 
To confirm integration of the plasmid into the chromosome, three different PCR reactions were 
conducted with oligonucleotides botK-KO-out-r, botK-KO-out-l, botK-KO-in-r and botK-KO-in-
l. Using primer pair botK-KO-out-r and botK-KO-out-l, a 0.9 kb fragment could be generated for 
S. sp. BC16019 wild type strain and no PCR product could be obtained for correct 
S. sp. BC16019::pKC1132-botOMT-KO mutant. Using primer pair botK-KO-out-l and botK-
KO-in-l, a 0.63 kb fragment could be generated for correct S. sp. BC16019::pKC1132-botOMT-
KO mutant and no product for wild type strain. Using primers botK-KO-out-r and botK-KO-in-r 
a 0.65 kb fragment could be generated for correct S. sp. BC16019::pKC1132-botOMT-KO 
mutant and no product for wild type strain. 
 
Modification of cosmid DG2 by Red/ET Recombination 
In all Red/ET recombination experiments linear DNA fragments (‘modification cassettes’) 
flanked by suitable homology arms were generated by PCR. The PCR reactions were carried out 
with Go-Taq® Flexi DNA polymerase (Promega, Germany) according to the manufacturer’s 
protocol. PCR products were concentrated and purified by ethanol precipitation prior to further 
use. In general, E .coli GB05-red cells harboring the parent vector to be modified were inoculated 
from an overnight culture (1:40 dilution), and cultivated on a thermomixer (Eppendorf) at 37 °C 
and 1000 rpm. When the OD600 value reached 0.2, 0.1% L-arabinose was added to the culture to 
induce expression of the recombinases. Cultivation was then continued until the OD600 reached 
0.4. The cells were then harvested by centrifugation, washed twice with ice-cold destilled H2O 
(dH2O), and resuspended in 40 l dH2O. PCR product (0.2-0.3 g) was mixed with the electro-
competent cells and transferred into an ice-cold electroporation cuvette (1 mm). The mixture was 
then electroporated at 1300 V (Eppendorf electroporator), followed by addition of 1 ml LB. The 
cells were next cultivated at 37 °C and 1000 rpm for 75 min, before the culture was concentrated 
and transferred to LB agar plates containing suitable antibiotics. The plates were incubated at 
37 °C overnight. Correct transformants were verified by restriction analysis and/or sequencing of 
the isolated cosmid DNA.  
Construction of DG2-kan: A kanamycin cassette was amplified from pRK-Pirate-km using the 
primers DG2-short-up and DG2-short-down (see Table below) containing 50 bp homologous 
sequences to the downstream region of botT and the T7 terminus of cosmid DG2. After Red/ET 
recombination, colonies were selected on LB agar supplemented with 60 g/ml apramycin and 
50 g/ml kanamycin at 37 °C. Replacement of the ~16 kb upstream region by integration of the 
kanamycin cassette into cosmid DG2 resulted in construct DG2-kan, which was verified by 
restriction analysis.  
Construction of DG2-kan-efflux-ermE: A spectinomycin cassette was amplified from pRK-spect 
(Gene Bridges, Germany) using the primers DG2-efflux-ermE-up and DG2-efflux-ermE-dn (see 
Table below) containing 50 bp homologous sequences to the 5’ region of botT (including the
ATG start codon) and to the 5’-upstream region of botT. In addition the PermE* promotor 
sequence (Bibb et al., 1994) was integrated into the primer DG2-efflux-ermE-up. Transformation 
of the PCR product into E. coli GB05-red cells carrying cosmid DG2-kan resulted in 
apramycin/spectinomycin resistant colonies. Subsequent restriction analysis of the isolated 
cosmid DNA showed the correct integration of the spectinomycin PermE* cassette upstream of 
botT to replace the native promoter structure. The sequence of the inserted PermE* promotor as 
well as the homology region in the 5’ part of botT was verified by sequencing using primers 
efflux-up and efflux-dn (see Table below).  
Construction of DG2-kan-botRMT1, DG2-kan-botRMT2, DG2-kan-botRMT3 and DG2-kan-
botOMT: To delete the four methyl transferase encoding genes botRMT1, botRMT2, botRMT3 
and botOMT, respectively, from the expression construct DG2-kan, different selection marker 
cassettes were introduced via Red/ET recombineering (see Figure 3 and Figure S1). For the 
deletion of botRMT1, the ampicillin resistance cassette was amplified from pJET1.2 (Fermentas) 
using the primer pair botA-KO-up and botA-KO-dn (see Table below) containing homology arms 
to the upstream and downstream region of botRMT1 as well as the PermE* promotor to assure 
transcription of downstream gene(s). Recombinant clones were selected on LB-agar containing 
ampicillin 100 g/ml and apramycin 60 g/ml. For the deletion of botRMT2, the chloramphenicol 
resistance cassette was amplified from pBACe3.6 (Frengen et al., 1999) using the primer pair 
botE-KO-up and botE-KO-dn (see Table below) containing homology arms to the upstream and 
downstream region of botRMT2 as well as the PermE* promotor to assure transcription of 
downstream gene(s). Recombinant clones were selected on LB-agar containing chloramphenicol 
25 g/ml and apramycin 60 g/ml. For the deletion of botRMT3, the zeocin resistance cassette 
was amplified from pKen35 (Wenzel et al., unpublished) using the primer pair botI-KO-up and 
botI-KO-dn (see Table below) containing homology arms to the upstream and downstream region 
of botRMT3 as well as the PermE* promotor to assure transcription of downstream gene(s). 
Recombinant clones were selected on LB-agar containing zeocin 25 g/ml and apramycin 60 
g/ml. For the deletion of botOMT, the ampicillin resistance cassette was amplified from 
pJET1.2 (Fermentas) using the primer pair botK-KO-up and botK-KO-dn (see Table below) 
containing homology arms to the upstream and downstream region of botOMT. Recombinant 
clones were selected on LB-agar containing ampicillin 100 g/ml and apramycin 60 g/ml. The 
resulting modified expression constructs, DG2-kan-botRMT1, DG2-kan-botRMT2, DG2-kan-
botRMT3 and DG2-kan-botOMT, were verified by detailed restriction analysis as well as 
sequencing using the primer pair botA-up/botA-dn for DG2-kan-botRMT1, botE-up/botE-dn for 
DG2-kan-botRMT2, botI-up/botI-dn for DG2-kan-botRMT3 and botK-up/botK-dn for DG2-kan-
botOMT (see Table below). 
Transformation of the expression constructs into heterologous host strains 
The original cosmid DG2 as well as DG2-kan, DG2-kan-botRMT1, DG2-kan-botRMT2, DG2-
kan-botRMT3 and DG2-kan-botOMT were transformed into standard Streptomyces host strains 
by bi-parental conjugation as described above. Exconjugants were selected on MS agar plates 
supplemented with 25 μg/ml nalidixic acid and 60 μg/ml apramycin. Chromosomal DNA of the 
generated mutant strains (S. coelicolor::DG2, S. albus::DG2, S. coelicolor::DG2-kan,
S. coelicolor::DG2-kan-botRMT1, S. coelicolor::DG2-kan-botRMT2, S. coelicolor::DG2-kan-
botRMT3 and S. coelicolor::DG2-kan-botOMT) was isolated as described above. The correctness 
of integration of the expression constructs into the C31 phage attachment site was verified by 
PCR analysis using primers attB-l, attB-r, attp-up and attp-dn (see Table below). Using primer 
pair attB-l and attB-r, a 0.47 kb fragment could be generated for S. coelicolor A3(2) wild type 
strain and S. albus J1047 wild type strain. No PCR product could be obtained for corresponding 
correct mutants. Using primer pair attB-l and attp-dn, a 0.6 kb fragment could be generated for 
corresponding correct mutants and no product for wild type strain. Using primers attB-r and attp-
up a 0.46 kb fragment could be generated for correct mutants and no product was found for the 
wild type strain. For heterologous bottromycin production, the generated mutants were grown in 
liquid TSB medium containing 60 μg/ml apramycin at 30 °C and 180 rpm for 3 days. Production 
analysis was carried out by HPLC-MS as described below. 
Induction of rifampicin resistance mutations in S. coelicolor::DG2 and S. coelicolor::DG2-
kan 
Spore suspensions from S. coelicolor::DG2 and S. coelicolor::DG2-kan (10, 20, 30, 40, and 50 μl 
from stocks having a concentration of 108 spores/ml) were plated out onto MS agar plates 
supplemented with 10, 50 and 100 μg/ml rifampicin. After incubation at 30 °C for 5 days several 
colonies appeared predominantly on plates with the lowest rifampicin concentration. From each 
expression system (S. coelicolor::DG2 and S. coelicolor::DG2-kan) 30 colonies were then 
screened for enhanced bottromycin production in comparison to the starting clones. Cultivations 
were carried out in 24-well tissue culture plates (Sarstedt 24 Well Tissue Culture Plate, Flat 
Bottom, Polystyrene, Sterile With Lid) containing 1.5 ml TSB medium per well amended with 60 
g/ml apramycin and 10 μg/ml rifampicin. During cultivation for 7 days at 50 rpm sterilized 
distilled water was added to the wells to compensate evaporation. After threefold extraction of 
the culture supernatant with equal amounts of ethylacetate, the organic phase was evaporated and 
the extracts were redissolved in 50 l methanol. Quantitative bottromycin production analysis 
was carried out as described below (injection volume was 5 l). From the 30 colonies analyzed 
from each mutagenesis experiment two to three mutants with around 20-fold higher bottromycin 
production yields were obtained, named as S. coelicolor::DG2-rif and S. coelicolor::DG2-kan-
rif). 
 
Analysis of bottromycin production and novel derivatives thereof 
For bottromycin production analysis, the cultures were harvested by centrifugation and 25 ml of 
the supernatant was extracted with an equal volume of ethyl acetate three times. The organic 
phase extract was evaporated and re-dissolved in methanol for HPLC-MS analysis. Standard 
analysis of crude extracts was performed on an HPLC-DAD system from the Agilent 1100 series, 
coupled to a Bruker Daltonics HCTultra ESI-MS ion trap instrument operating in positive 
ionization mode. Compounds were separated on a Luna RP-C18 column (125 × 2 mm; 2.5 m 
particle diameter; flow rate 0.4 ml/min, Phenomenex), with a mobile phase of water/acetonitrile 
each containing 0.1% formic acid, using a gradient from 5% - 95% acetonitrile over 20 min. 
Detection was by both, diode array and ESI-MS. High-resolution mass spectrometry was 
performed on an Accela UPLC-system (Thermo-Fisher) coupled to a linear trap-FT-Orbitrap 
combination (LTQ-Orbitrap), operating in positive ionization mode. Separation was achieved 
using a BEH RP-C18 column (50 × 2 mm; 1.7 m particle diameter; flow rate 0.6 ml/min, 
Waters), with a mobile phase of water/acetonitrile each containing 0.1% formic acid over 9 min. 
The UPLC-system was coupled to the LTQ-Orbitrap by a Triversa Nanomate (Advion), a chip-
based nano-ESI interface. The yield of bottromycin A2 was determined from the peak area 
(extracted ion chromatogram at m/z [M+H]+ = 823.4528) by reference to a standard curve 
generated with pure bottromycin A2. Determination of bottromycin B2 and other novel 
bottromycin derivatives bottromycin D2 and E2 produced by respective mutants were achieved 
via extracted ion chromatogram at m/z [M+H]+ = 809.4385 (for bottromycin B2 and E2), at 
[M+H]+ = 795.4208 (for bottromycin D2). For quantitative measurement of bottromycin A2 
production, a standard curve was established by preparing a concentration gradient (from 0.2 
mg/ml to 0.2 ng/ml in a dilution factor 1:10) of pure bottromycin A2 as reference substance. To 
determine the peak area, extracted ion chromatogram at m/z [M+H]+ = 637.3992, m/z [M+H]+ = 
476.3201 and m/z [M+H]+ = 315.0995 were selected to be observed.  
Table. Oligonucleotides used in this study (related to Supplemental Experimental Procedures) 
Primers Sequence (5’-3’) 
botK-KO-up GATATCACGCCCGCTGACGCTCGACGCCCGCT (underlined: introduced stop codon) 
botK-KO-dn AAGCTTCCAGTTCGCGTGGGTCGTTCA 
botK-KO-out-l GCTCCCGGTCGGTCGGAGGCTCC 
botK-KO-out-r TGTGCGCCAGAGAGGCGAGAA 
botK-KO-in-l TTCACACAGGAAACAGCTATGA 
botK-KO-in-r AGGGTTTTCCCAGTCACGACGTTG 
contig572-bot-for CCCCAACTACGACGG TTTC 
contig572-bot-rev ACCCGG TGAGGATGTTCCAG 
pOJ436-T3 TTAATTGGGAGTGATTTCC 
pOJ436-T7 CATCACCGGCGCCACAGGTG 
DG2-short-up GATCCCCCATCCCGGGCCAGGGCTCGGAAACAGCGGATACCCCGACGGCCGCTGCTCTAGTACACCTGAATAACT 
DG2-short-dn GATCACCAGGCCCAGCACCACACCGAGGGCGAAGGTCAGCCGCCAGCCGAGTCGTTGCTGTATCTCCAGATAACT 
DG2-efflux-ermE-up 
GTGTTGCCCAGCAGGGACAGGCCGTGGGAGATGAGGTAGAGCGGCAGCATTT
CCGCTCCCTTCTCTGACGCCGCTGGATCCTACCAACCGGCACGATTGTGCCCAC
AACAGCATCTCGATTTTCGTTCGTGAATACATG, (underlined: PermE* promoter 
sequence) 
DG2-efflux-ermE-dn ACGCCGGTCAACCATCCGACGGGCCATCGGCCCACGACCAGAATGCCCCGTTATAATTTTTTTAATCTGTTATTTA 
efflux-up ACGACGGGGAGTGCGGCGACGCAGG 
efflux-dn CCTCGGCCGCCGAGGGAGTTCGGAG 
botA-KO-up GTGCCTGCCGCCAAAAACGTTTCTCTTGTATCAATGCCTTGGAACTGAGACGAAAGGGCCTCGTGATACGCCT 
botA-KO-dn 
TGAGGAAATCCGCGGTCATGCAGTCGAATACGACTACGGGTCCCATTTCCGCT
CCCTTCTCTGACGCCGCTGGATCCTACCAACCGGCACGATTGTGCCCACAACA
GCATCGGTCTGACAGTTACCAATGC 
BotE-KO-up AGCTCGCGCTCGTGGCACCACCCTGGAACAGCCTGTACCGCCCGTGATACCTGTGACGGAAGATCAC 
BotE-KO-dn 
ACACCTCGAAGACGTCCCTACGGCTCGTGCCGTTACCGTCCCGCACTTCCGCTC
CCTTCTCTGACGCCGCTGGATCCTACCAACCGGCACGATTGTGCCCACAACAG
CATCGGGCACCAATAACTGCCTTA 
BotI-KO-up ATGACCGGAACGACCGAGAGGACCGAGGCGACCGGCCCGGCCGATTGAGGATCTGATCAGCACGTGTT 
BotI-KO-dn 
CAGGTCCTCGGCGCGGGTCTGGTCCTCGGTGGGGGCCGTGGTCATTTCCGCTCC
CTTCTCTGACGCCGCTGGATCCTACCAACCGGCACGATTGTGCCCACAACAGC
ATCTCAGTCCTGCTCCTCGGCCA 
BotK-KO2-up CCCGGTCGGTCGGAGGCTCCCGGTCGGTCGGAGGCTCCGGCGGGAGGTCTGACAGTTACCAATGC 
BotK-KO2-dn GTGAAGATTTCCCTGACCGGCGCGGCGGAGACCCTGCTCGCACCCTGAGACGAAAGGGCCTCGTGATACGCCT 
botA-up TGAATGAAGCCATACCAA 
botA-dn GAAATGTTGAATACTCATA 
botE-up GCAAATATTATACGCAAGGC 
botE-dn TAATATCCAGCTGAACGGT 
botI-up GGACAACACCCTGGCCTG 
botI-dn GTCGTCCTCCACGAAGTC 
botK-up GAAATGTTGAATACTCATA 
botK-dn TGAATGAAGCCATACCAA 
attB_l CAGGTTCACCCACAGCTG 
attB_r CTCAACTAAAGTGGGGCG 
attp_up AGAGATACAGGGTCATGGAA 
attp_dn AAATGCCCGACGAACCTGAA 
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1. General scope of this work 
The present thesis deals with the identification, elucidation and engineering of biosynthetic pathways 
of the natural products cinnabaramides from Streptomyces sp. JS360 and bottromycins from 
Streptomyces sp. BC16019. Synthetic biotechnology tools were employed to generate their novel 
natural product derivatives. Moreover, detailed biochemical and structural characterizations were 
performed on one key enzyme responsible for the formation of an unusual polyketide extender unit 
incorporated in the cinnabaramide biosynthetic assembly line which contributed to a better 
mechanistic understanding of this family of enzymes and revealed how the primary metabolic 
enzymes evolved to produce dicarboxylic acids incorporated in secondary metabolic pathways. 
Investigation of active site mutations were conducted to set the stage for generation of deliberately 
altered polyketides with improved bioactivity and bioavailability for clinical application. 
 
2. Cinnabaramides biosynthesis in Streptomyces sp. JS360 
Cinnabaramides are a class of compounds isolated from a terrestrial Actinomycete Streptomyces sp. 
JS360 and are a potent and selective inhibitor of the human 20S proteasome. The strain is known to 
produce cinnabaramides A-G, each containing a characteristic γ-lactam-β-lactone bicyclic ring 
structure attached to a cyclohexenyl unit together with a hexyl side chain (Figure A9 and C1b).
[123]
 
Significant structural similarities were observed between cinnabaramides and salinosporamides, a 
family of type I PKS/NRPS hybrid antitumor metabolites produced by a marine Actinomycete 
Salinispora tropica CNB-440.
[140-142]
 Structures of cinnabaramides and salinosporamides only differ by 
the polyketide side chains, salinosporamides incorporate a chloroethylmalonyl-CoA into the 
biosynthetic pathway resulting in a chloroethyl side chain
[143;144]
 while we demonstrate in this work 
that cinnabaramides incorporate a hexylmalonyl-CoA leading to a hexyl side chain (Figure 
C1b).
[124;145]
 During the present thesis, the cinnabaramides biosynthetic pathway from Streptomyces sp. 
JS360 was elucidated, cloned and sequenced. The uncovered type I PKS/NRPS hybrid assembly line 
exhibited several unique features in utilization of unusual building blocks and their flexibility on 
substrate recognition.  
 
2.1 Cinnabaramides biosynthesis is directed by a hybrid type I PKS/NRPS incorporating 
unusual building blocks 
 
Based on the known hybrid PKS/NRPS machinery for salinosporamides
[143]
 and the high structural 
similarity to cinnabaramides, the biosynthetic origin for cinnabaramides was predicted to follow a 
PKS/NRPS hybrid architecture (Figure C1a). According to the co-linearity between the required 
biosynthetic steps and the complement of the existing modules, we presumed that the cinnabaramide 
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biosynthetic pathway is initiated by selection and loading of acetyl-CoA by the first AT domain CinA-
AT1. This hypothesis is supported by the in silico prediction of substrate specificity of the CinA-AT1 
domain and by the comparison to the salinosporamide SalA-ATL domain which was also proven to be 
specific for acetyl-CoA via stable isotope feeding experiments.
[146]
 cinA encodes a bi-modular PKS 
(Figure C1b) which shows uncommon domain organization harboring contiguous AT domains 
responsible for loading and extension distinctly different from the standard prototypic PKS 
organization of AT1-ACP-KS-AT2-ACP2. Interestingly, this noncanonical type of architecture 
consisting of an intermixed loading and first extension module is found in several myxobacterial 
systems, such as those involved in stigmatellin, soraphen and aurafuranone biosyntheses.
[48;147;148]
 The 
substrate specificity analysis of the CinA-AT2 domain revealed a distinct difference from its 
counterpart in the salinosporamide gene cluster SalA-AT1 which is specific for an unusual PKS 
extender unit chloroethylmalonyl-CoA.
[142;146]
 Based on this analysis and the structures of 
cinnabaramide harboring a hexyl side chain, we inferred that the second PKS module catalyzes the 
chain elongation of the acetyl-S-ACP intermediates with the unusual extender unit hexylmalonyl-S-
ACP resulting in the incorporation of the hexyl side chain. Similar example was reported in 
biosynthesis of thuggacins from myxobacterium Sorangium cellulosum So ce895, a family of 
macrolide antibiotics bearing hexyl side chains.
[35]
 However, CinA-AT2 also strongly differs 
(similarity ˂20% on the protein level) from the hexylmalonyl-CoA specific TugC-AT3 involved in the 
biosynthesis of thuggacins.
[35;149]
 This fact prompted us to verify this hypothesis by closer examination 
into the biosynthetic mechanism of the unusual PKS extender unit hexylmalonyl-CoA.  
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Figure C1. A) Schematics of the cin locus from Streptomyces sp. JS360 and the sal locus from Salinospora 
tropica CNB-440. Similar genes are involved in both salinosporamide and cinnabaramide biosyntheses: genes 
involved in construction of the core γ-lactam-ß-lactone bicyclic ring (in dark gray), genes involved in assembly 
of the non proteinogenic amino acid ß-hydroxyl-cyclohex-2’-enylalanine (in blue), and genes involved in 
regulation and resistance (in light gray). Specific genes existing only in cinnabaramide biosynthesis: genes 
involved in the hexylmalonyl-CoA pathway (in red) and genes involved in hydroxylation of C12 in 
cinnabaramide B and D (in purple). Specific genes existing only in salinosporamide biosynthesis: partial 
transposases (in black) and genes involved in the chloroethylmalonyl-CoA pathway (in green). Unknown 
functional genes involved in biosynthesis of cinnabaramides and salinosporamides (blank). B) Proposed 
PKS/NRPS cinnabaramide biosynthetic assembly line. 
 
Based on previous observations in other natural product pathways involving unusual PKS extender 
units, e.g., as mentioned above, in the biosynthetic gene cluster of thuggacins, the unusual extender 
unit hexylmalonyl-CoA is thought to be generated from 2-octenoyl-CoA converted by a crotonyl-CoA 
carboxylase/reductase (CCR) analogue TgaD
[35]
, and later on, predominantly triggered by the work 
relating to the ethylmalonyl-CoA pathway in Rhodobacter sphaeroides in 2009
[150]
, whereas a purified 
CCR enzyme was in vitro characterized to catalyze the reductive carboxylation of (E)-crotonyl-CoA 
resulting in the production of ethylmalonyl-CoA, we predicted that the hexyl chain of cinnabaramides 
might originate from 2-octenoyl-CoA via a similar reductive carboxylation. Similar biochemical steps 
have also been described in production of PKS extender units such as ethylmalonyl-CoA and 
chloroethylmalonyl-CoA in the salinosporamide pathway.
[151]
 Indeed, within the cin gene cluster, we 
found a potential gene, cinF, encoding a protein showing 90% sequence identity on the protein level to 
a putative CCR from Streptomyces hygroscopicus (Accession No. AAR32675). Thus, CinF was 
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thought to be the key enzyme for formation of the unusual extender unit hexylmalonyl-CoA in 
cinnabaramide pathway (Figure C2). However, the sequence similarity between CinF and TgaD is 
unexpectedly low (16% identity on the protein level) despite their assumed identical functionality.
[145]
 
First of all, the disruption of cinF led to a complete abolishment of cinnabaramide production 
indicating that CinF is indispensable for the biosynthesis of cinnabaramides (L. Huo and R. Müller, 
unpublished data). We thus hypothesized that CinF catalyzes the reductive carboxylation of 2-
octenoyl-CoA or -ACP, leading to hexylmalonyl-CoA or -ACP, respectively (Figure C2). This 
hypothesis has been verified by further investigation of CinF biochemically and structurally. These 
results have identified CinF as a hexylmalonyl-CoA synthase responsible for catalyzing the conversion 
of 2-octenoyl-CoA to hexylmalonyl-CoA in the presence of hydrogen carbonate and reduced 
nicotinamide adenine dinucleotide phosphate (NADPH).
[145]
 Moreover, further mutagenetic studies on 
the active site of CinF was also performed
[145]
 and is discussed below in Discussion 2.2 Biosynthetic 
mechanism of the hexylmalonyl-CoA pathway. In addition, a putative acyl-CoA dehydrogenase 
encoding gene, cinI, is presumably involved in generation of 2-octenoyl-CoA from octanoic acid that 
could originate from primary fatty acid degradation and/or synthesis (Figure C2).  
 
Figure C2. Proposed biosynthetic pathway of production of the hexyl side chain and its incorporation into 
cinnabaramides biosynthesis. 
 
After we identified that the hexylmalonyl-CoA is the native extender unit recognized by CinA AT2 
domain, it was subsequently demonstrated CinA AT2 has relaxed substrate specificities towards 
various chlorinated 2-octenoic acids.
[124]
 This is inspiring for us to use synthetic biotechnological tools 
to generate more polyketide-chain altered cinnabaramide derivatives of novel structures and/or 
AT2 ACP C
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improved bioactivities. Detailed discussion is in Discussion 2.3 Creation of molecular diversity 
based on the cinnabaramide scaffold via synthetic biotechnology. 
Subsequently, CinB and the C-terminal domain of CinA form the NRPS module of the assembly line, 
which is supposed to be responsible for incorporating the non-proteinogenic amino acid 2’-
cyclohexenyl-alanine (Figure C1). The deduced substrate specificity code of the CinB-A domain is 
significantly similar to the SalB-A domain which has been proven to be specific for selection and 
activation of the exactly same substrate.
[140;152]
 We thus proposed that the elongation of the 
cinnabaramide intermediate proceeds with extension of the same amino acid residue. Indeed, this 
hypothesis was supported by the feeding of the synthesized (2S,4R)-β-cyclohexenylalanine and the 
diastereomeric (2S,4S)-cyclohexenylalanine to the growth culture of S. sp. JS360 resulting in the 
production of deuterated cinnabaramides. The work of Moore’s group has proposed that in the sal 
locus a set of enzymes including 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase 
(SalU), prephenate dehydratase (SalX) and L-amino acid amino transferase (SalW) are involved in the 
non proteinogenic amino acid formation. This pathway employs phosphoenolpyruvate and D-
erythrose-4-phosphate as starting points, followed by a branch of the phenylalanine pathway leading to 
the formation of dihydroprephenate. After decarboxylative dehydration to yield 2,3-
dihydrophenylpyruvate that undergoes a 1,3-reduction and transamination, the 3-R-cyclohex-2-enyl-L-
alanine is finally formed.
[120;143]
 Recently, another similar pathway has been reported in Bacillus 
subtilis in the biosynthetic pathway of tetrahydrotyrosine as part of anticapsin biosynthesis.
[153]
 
Expectedly, almost all of the corresponding counterparts of these involved enzyme encoding genes 
could also be found in the cin locus which is another supportive evidence for the hypothesis that 2’-
cyclohexenyl-alanine is the native building block for the cinnabaramide NRPS pathway. Thus, a 
biosynthetic pathway of 2’-cyclohexenyl-alanine could also be postulated for cinnabaramide 
biosynthesis (Figure C3). It is noteworthy to state that since SalB-A domain exhibited relaxed 
substrate specificities towards a number of aliphatic amino acids
[120]
 and the substrate specificity code 
of CinB-A domain is highly similar to SalB-A domain, we determined that the CinB-A domain is also 
tolerant to other proteinogenic or non-proteinogenic acids. This encouraged us to use synthetic 
biotechnological tools to generate more amino acids-altered cinnabaramide derivatives of novel 
structures and/or improved bioactivities. Detailed discussion is below in Discussion 2.3 Creation of 
molecular diversity based on the cinnabaramide scaffold via synthetic biotechnology.  
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Figure C3. Proposed biosynthetic pathway of non proteinogenic amino acid building block 2’-
cyclohexenyl-alanine for cinnabaramides biosynthesis. Scheme modified according to the reference.
[154] 
 
After the NRPS module incorporates 2’-cyclohexenyl-alanine into the assembly line, the resultant 
PCP-tethered intermediate undergoes an intramolecular condensation presumably promoted by the 
ketosynthase (CinC) to generate the γ-lactam ring, which leads the CinB-bound substrate to give rise 
to the offloaded β-lactone (Figure C1). CinE, which shows a high similarity to SalF, is a putative type 
II thioesterase, catalyzes the release and cyclization of the intermediate to generate the β-lactone ring 
structure, and it is thought to be also responsible for removing mis-primed precursor molecules from 
PKS/NRPS modules.
[143]
  
To sum up from above, cinnabaramides biosynthetic gene cluster possesses a PKS/NRPS hybrid 
structure which employs unusual building blocks incorporated into the pathway. The analysis of such 
hybrid systems is of special interest for combinatorial biosynthesis because the combination of PKS 
and NRPS can lead to an immense variety of novel structures.
[155;156]
 Thus, future combinatorial 
biosynthesis work on cinnabaramide biosynthetic pathway could be planned to generated further 
derivatives of interesting chemical structures and/or bioactivities. Besides, the feature that both PKS 
and NRPS pathways exhibited relaxed substrate specificities could allow us to generate novel 
cinnabaramides derivatives via synthetic biotechnological tools, such as precursor-directed 
biosynthesis and/or mutasynthesis. The possible challenging obstacle would be the limited flexibility 
of substrate specificity of the megasynthetases, especially of the ‘gate keeper’ AT domain and A 
A PCP
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domain. Thus, further pathway engineering on CinA-AT2 domain and CinB-A domain to alter their 
substrate specificity towards desired scaffolds could be the plan to unblock the obstacle. A number of 
successful examples have been reported using rational manipulations domains/modules to alter the 
selection of building blocks by site-directed mutagenesis, domain/module exchange, module insertion, 
fusion or deletion.
[157-167]
 Despite the reduced catalytic efficiency usually observed after the pathway 
engineering, this strategy is definitely worth trying in the future work. 
Additionally, two putative cytochrome P450 enzyme encoding genes are found nearby, cinD inside the 
gene cluster and cinL outside of the gene cluster (Figure C1). We suggested that they are both 
involved in post-assembly line hydroxylation enabling the production of various cinnabaramide 
derivatives (cinnabaramides A, B, D, E). Compared to the salinosporamide gene cluster, no 
counterpart of cinL could be found suggesting that CinL possibly plays a role in hydroxylation of 
cinnabaramides B and D at C12 because no natural salinosporamide analogues are hydroxylated at the 
corresponding carbon positions.
[143]
 The generated cinL-deficient mutant was unable to produce 
cinnabaramide D but yielded distinctly more cinnabaramide E thereby strongly supporting this 
speculation (L. Huo and R. Müller, unpublished data). Accordingly, CinD is exclusively supposed to 
be involved in hydroxylation of the 2’-cyclohexenyl-alanine residue resulting in the β-hydroxy-2’-
cyclohexenyl-alanine residue in cinnabaramides A, B, D and E. It is noteworthy that the 
salinosporamide megasynthetase was shown to tolerate both secondary and tertiary carbons in the γ-
position of the amino acid precursors but substitution in the β-position was not accepted.[140] Based on 
this observation we administrated deuterated cyclohexenyl-serine, in which the β-position is 
substituted with a hydroxyl group, into the culture of Streptomyces sp. JS360. No incorporation of the 
supplemented compound was observed indicating that the cinnabaramide biosynthetic megasynthetase 
cannot tolerate alterations in the β-position of the amino acid precursor.[124] We suggested that the 
reason might be that the substitution directly affects the functionality of CinD in the pathway. These 
results not only give us very important guidance for precursor-directed biosynthesis and/or 
mutasynthesis, but also open the door for post-assembly line enzyme modifications. Since the cinL-
deficient mutant indeed produced significantly more cinnabaramide E but no cinnabaramide E 
anymore, the deletion of CinD could also be considerable, which would lead to an selective production 
of novel cinnabaramides containing non-hydroxylated 2’-cyclohexenyl-alanine residue. Furthermore, 
the combined deletions of CinD and CinE could be optional to result in more novel cinnabaramides.  
Last but not the least, the cin locus harbors genes responsible for regulation, self-resistance and 
unknown functions for which their encoding proteins are still to be investigated. Finally, the 
characterized biosynthetic gene cluster was cloned into one cosmid and heterologously expressed in 
Streptomyces coelicolor A3(2) and Streptomyces albus J1047 under the control of the native 
regulatory elements (L, Huo and R. Müller, unpublished data). This confirmed the involvement of all 
genes in cinnabaramide biosynthetic pathway and established a platform for further genetic 
engineering to optimize the heterologous production titer, such as the promoter exchange, deregulation 
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of the native regulation system and introduction of an inducible system into the heterologous host and 
enhancement of the self-resistance. Some of them was already successfully applied in yield 
optimization of heterologous production of bottromycin
[125]
, which gave us a very good model. In the 
other hand, this heterologous platform could also be utilized in combination of Red/ET technique to 
generate unnatural derivatives of cinnabaramides. 
 
2.2 Biosynthetic mechanism of the hexylmalonyl-CoA pathway  
 
Except for “usual” extender units as malonyl-CoA and methylmalonyl-CoA incorporated in PKS,[24] 
several observations have been reported in polyketide biosynthetic pathways involving unusual 
extender units including methoxylmalonyl-CoA,
[168;169]
 aminomalonyl-CoA,
[170]
 hydroxylmalonyl-
CoA,
[170]
 ethylmalonyl-CoA,
[171]
 hexylmalonyl-CoA,
[35;124]
 chloroethylmalonyl-CoA
[146]
 and 2-
carboxyl-5-methylhexanoyl-CoA;
[172]
 Interestingly, the biosynthetic origins of most unusual extender 
units are poorly understood to date. According to the literature,
[168-170]
 a very limited number of 
biosynthetic pathways of these usual extender units have been characterized, such as the 
methoxymalonyl-CoA originates from a glycerol-derived precursor, which could be bound to a CP and 
further processed to form methoxymalonyl-CoA.
[53;173]
 Later report revealed that hydroxymalonyl-
CoA and aminomalonyl-CoA can also be biosynthesized via similar fashion.
[174]
  However, none of 
those could retrobiosynthetically explain the formation of polyketides side chains (Figure C4). 
Until the recent reports on the biochemistry of the CCR family of enzymes appeared,
[150;175]
 the 
formation of many of those unusual extender units could possibly be explained retrobiosynthetically 
(Figure C4). As a new representative of CCRs, CinF was biochemically characterized in vitro and was 
found to convert 2-octenoyl-CoA and 2-octenoic acid N-acetylcycteamine (NAC) thioester into 
hexylmalonyl-CoA and hexylmalonic acid SNAC thioester in the presence of hydrogen carbonate and 
reduced nicotinamide adenine dinucleotide phosphate (NADPH).
[145]
 These results confirmed the 
hypothesis that CinF is responsible for providing hexylmalonyl-CoA for the synthesis of 
cinnabaramides.
[124]
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Figure C4: Reactions catalyzed by crotonyl-CoA carboxylase/reductases (CCRs). A) CCRs generate a 
number of different building blocks for polyketide biosynthesis while consuming NADPH and CO2. B) Detailed 
production of unusual building blocks for polyketide synthesis by means of reductive carboxylation and 
installation of bacterial polyketide metabolites: (1) hexylmalonyl-CoA; (2) chlorocrotonyl-CoA; (3) 2-carboxyl-
5-methylhexanoyl-CoA; (4) 2-carboxyl-4-methylhexanoyl-CoA; (5) 2-carboxyl-4-methylpentanoyl-CoA; (6) 
propylmalonyl-CoA; (7) ethylmalonyl-CoA; and (8) 2-(2-oxobutyl)-malonyl-CoA. 
 
Furthermore, we solved the structure of the enzyme in complex with NADP
+
 and its substrate 2-
octenoyl-CoA at high resolution in collaboration with the Structural Biology Department at Helmholtz 
Centre for Infection Research (HZI, Braunschweig, Germany). After several trials we failed to 
generate detectable CO2 binding crystals with Na2CO3 or CS2 as mimics of CO2. We then turned to 
docking CO2 into the CinF structure which suggested that residues E167 and N77 were involved in 
binding and activation of CO2 (Figure C5a). To verify this hypothesis we tested several mutants of 
these residues (CinF
E167A
, CinF
E167K
, CinF
E167Y
, CinF
N77A
, CinF
N77E
 and CinF
N77Y
) for their ability to 
perform the reduction and carboxylation reactions. The activity assays showed that all 6 CinF mutants 
lost their reductive carboxylation activity but partially retained the reductive activity versus 2-
C. Final Discussion 
31 
 
octenoyl-CoA.
[145]
 These data strongly support our hypothesis and our in silico analysis regarding the 
CO2 binding site. 
 
Figure C5. Ligand binding to CinF. A) Model of CO2 docked into the structure of CinF, CO2 is shown as 
cyan/red sticks, dashed lines indicate hydrogen bonds. B) Close-up of the hydrophobic substrate binding pocket 
for 2-octenoyl-CoA.  C) Comparison of the substrate binding sites of CinF (in blue), CCR from S. coelicolor (in 
gray) and SalG (in purple). 
 
CinF has a hydrophobic binding pocket for the long octenoyl chain (Figure C5b) while the other 
members of the carboxylase-reductase family have distinctly smaller ones for shorter chains. For 
example, the pocket is blocked by the large residues Phe370 and Ile171 in a crotonyl-CoA-specific 
CCR from S. coelicolor (PDB code: 3KRT) whereas in CinF the corresponding residues Gly362 and 
Ala163 are small to form a larger pocket. The chlorocrotonyl-CoA-specific SalG also has an Ala163 
as in CinF, but instead of the Gly362 or Phe370 it has an Ile362 (Figure C5c).
[146]
 These observations 
prompted us to determine whether these two positions are crucial for CCR substrate specificity in 
terms of the length of the aliphatic chain. Mutagenetic studies on G362F, G362I and A163I render 
CinF unable to convert 2-octenoyl-CoA into product, indicating their relevance to the activity. 
Furthermore, the activity screening towards various substrates including crotonyl-CoA, 2-octenoyl-
CoA and 2-octenoic acid SNAC thioester showed that CinF
G362F
 and CinF
A163I
 exhibited weak catalytic 
activity toward crotonyl-CoA, whereas CinF
G362I
 completely lost the activity towards all substrates. It 
was therefore possible to suppress the 2-octenoyl-CoA converting activity by one single mutation in 
the active site while retaining some of its crotonyl-CoA converting activity. The two crucial residues, 
Gly362 and Ala163, in substrate binding pocket explain why CinF is able to use the longer 2-octenoyl-
CoA chain while the other CCRs are only able to accept substrates with shorter chains. Based on this, 
it becomes possible that various substrates harboring different chain lengths can be accommodated by 
varying the size of specific side chains within the substrate-binding pocket leading to different 
substrate specificities for these enzymes. Through this, engineering of CCRs to produce various PKs 
incorporating uncommon extender units is of high interest for drug development. For this purpose, we 
already further generated and biochemically characterized more CCRs, such as TgaD, Leu10 and CCR 
involved in icumazole biosynthetic pathway (Figure C4) (L. Huo, F. Yan and R. Müller, unpublished 
data). The results revealed that each CCR has its own favorite substrate despite they share a common 
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reductive carboxylation mechanism. A detailed description of the CCR catalyzed reaction mechanism 
has been reported by Erb group very recently.
[176]
 Based on the determined various substrate 
specificities from generated CCRs and available crystal structure of CinF, especially the well-known 
active center and substrate recognition pocket, we can align the CinF sequence with other CCRs and 
make a series of rational site-directed mutagenesis on CinF substrate recognition pocket, expecting 
that modified CinF variants are able to catalyze the formation of shorter, longer, hydroxylated, 
halogenated etc. dicarboxylic acids. All of them could be served as extender units for polyketide 
biosynthesis, which could tremendously diversify the natural products. In conclusion, these findings 
provide a solid basis for attempts to modify the CCRs substrate specificity toward generating novel 
polyketide extender units and eventually the production of altered polyketide structures. However, 
generation of novel extender units is just the first step but not the last. Based on PKS enzymology, 
incorporation of those extender units into polyketides is dependent on acyl-transferase domains 
required for recognition and loading onto the corresponding carrier proteins of the PKS. Furthermore, 
the subsequent elongation modules also need to be capable of processing the altered intermediate and 
the corresponding unsaturated substrate for the CCR reaction must be available. Given these obstacles 
the success of biosynthetic engineering very challenging but definitely worth trying; nonetheless, first 
successful examples have been shown for the cinnabaramide biosynthetic pathway, specifically 
unnatural dicarboxylic acids were accepted by the PKS and subsequently processed to produce 
chlorinated analogues (discussed below).  
 
2.3 Creation of molecular diversity based on the cinnabaramide scaffold via synthetic 
biotechnology 
 
It has been reported that in salinosporamide biosynthesis the enzymes responsible for activation and 
incorporation of the native sal-specific amino acids exhibit relaxed substrate specificities toward a 
number of aliphatic amino acids. Moore and coworkers used this promiscuity to generate a series of 
salinosporamides analogues with altered bioactivities against human cancer cell lines;
[177]
 however, no 
cinnabaramides derived from proteinogenic amino acids have been detected in extracts of the wild 
type producer. Interestingly, the native substrate (2S,4R)-β-cyclohexenylalanine and the 
diastereomeric (2S,4S)-cyclohexenylalanine were both incorporated after feeding to the growth media 
of S. sp. JS360,
[178]
 indicating that either 1) the CinB A domain tolerantly activates the specific native 
substrates regardless of the chemical configurations but other free amino acids cannot be activated for 
further incorporation or 2) in vivo insufficient quantities of amino acids are available for secondary 
metabolite biosynthesis. Since the latter scenario is very unlikely we assume that it should be possible 
for the CinB A domain to directly transfer alternative amino acid N-acetylcycteamine (NAC) 
thioesters as mimics to the corresponding activated CoA thioesters to the CinB PCP domain and 
further incorporate them in the respective position of cinnabaramides. It has been reported that two 
salinosporamide derivatives with saturated cyclohexane or cyclopentane rings were successfully 
prepared by mutasynthesis through administration of derivatives and branched-chain amino acids to 
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the culture of a S. tropica salX-deficient mutant.
[177]
 Similarly, the corresponding counterpart of salX 
in the cin gene cluster, cinQ, encoding a putative L-amino acid aminotransferase was inactivated 
leading to complete elimination of cinnabaramide production in S. sp. JS360 cinQ-deficient mutant. 
By feeding of cyclopentyl-DL-alanine to the growth medium of the S. sp. JS360 cinQ-deficient mutant 
a novel cyclopentyl-cinnabaramide analogue was generated via mutasynthesis. However, this 
successful incorporation of the free amino acid contrasted the hypothesis of specificity of the CinB A 
domain for the native substrates β-cyclohexenylalanine. A possible explanation for this would be the 
administrated cyclopentyl-DL-alanine exhibits a highly similar backbone to the native substrate which 
is tolerated by the active sites of CinB A domain. The isolated cyclopentyl cinnabaramide A retains 
the antifungal activity despite a significant loss in cytotoxicity (Figure C6).
[124]
 Furthermore, a series 
of amino acids and their corresponding synthetic amino acid N-acetylcycteamine (NAC) thioesters, 
e.g., cyclohexyl-DL-alanine, leucine, phenylalanine, and tyrosine were individually fed into the culture 
of the S. sp. JS360 cinQ-deficient mutant. High-performance liquid chromatography (HPLC) coupled 
mass spectroscopy (MS) data showed that only the corresponding amino acid SNAC esters were 
successfully incorporated into the cinnabaramide biosynthetic pathway resulting in various 
cinnabaramide analogues while feeding with free amino acids lead to no incorporation (Figure C6) (L. 
Huo, P. Barbie, U. Kazmaier and R. Müller, unpublished data). The successful incorporation of all 
thioesters confirms the assumption that the tolerant CinB A domain, as its counterpart in 
salinosporamide pathway, could transfer the alternative amino acid N-acetylcycteamine (NAC) 
thioesters mimicking their active CoA esters to the CinB PCP domain and the corresponding PCP 
bound intermediates could be recognized by the condensation domain so the biosynthesis could 
proceed further. This successful mutasynthesis studies on cinnabaramide NRPS pathway set a stage 
for us to utilize the relaxed substrate specificity of CinB A domain to generate the amino acids-altered 
cinnabaramide derivatives by feeding of N-acetylcycteamine (NAC) thioesters of proteinogenic and 
non-proteinogenic amino acids. Based on the fact that the generated cyclopentyl cinnabaramide A 
retains the antifungal activity despite a significant loss in cytotoxicity, a compound library containing 
various amino acids-derived cinnabaramides is supposed to be set up and be used for the structure-
activity relationship (SAR) study in order to illustrate the mode of action of cinnabaramide antifungal 
activity which remains still unclear. The upcoming bottleneck could be the limited tolerance of CinB 
A domain towards desired amino acids. As discussed above, possible solutions would be rational 
engineering of modules/domains making them adapt to the corresponding fed building blocks. 
Using precursor-directed biosynthesis (E)-6-chlorooct-2-enoic acid, (E)-8-chlorooct-2-enoic acid, and 
their corresponding N-acetylcycteamine (NAC) thioesters were unambiguously incorporated into the 
cinnabaramide biosynthetic pathway and resulted in production of chlorinated cinnabaramide A and 
other derivatives. These results demonstrate the promiscuity of the CinA AT2 domain. The inability to 
generate derivatives of (E)-4-chlorooct-2-enoic acid or its -SNAC ester indicates that the presence of a 
chlorine atom at this position might cause the improper positioning of the substrate in the CinA AT2 
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active site. The alternative explanation would be that this substrate cannot be accepted by CinF for 
prerequisite reductive carboxylation leading to the formation of the corresponding 
chlorohexylmalonyl-CoA as the very substrate recognized by the CinA AT2 domain. Further activity 
screening showed that the cytotoxic activities of the 15-chloro derivative were superior to those of 
cinnabaramide A while the 17-chloro derivative showed enhanced bioactivity only towards human 
myeloma RPMI-8226 cells. In general, the cytotoxic effects are still significantly weaker than those of 
salinosporamide A; however, the chlorinated derivatives mostly retain the cinnabaramides antifungal 
activity which is much strong than salinosporamide A (Figure C6).  
Since the key to the superior activity of salinosporamide lies in the chlorine atom attached to the side 
chain which is required for the irreversible binding to the target
[131]
, it is definitely worth further 
conducting the precursor-directed biosynthesis with other chlorinated enolates or corresponding –
SNAC esters in order to generate various chlorinated cinnabaramides, which might give rise to a much 
more promising anti-cancer activity than salinosporamides, especially for feeding of the (E)-4-
chlorooct-2-enoic acid or its -SNAC ester which could in principle lead to the production of 13-chloro 
cinnabaramide representing a most similar structure to salinosporamide. Given that the first attempt 
failed and that might be caused by intolerant CinA AT2 domain, corresponding domain exchange or 
site-directed mutagenesis work is supposed to be done for adapting the AT specificity for the (E)-4-
chlorooct-2-enoic acid. Another option would be the mutagenic study of CinF, in order to enable CinF 
to convert the administrated chlorinated carboxylic acids to corresponding chlorohexylmalonyl-CoAs 
by altering its substrate specificity. Eventually, the chlorohexylmalonyl-CoAs could be recognized and 
incorporated into the pathway resulting in production of novel chlorinated cinnabaramide derivatives.  
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Figure C6. Rational engineering of cinnabaramide biosynthesis to generate structural diversity via 
synthetic biotechnology. A) Summary of generated cinnabaramide analogues. B) Biological activities of the 
isolated cinnabaramide derivatives.  
 
3. Bottromycin biosynthesis from Streptomyces sp. BC16019 
3.1 Bottromycin biosynthesis in Streptomyces sp. BC16019: Heavily modified peptides exhibiting 
unusual biosynthetic features 
Bottromycins, initially isolated from the fermentation broth of Streptomyces bottropensis in 
1957,
[126;132-135]
 represent a class of antibiotics exhibiting inhibitory activity on bacterial protein 
synthesis. Bottromycins were initially found to be active against Gram-positive bacteria and 
mycoplasma.
[132]
 Later on, bottromycins also showed their extended antibacterial abilities against 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).
[136]
 
Mode of mechanism studies revealed that the aminoacyl-tRNA binding site (A-site) on the 50S 
ribosome is the target of bottromycins.
[137-139]
 This site is currently not targeted by clinically used 
antibiotics leading to no observed cross-resistance between bottromycins and other therapeutic 
antibiotics, which leave bottromycins as a promising class for development into novel antibiotics.
[179]
  
In this work we employed a terrestrial actinomycete, Streptomyces sp. BC16019, which is able to 
produce bottromycin A2 and B2 (Figure A10). Inspired by the promising structural features and 
biological activity, we first identified the biosynthetic locus of bottromycins in the genome of 
Streptomyces sp. BC16019. In silico analysis of the bot gene cluster revealed that the biosynthesis of 
bottromycins follows a ribosomal pathway. A 44-amino acid encoding structural gene botA was found 
flanked by a set of genes in charge of post-translational modifications. Unlike the typical RiPPs which 
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harbor a N-terminal leader peptide appended to the core peptides,
[180]
 the BotA precursor peptide lacks 
the N-terminal leader sequence and only contains a single N-methionine residue instead which is 
experimentally verified to be cleaved off by a putative leucyl peptidase BotP (L. Huo and R. Müller, 
unpublished data). This unique organization for precursor peptides has not been previously described 
for ribosomal peptide pathways. As in some reported cases of RiPPs, BotA contains an additional C-
terminal extension sequence which is supposed to be responsible for the recognition by the post-
translational modification (PTM) enzymes in the absence of the N-terminal leader.
[180]
 Furthermore, 
additional tasks can be attributed to the C-terminal extension such as directing the export of mature 
compound, stabilizing the precursor peptide against degradation and keeping the peptide inactive 
during biosynthesis in the cell.
[180]
 A putative α/β hydrolase BotH most likely catalyzes the final 
proteolytic cleavage of the C-terminal extension from the precursor peptide and a number of tailoring 
enzymes are involved in the production of the highly modified bottromycin scaffold.  
Like other RiPPs, such as thiopeptides, cyanobactins and linear azole-containing peptides,
[29]
 a 
thiazole ring also exist in bottromycins. This heterocycle is often produced by cyclodehydration of a 
cysteine when the thiol attacks the carbonyl carbon of the adjacent amino acid resulting in a thiazoline 
ring. This thiazoline ring can be subsequently oxidized to thiazole. This biosynthetic process was 
shown in the microcin B17 biosynthetic pathway where a three-protein complex consisting of a 
cyclodehyratase, a “docking protein” and a flavin mononucleotide (FMN)-dependent dehydrogenase 
are required for thiazole ring formation.
[181]
 The biochemical functionality of cyclodehyratase and 
flavin mononucleotide (FMN)-dependent dehydrogenase were clearly assigned as cyclodehydration of 
cysteine and thiazoline oxidation respectively. However, the precise function of the “docking protein” 
remained unclear. The hypothesis that it might play a role in regulation of the cyclodehyratase activity 
and initiation of an active complex was investigated by D. A. Mitchell and coworkers.
[182]
 A recent 
study on a “docking protein” belonging to the Ycao-like protein family revealed that it alone catalyzes 
the cyclodehydration with consumption of ATP.
[183]
 In the bottromycin biosynthetic pathway, two 
putative “YcaO-like proteins,” BotC and BotCD, were identified as possible cyclodehydratases. 
Because BotCD shows not only the homology to “YcaO like protein” but also to the “docking_ocin 
superfamily” of proteins (Accession number: TIGR03604; members of this protein family include 
enzymes related to SagD), which includes “docking proteins” involved in heterocycle formations in 
other RiPP pathways,
[184]
 we speculated BotCD is the enzyme responsible for the formation of 
thiazoline. Therefore, BotC is presumed to be involved in the macrocyclization process discussed 
below. After the thiazoline formation a subsequent oxidation to thiazole via a FMN-dependent 
dehydrogenase would be expected; however, no homologues to this family of enzymes could be found 
in the bot locus. Thus, we assumed two possible mechanisms of thiazole formation in bottromycin 
biosynthesis (Figure C7). One possibility would be an oxidative elimination occuring after the 
proteolysis of the C-terminal extension sequence and cyclodehydration. Another possibility would be 
the proteolysis of the C-terminal extension sequence and subsequent oxidative decarboxylation of the 
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cysteine residue happens prior to cyclodehydration. Similar routes were reported in aminovinyl-
cysteine-containing ribosomal peptide biosynthesis including formation of reactive “thio-enol” 
intermediates via oxidative decarboxylation of C-terminal cysteine residues
[185]
 which supports this 
hypothesis. However, these complex enzymes are characterized as homo-oligomeric flavin-containing 
cysteine decarboxylases but no homologous proteins could be found in the bot locus, leaving the 
underlying biochemistry of bottromycin “exo-thiazole” formation a mystery. 
Another intriguing structural feature of bottromycins, especially for RiPPs, is the macrocycle formed 
between the N-terminal glycine residue and the second valine residue (Figure A10 and C7). 
According to the cyclodehydration chemistry described in textbooks the following pathway for this 
macrocycle formation was proposed: a nucleophile attack of the glycine amino group on the valine 
carbonyl carbon followed by dehydration. This macrocyclodehydration reaction mechanism results in 
an amidine moiety which is very unique amongst all the known RiPPs or even other natural products. 
To the best of our knowledge, this amidine moiety was only reported in coformycin
[186]
 and ectoine
[187]
 
(also named as pyrostatin B
[188]
). The studies on ectoine metabolism revealed the cyclic amidine was 
formed via a cyclodehydration-like reaction which supports our hypothesis. Interestingly, the ectoine 
synthase (EctC) responsible for amidine formation belongs to a family of carbon-oxygen lyases which 
is widespread in microorganisms.
[189]
 Not surprisingly, the EctC analogue encoding genes could also 
be identified in the genome of bottromycin producer S. sp. BC16019 as well as the heterologous host S. 
coelicolor.
[125]
 Thus, we cannot exclude the involvement of the ectoine biosynthetic enzyme(s) in the 
amidine moiety formation for bottromycin biosynthesis, although the locus of the EctC analogue 
encoding gene is very far away from the bot gene cluster. Alternatively, we assume that BotC or 
BotCD might catalyze the cyclodehydration reaction, whereas BotC is favorably supposed to be 
involved while BotCD is more likely to be responsible for the formation of thiazoline (as discussed 
above).   
In addition to the previously discussed PTM enzymes involved in bottromycin precursor peptide 
maturation process, a putative amidohydrolase and putative cytochrome P450 encoding genes, botAH 
and botCYP, are also located in the bot gene cluster. Despite their unassigned biochemical 
functionalities, we speculated that they might be involved in either the macrocyclodedydration 
reaction or the exo-thiazole ring formation. Besides, a putative transcriptional regulator, BotR, and a 
putative multi-drug transporter, BotT, are also found in the bot locus. Additionaly, the genetic 
engineering work based on the established heterologous expression system revealed that BotT plays a 
role in the self-resistance mechanism of the native producer.
[125]
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Figure C7. Maturation of the ribosomal bottromycin peptide scaffold. The bottromycin precursor peptide 
consists of the core peptide as well as a C-terminal extension (underlined) likely serving as a recognition 
sequence. Maturation of the bottromycin peptide scaffold requires a number of posttranslational modifications 
(highlighted in grey) the timing of which is currently unknown. These include various methylations, proteolytic 
digestion, ‘macrocyclodehydration’ and thiazole ring formation.  
 
3.2 Engineering of the bottromycin biosynthetic pathway in a heterologous host 
Faced with the tough genetic manipulation of the bottromycin native producer, we successfully 
engineered a heterologous expression system in order to characterize the bottromycin biosynthetic 
pathway. After mobilization of the proposed biosynthetic gene cluster localized on cosmid DG2 into 
Streptomyces coelicolor A3(2) and Streptomyces albus J1074, which were chosen as the suitable 
heterologous hosts because they are closely related to the native producer (see Introduction 4.1 
Heterologous expression: General aspects), bottromycin A2 production could be detected via 
HPLC-MS in both S. coelicolor::DG2 and  S. albus::DG2 mutants.
[125]
 These results indicate that the 
transformed biosynthetic pathway was complete and active in the heterologous hosts under the control 
of its native regulatory elements. However, similar to the commonly encountered bottleneck in 
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heterologous expression,
[93]
 much lower (almost 100 times) production yields (S.coelicolor::DG2: ca. 
4 μg/l; S. albus::DG2: ca. 1 μg/l) were observed compared to the native producer. Soon after, the 
bulky expression construct DG2 was simplified by deletion of ca. 16 kb insert fragment at the 5’ end 
of the bot gene cluster using Red/ET recombineering.
[190;191]
 The resulting DG2-kan construct was 
transformed into S. coelicolor leading to a not significantly affected production titer compared to 
S.coelicolor::DG2. The result demonstrated that the deleted region is not involved in bottromycin 
biosynthesis (Figure C8).   
Because of the high antibacterial activity of bottromycins and the fact that growth of S. coelicolor is 
impaired at bottromycin concentrations of 2 μg/l, we presumed that the limiting factor of the low 
production titer might lie in the self-resistance mechanism. Thus, further production optimization 
approaches were subsequently conducted with respect to undirected and directed strategies in order to 
improve the self-resistance of the heterologous hosts. The undirected approach was based on the 
observation that certain drug-resistant mutations in the rpoB gene (RNA-polymerase β-subunit 
encoding gene) or the rpsL gene (the ribosomal S12 protein encoding gene) might lead to a significant 
enhancement of the secondary metabolite’s production in Gram-positive bacteria.[192-196] Mutations 
could be triggered, e.g., by challenging the bacterial cells with rifampicin resulting in mutations in 
rpoB or by streptomycin resulting in mutations in rpsL. After using rifampicin mutagenesis some of 
the generated mutants exhibited roughly 10 times higher production titer than the starting clones 
(Figure C8).
[125]
 In parallel to this successful undirected approach, the putative efflux pump or multi-
drug transporter (BotT) was targeted in the directed approach. In order to overexpress the botT gene 
we replaced its native promoter with the PermE* promoter
[197]
 by insertion of a spectinomycin cassette 
via Red/ET recombineering resulting in the construct DG2-kan-efflux-ermE. The S. coelicolor::DG2-
kan-efflux-ermE mutant produced ca. 20 times higher yield than S. coelicolor::DG2 (Figure C8).
[125]
 
In summary, both undirected and directed mutagenetic approaches were employed to successfully 
improve the heterologous bottromycin production and the combination of these two strategies should 
lead to a further enhancement of bottromycin production titer. Additionally, the establishment of the 
bottromycin heterologous expression system allows for further characterization of the biosynthetic 
pathway in the heterologous host rather than the poorly manipulable native producer. 
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Figure C8. Heterologous bottromycin production. A) Inserts of the three expression constructs used for 
heterologous bottromycin production. The original cosmid DG2 was modified via Red/ET recombineering to 
delete the 5’-flanking region (orf7-orf20) by insertion of kanR and, in the next step, to insert the PermE* 
promoter upstream of botL together with spec
R
. B) Quantification of heterologous bottromycin production by 
HPLC-MS analysis of the culture extracts from different S. coelicolor mutant strains. Sections of extracted ion 
chromatograms at m/z = 823.45 corresponding to the [M+H]
+
 ion of bottromycin A2 (1) are illustrated as 
representative readouts of productivity. The S. coelicolor A3(2) host strains contain one of the three expression 
constructs shown in (A). ‘Rifampicin-induced mutagenesis’ was performed with S. coelicolor::DG2 and DG2-
kan (‘DG2-rif’ and ‘DG2-kan-rif’). 
 
Using the established heterologous platform and synthetic biotechnology technique we functionally 
elucidated the methylation steps comprising one O-methyl transferase and three radical SAM-
dependent methyl transferases required for alkylation of non-activated carbons. After the target 
deletions of the four methyl transferases were individually performed by replacement of different 
antibiotic resistant genes (ampicillin, chloramphenicol and zeocin) using Red/ET recombineering, the 
respective heterologous expression of the modified pathways were followed up. By comparing the 
fragmentation patterns of the detected bottromycin scaffolds the corresponding methyl transferases 
could be unambiguously assigned: BotRMT3 catalyzes the C-methylation of the proline residue, 
BotRMT1 is responsible for C-methylation of the phenylalanine residue and BotRMT2 turned out to 
catalyze the C-methylations of both valine residues. In addition, experimental evidence showed that 
BotOMT catalyzes the O-methylation of the aspartic acid residue although the corresponding non-
methylated free acid product was not detected in the extracts of the corresponding mutant.
[125]
 It would 
be very intriguing if the non-methylated novel bottromycin derivatives could be isolated and screened 
for bioactivity which could not be accomplished in the present work due to their low production yields. 
However, based on the strategies mentioned above, we are absolutely convinced that the production 
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titer could be easily improved and the isolation of these novel bottromycin derivatives could be 
achievable.  
Future work would be still focused on generation of more bottromycin derivatives because the 
promising activity and the novel binding target making them to be potentially developed as new 
antibiotics. As a RiPP, despite the large biosynthetic gene cluster the structure backbone of 
bottromycin is actually determined by the 24 bp core peptide sequence involved in the 135 bp long 
botA gene. Such a short oligonucleotide can be easily synthesized in different versions.  These botA 
variants may contain the altered core peptide sequences but the exactly same C-terminal extension 
sequence which can lead to various bottromycin scaffolds as well as guarantee the functionality of 
PTM enzymes. Combined with the established heterologous system with an improved production titer, 
this in vivo strategy could efficiently help us to generate a number of bottromycin derivatives.  
Another route to generation of more bottromycin derivatives refers to the in vitro reconstitution of 
bottromycins. Based on this, different versions of BotA precursor peptides could also be easily 
synthesized whereas only the core peptide sequence woul0d be altered. Until recently, the recombinant 
proteins of most PTM enzymes were expressed and purified in E. coli (L. Huo, J. Köhnke, S. C. 
Wenzel and R. Müller, unpublished data). The short BotA precursor peptide was also generated by 
chemical synthesis. According to the ambiguous annotations of these PTM enzymes, to find out how 
these enzymes finish the teamwork in turn, especially how the amidine-ring structure is enzymatically 
formed is challenging because this moiety is very rare among the RiPPs biochemically described so far. 
Even extended to the whole natural products, only coformycin and ectonine harbour this characteristic 
structural feature.
[198;199]
 However, several RiPPs were successfully reconstituted in vitro
[200-202]
, which 
is an optimistic support for this strategy. This work is definitely worth being continued in the future. 
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